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ABSTRACT  
Isolation and Characterisation of Novel DNA Aptamers against 
Mycobacterium tuberculosis Biomarkers: New Tools for Tuberculosis Diagnostics 
B. Amos-Brown 
Institute of Infectious Disease and Molecular Medicine, Division of Chemical and Systems Biology, 
Department of Integrative Biomedical Sciences, University of Cape Town 
 
Tuberculosis is a curable disease with an average treatment success rate of 86 %. Despite this, there 
were an estimated 1.5 million deaths due to tuberculosis in 2013, most of which occurred in low and 
middle-income countries. In order to overcome tuberculosis in developing countries innovation in 
diagnostics is key to administering treatment. 
While detection of whole mycobacteria has been favoured in the past to diagnose tuberculosis, 
culturing mycobacteria is costly, and microscopy is often not sensitive enough due to low bacterial 
loads. Detection of Mycobacterium tuberculosis biomarkers in urine, a safe and easy specimen to test, 
could offer a cost effective and simple solution to identify patients with tuberculosis.  
Enzyme linked immunosorbent assays (ELISAs) were performed on concentrated tuberculosis patient 
urine to detect two M. tuberculosis biomarkers: lipoarabinomannan (LAM) and early secreted 
antigen-6 kDa (ESAT-6). Concentrating urine improved the detection of LAM in human 
immunodeficiency virus (HIV) negative patients and patients with a CD4 count > 200 cells/µl. 
ESAT-6 was not detected by ELISA due to a high background signal caused by the available 
antibodies cross reacting with a human protein present in urine which was identified by western blot 
and mass spectrometry. Targeted mass spectrometry did not detect ESAT-6 or its dimer partner, 
culture filtrate protein-10 kDa (CFP-10) in tuberculosis positive patient urine. 
Since concentrating urine samples is impractical in a clinical setting a more sensitive diagnostic is 
needed to detect LAM in urine and ESAT-6 or CFP-10 in other samples. Aptamers can be packed 
more densely on biosensor surfaces increasing the dynamic range of detection while matching the 
affinity that an antibody has for a biomarker. Chemically modified DNA aptamers were isolated for 
LAM and the ESAT-6.CFP-10 dimer. The aptamers were characterised by enzyme linked 
oligonucleotide assays (ELONAs) and biolayer interferometry. One aptamer bound with high affinity 
to ESAT-6 while one aptamer bound with low affinity to LAM.  
The use of aptamers as capture agents for detecting biomarkers in biological specimens thus appears 
to be a viable option for diagnosing tuberculosis, although availability and concentration of individual 
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1 LITERATURE REVIEW 
1.1 Introduction 
Mycobacterium tuberculosis is a pathogen that has evolved over an extended period in a niche 
environment, the human lung (Comas et al., 2013). Robert Koch identified M. tuberculosis as the 
causal agent of  tuberculosis (TB) over a century ago (Koch, 1890), but there was no effective 
treatment at the time. Drugs against TB such as isoniazid (Fox, 1961) were discovered during 
the mid to late 20th century and are still used today. TB is a curable disease with an average 
treatment success rate of 86 %. However, there were an estimated 1.5 million deaths due to TB 
in 2013 and the majority of these deaths occurred in low and middle income countries (WHO, 
2014a). The economic cost of TB care in resource-poor countries places a large burden on 
strained economies (Ukwaja et al., 2012).  In order to overcome TB in developing countries, 
innovation in diagnostics is key to treating TB; without accurate diagnosis, the correct 
treatment cannot be administered. 
1.2 Distribution and Burden of Disease/ Epidemiology 
TB is most prevalent in Africa and Asia and the total number of active TB cases in 2013 was 
9 million (Figure 1.1) (WHO, 2014a). Each country has its own unique challenges. Some of the 
risk factors associated with TB include Human Immunodeficiency Virus (HIV) infection, 
poverty and silicosis. An estimated 1.1 million people were co-infected with TB and HIV in 2013 
(WHO, 2014a). HIV infected patients are more susceptible to TB due to their immune 
compromised state (Daley et al., 1992; Corbett et al., 2003). Malnutrition, especially a lack of 
protein in the diet, can also compromise cell-mediated immunity which is the primary defence 
against TB (Cegielski and McMurray, 2004).  While poverty can lead to malnutrition, crowded 
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living arrangements and limited access to health care aggravate the transmission of TB. Mine 
workers or others with silicosis are at a higher risk of TB infection due to damaged lung tissue 
(Corbett et al., 1999). The above factors highlight the need for interventions which are cost 
effective and functional in resource-poor settings.  
 
 
Figure 1.1 Estimated TB incidence rates 
Highest incidence in Sub-Saharan Africa. Adapted from WHO 2014 Report  (WHO, 2014a). 
 
1.3 Physiology of Mycobacteria 
M. tuberculosis is part of the Actinomycete family which includes environmental bacteria 
typically found in the soil and a subset of pathogenic bacteria, such as M. tuberculosis, M. avium, 
M. bovis and M. kansasii. A distinguishing feature of environmental mycobacteria  is that they 
typically grow faster than the pathogenic species (Madigan et al., 2012).  
All mycobacteria are rod-shaped and Gram positive except that they have a substantially higher 
lipid content (40%) in their outer layer than typical Gram positive (5%) or Gram negative 
bacteria (10%) (Youmans, 1979). This property prevents the common red Gram stain from 
exiting the bacteria even after washing with 3% HCl in alcohol, hence Ziehl–Neelsen or acid-
fast staining is useful for identifying mycobacteria (Madigan et al., 2012). This additional layer 
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of lipids also helps the bacterium to survive the adverse conditions of the macrophage and 




The lipid layer containing mostly mycolic acids is covalently linked to the arabinogalactan 
component of the wall which is in turn linked to the peptidoglycan layer (Figure 1.2). Teichoic 
acids which are embedded in the cell wall are responsible for the net negative charge on the 
cell surface. Some teichoic acids are covalently bound to lipids (Madigan et al., 2012). 
Lipoarabinomannan (LAM) is found embedded in the cell membrane or near the surface of the 
cell wall (Alsteens et al., 2008).  LAM will be discussed in more detail in Chapter 2 and Chapter 4. 
1.4 Aetiology and pathogenesis 
TB is transmitted via small droplets exhaled by people with active TB (Figure 1.3). After 
M. tuberculosis is inhaled into the lungs, a complex immune response ensues and M. tuberculosis 
 
Figure 1.2  Mycobacterial cell wall  
(http://2009.igem.org/wiki/index.php?title=Team:SupBiotech-Paris/Concept1&oldid=159486) 
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orchestrates a counter attack by dysregulating several pathways of the immune system (Ellner, 
1997; Baena and Porcelli, 2009; Urdahl, Shafiani and Ernst, 2011).  
 
Figure 1.3 Tuberculosis pathogenesis 
M. Tuberculosis is inhaled and enters the lung. Mycobacteria replicate inside 
macrophages and granulomas are formed. Necrotic granulomas release the 
mycobacteria, which are transmitted via aerosols [adapted from (Cambier, Falkow and 
Ramakrishnan, 2014)]. 
 
The range of virulence observed amongst clinical isolates is surprising given the limited genetic 
diversity of M. tuberculosis (Mathema et al., 2006). Gagneux et al. suggest that six phylogenetic  
lineages are associated with particular geographical regions which has implications for the 
study of TB epidemiology (Figure 1.4)(Gagneux et al., 2006).  The W. Beijing strain is of 
particular interest as it appears to be increasing in prevalence indicating greater fitness than 
other strains (Liu et al., 2014).  While identifying genetic mutations may give clues to 
phenotypic differences (Sreevatsan et al., 1997), further proteomic studies are needed to 
illuminate  phenotypic diversity (Parwati, van Crevel and van Soolingen, 2010; Peters et al., 
2016). 
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Figure 1.4 M. tuberculosis global phylogeny. 
Large sequence polymorphisms (LSPs) define the global phylogeny for M. 
tuberculosis. Numbers indicate the names of the LSPs or regions of difference. 
Geographic regions are associated with specific lineages as indicated. [adapted from 
(Gagneux et al., 2006) ] 
 
The study of the immunopathology of M. tuberculosis is ongoing as it is difficult to recreate the 
precise diseased environment found in human lungs. Many studies have been performed in 
mice models where M. tuberculosis remains inside the macrophages; as the current dogma 
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suggests, it is an intracellular pathogen for most of its lifespan. However, Orme argues that 
M. tuberculosis is largely an extracellular pathogen and it drives the human immune response 
to necrosis in order to prepare for escape (Turner, Basaraba and Orme, 2003; Orme, 2014), yet 
mice do not ordinarily develop necrotic lesions after M. tuberculosis infection. Hence, more 
studies are needed in the Kramnik mice model (Driver et al., 2012) or guinea pigs to study M. 
tuberculosis in an extracellular necrotic environment (Turner, Basaraba and Orme, 2003).  
Not all people exposed to M. tuberculosis progress to active disease, but may instead develop a 
latent infection. Latent infection is classified as having an M. tuberculosis infection which is not 
detected clinically. The state of the mycobacteria during latent infection is not well understood, 
but it seems they form a spectrum of dormant to replicating bacteria which are intrinsically 
resistant to drugs and the immune response. Orme argues that the classic idea of molecular 
latency is false and argues instead that M. tuberculosis prepares for transmission by entering a 
persistent state rather than a truly dormant one (Orme, 2014). 
 Most TB cases are restricted to lung infections. However, some cases progress to 
extrapulmonary disease where the bacteria spread to other organs. One of the more dangerous 
types of extrapulmonary TB is meningeal TB, where the mycobacteria access the membrane 
around the brain and can be found in the cerebrospinal fluid. It is estimated that 15-20% of TB 
patients develop meningeal TB and as many as 50 % of HIV positive patients (Berenguer et al., 
1992; Kashyap et al., 2009) 
The rise in TB has been partly attributed to the HIV epidemic which flared in the 1980s. HIV 
patients are more susceptible to TB because T-cells critical in the defence against 
M. tuberculosis are depleted in HIV patients (Kalsdorf et al., 2009). The majority of co-infections 
are restricted to Africa rather than Asia and South America (other endemic regions) (WHO, 
2011e). In an effort to reduce TB transmission, mortality and morbidity, HIV patients are 
screened for TB symptoms. Unfortunately, they are more difficult to diagnose due to 
extrapulmonary disease, paucibacillary sputum samples and lack of typical symptoms (Reid 
and Shah, 2009). 
1.5 Vaccination 
Vaccines typically dramatically lower the transmission of the target disease and can even lead 
to eradication of infectious diseases in some cases (e.g. polio and small pox). In the case of TB 
there is only one vaccine currently in use. It is derived from an attenuated strain of 
Mycobacterium bovis named M. bovis Bacillus Calmette-Guérin (BCG).  The live BCG vaccine 
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confers variable protection, especially if an individual has been exposed to M. tuberculosis or 
other mycobacteria.  Latitudes closer to the equator have reported reduced efficacy of the 
vaccine, probably due to increased exposure to environmental non-tuberculous mycobacteria. 
Unexposed children benefit more from vaccination than adults. BCG protects against childhood 
miliary or meningeal TB but has variable success in preventing pulmonary TB. This protective 
immunity does not last beyond childhood and booster doses of BCG do not confer any additional 
protection (Rodrigues et al., 2005).  Because of this limited benefit, BCG vaccination is currently 
only recommended in endemic TB regions.  The question of why BCG vaccination is so 
ineffective in high burden settings remains the subject of much on-going research, but there is 
not yet a clear-cut answer. 
While efforts to develop an effective vaccine continue, the complex relationship of 
M. tuberculosis with the human immune response has made it difficult to pin down an effective 
vaccine. Gene expression studies that map the immunopathology of TB in theory should  help 
to design better vaccines  (Bloom et al., 2013).  The challenge though lies in finding immune 
correlates of protection against TB infection. Currently the only method to verify if a vaccine is 
effective is to determine if the vaccinated group have higher rates of active TB than BCG 
vaccinated or non-vaccinated individuals (McNerney et al., 2012).  
1.6 Treatment 
Tuberculosis is a treatable disease.  The majority of bacteria are eliminated within the first two 
weeks of treatment for drug susceptible TB (Donald and Diacon, 2008).  However, in order to 
eliminate persistent mycobacteria, treatment regimens are typically six to nine months. A 
typical regime consists of 2 months of isoniazid, rifampin, pyrazinamide, and ethambutol 
followed by a 4 months of isoniazid and rifampin (Nahid et al., 2016). Due to this long regime, 
patients often default on their treatment, which increases the risk of drug resistant strains 
evolving and taking hold in a community (Parsons et al., 2011).  
Most of the first line drugs target an element of the cell wall or membrane. Isoniazid interferes 
with mycolic acid synthesis, while ethambutanol inhibits the polymerisation of arabinans 
destined for arabinogalactan and LAM (Chatterjee, 1997). Pyazinamide disrupts membrane 
energetics and transport, and rifampin inhibits RNA polymerase (Wehrli, 1983; Zhang, 2003). 
Drug resistant strains are difficult and expensive to treat. New drugs to treat drug resistant 
strains have been slow to emerge. The only recent drug is bedaquiline which targets ATP 
synthase (Diacon et al., 2009, 2012; Cox and Laessig, 2014; Pym et al., 2016).  
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Diagnostic tests that could monitor the progress of treatment would be beneficial for 
identifying patients who had resistant strains and would perhaps shorten the course of 
treatment.   
1.7 Diagnostics 
Global case detection rates are estimated to be 64% of all incident tuberculosis cases, which 
means a projected 36% of cases remain undiagnosed and therefore untreated. In endemic 
countries, the estimate for case detection rates vary from 17% to 87%, leaving many infectious 
patients to transmit the disease (WHO, 2014b). While restricted resources and poor case 
reporting are factors for low case detection rates, current diagnostic tests and practices are 
inadequate to detect tuberculosis effectively.  Hence, better diagnostics and practices are 
needed which can be used in diverse settings.  
Diagnostic tests aimed at resource-poor settings should be cost effective and convenient 
(Pantoja, Kik and Denkinger, 2015). The 2012 diagnostic market in South Africa was estimated 
at 98 million USD while the Brazilian market was estimated at 16-17 million USD (TB 
Diagnostics Market Analysis Consortium, 2014, 2015). Current spending on diagnostics 
indicates what is affordable and if assistance is required for initial capital costs of new 
diagnostic tools. The successful roll-out of  the  Xpert MTB/RIF®  assay in South Africa shows 
that there is a market for new and improved diagnostic tools in developing economies (TB 
Diagnostics Market Analysis Consortium, 2015).  Disinvestment of  redundant resources will 
also affect the market and should be considered when implementing new strategies (St John 
and Price, 2014).  
New and current diagnostic tests are usually compared to the gold standard test to judge their 
effectiveness. Four metrics derived from this comparison are: sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV). 
Sensitivity and specificity are the most commonly used metrics for research and policy 
purposes. However, they should not be confused with analytical sensitivity and specificity, i.e. 
limit of detection and  ability of a molecule to recognise another molecule specifically (Saah and 
Hoover, 1997). For the following discussion, sensitivity and specificity will refer to the 
diagnostic metrics. Sensitivity is the proportion of people with disease who will test positive 
and specificity is the proportion of people without the disease who will test negative. Note that 
these metrics do not give an indication of how many people may have a false positive (FP) or 
false negative (FN) result. PPV “represents a proportion of patients with a positive test result 
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in the total of subjects with positive result [true positive (TP)/TP+FP]” and NPV represents the 
“proportion of subjects without the disease with a negative test result in the total of subjects 
with negative test results [ true negative (TN)/TN+FN]” (Šimundić, 2008). Hence, PPV and NPV, 
which indicate the probability that a positive result or negative result is true, are more useful 
in clinical settings.  PPV and NPV values will vary depending on the prevalence of a disease in a 
population. Current TB diagnostics that are in routine use are described in the following 
sections. 
1.7.1 Culture 
The gold standard diagnostic for identifying M. tuberculosis is to culture the mycobacteria from 
patient specimens, typically sputum. Historically, this was time consuming due to 
M. tuberculosis only doubling every ~ 24 hours. The current automated liquid culture systems 
can produce results within 14 days. However, turn-around time depends on how many bacilli 
were in the patient specimen and logistics such as backlogs at testing centres. Automated 
culture systems have high sensitivity (75-100%) and specificity (>99%), and the ability to 
identify drug resistant strains with drug susceptibility tests (DST)  (Palomino et al., 2008). 
However, liquid cultures are prone to contamination, consequently they are subject to various 
tests to confirm the presence of M. tuberculosis, such as observing the morphology, or 
performing Ziehl-Neelsen staining and  biochemical tests (Asmar and Drancourt, 2015) . While 
this method serves well as a gold standard, it requires disproportionate time, infrastructure 
and highly trained personnel to be an effective diagnostic.   
1.7.2 Smear Microscopy 
Ziehl–Neelsen or acid-fast smear microscopy is the most common first line diagnostic because 
it is affordable and rapid. However, the sensitivity varies from 32 to 94 % depending on the 
bacterial burden, quality of the sputum sample and the skill of the technician (Steingart, Henry, 
et al., 2006).  The proportion of smear negative patients increases in regions with high rates of 
HIV-associated TB (Elliott et al., 1993; Colebunders and Bastian, 2000; Getahun et al., 2007). 
Historically, smear negative tuberculosis had reasonable outcomes; however, smear negative 
HIV positive patients are at greater risk of mortality (Mukadi, Maher and Harries, 2001). 
Children also tend to be smear negative since they have difficulty producing sputum without 
swallowing (Zar et al., 2005). 
 Sputum induction improves the diagnosis of HIV and paediatric patients by smear microscopy, 
a less invasive method than gastric or bronchial lavages (Zar et al., 2005; Peter et al., 2014). 
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Other techniques to improve sensitivity include concentrating sputum samples, light emitting 
diode (LED) microscopes and fluorescent auramine staining. FM-LED microscopy improves 
sensitivity by an average of 10% due to the larger area of the slide that is examined. Only a 25x 
objective lens is needed for FM-LED microscopy, which reduces the risk of technicians missing 
bacilli in low density samples (Steingart, Henry, et al., 2006; Steingart, Ng, et al., 2006).  The 
WHO recommended FM-LED microscopy to replace Ziehl-Neelsen staining in 2011, but by 2013 
only 6 % of labs worldwide had adopted this system (WHO, 2011b, 2016a). South Africa is one 
of the exceptions with 97% penetration of FM-LED microscopy (WHO, 2013b). 
Despite improvements to this method, sensitivity remains variable: it cannot be used for 
determining drug resistance, and it requires infrastructure and highly trained technicians 
(Steingart, Henry, et al., 2006). Hence  smear microscopy is being phased out in many countries 
in favour of the rapid Xpert® MTB/RIF assay for diagnostics  (WHO, 2016a). 
1.7.3 Nucleic Acid Amplification Tests (NAAT) 
The Xpert® MTB/RIF assay uses real-time PCR for the detection of M. tuberculosis and 
mutations in the 81-bp rifampin resistance-determining region (RRDR) of the rpoB gene.  
The assay sensitivity is better than smear microscopy, thus detecting patients that are typically 
smear negative (Blakemore et al., 2010; Helb et al., 2010; Armand et al., 2011; Boehme et al., 
2011; Marlowe et al., 2011; Detjen et al., 2015). The new Xpert® MTB/RIF Ultra assay has been 
designed to overcome some of the shortfalls of the first-generation assay with improvements 
in sensitivity in the hope of targeting paucibacillary samples from paediatric, HIV-associated 
and extrapulmonary TB. It promises to be of equal sensitivity as culture, needing only 61 CFUs, 
but specificity may be sacrificed in  patients who have non-viable bacilli present after a recently 
treated TB infection (Alland et al., 2015; Foundation for Innovative New Diagnostics (FIND), 
2017; Zar, Workman and Nicol, 2017).  
Additionally, it was found to be a cost effective first line diagnostic in sub-Saharan Africa but 
more studies are needed to assess other endemic regions (WHO, 2013a; Langley et al., 2014).  
The disadvantages of this technique are the continued need for skilled personnel and 
laboratories, the dependence on intact mycobacteria (Scott et al., 2011) and an inability to 
distinguish between live and dead bacteria (WHO, 2011c).   
Loop mediated isothermal amplification (LAMP) is another method of detecting M. tuberculosis 
DNA. It does not require a constant supply of electricity  which is a benefit in developing 
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countries where electricity may be intermittent, and it can be performed in under an hour.  This 
method allows for large amounts of amplicon to be generated which can be visually detected 
by using “double-stranded DNA-binding dyes, such as SYBR green, by detecting the turbidity 
caused by precipitating magnesium pyrophosphate or by using a non-inhibitory fluorescing 
reagent that is quenched in the presence of divalent cations” (WHO, 2016b) . 
LAMP has been used to target several genes as tabulated by Aryan et al (2013). The IS6110 gene 
is commonly used since there are multiple copies of this gene in M. tuberculosis (Aryan et al., 
2013). Current genes targeted by LAMP assays do not detect drug resistance though, hence the 
Xpert® MTB/RIF assay is recommended ahead of LAMP unless there is an electricity supply 
issue (WHO, 2016b). 
LAMP is more sensitive than smear microscopy and is recommended for smear negative cases.  
Compared to the Xpert® MTB/RIF assay, LAMP is less sensitive (78%), but has the same 
specificity (98%) as the first-generation assays. However, LAMP is more cost effective than the 
Xpert® MTB/RIF assay given that it is cheaper to implement and requires less infrastructure 
as per cost-effectiveness calculations performed for Malawi and Vietnam. TB-LAMP had a 
weighted average cost of between USD 13.78 and USD 16.22 and the Xpert MTB/RIF assay was 
USD 19,17 to USD 28,34 (Sohn, 2016). The WHO has recommended it for  pulmonary TB, i.e. 
sputum samples, but not extrapulmonary specimens in labs where microscopy can be 
performed (WHO, 2016b). 
While most efforts to improve tuberculosis diagnostics have focussed on NAATs there is an 
inherit limitation to this approach.  DNA is quickly hydrolysed in serum restricting NAATs to 
samples where DNA is preserved within the whole bacterium such as sputum. Sputum poses a 
risk to health care workers and the most vulnerable patients (HIV patients and children) have 
difficulty producing sputum or have paucibacillary specimens (Zar et al., 2005; J. G. Peter et al., 
2012). Additionally, the need for electricity and skilled personnel are not trivial drawbacks, 
especially in the case of the Xpert® MTB/RIF assay. 
1.7.4 Immune Response Diagnostics 
Diagnostic assays such as interferon-γ (IFN-γ) release assays (IGRAs), the tuberculin skin test 
(TST) or antibody response assays measure the adaptive immune response against 
M. tuberculosis.  Briefly, interaction with foreign antigens activates the differentiation of 
T helper (Th) cells into Th-1 and Th-2 cells. Activated Th-1 cells secrete cytokines such as IFN-
γ to activate the bactericidal pathways of macrophages and dendritic cells. Th-2 cells stimulate 
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a B-cell response to produce antibodies, which is less well understood in the context of TB 
(Achkar, Chan and Casadevall, 2015). Adaptive immunity retains memory T-cells after an 
infection is cleared, thus repeat infections can be dealt with swiftly.  
Immuno-diagnostics are primarily used to diagnose latent TB or determine exposure to 
M. tuberculosis. The WHO (2015a) state that “latent tuberculosis infection (LTBI) is defined as 
a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens 
without evidence of clinically manifested active TB”. However, TB is a spectrum between latent 
and active dependent on several variables  rather than two binary states (Barry et al., 2009).  
For the TST or “Mantoux” test, M. tuberculosis antigens are injected under the skin and a delayed 
hypersensitivity reaction is measured the following day.  The TST has been improved over time 
by using more specific antigens, hence the modern TST is able to discriminate between BCG 
vaccinated individuals and those exposed to M. tuberculosis (Elhay, Oettinger and Andersen, 
1998; Colangeli et al., 2000; Arend et al., 2008; Wu et al., 2008). 
For IGRAs, whole blood or PBMC’s are stimulated with TB antigens to elicit the release of IFN-γ 
from T-cells that have been previously sensitized by M. tuberculosis. IGRAs were designed to 
replace the TSTs for diagnosis of latent TB, but they are more expensive and do not outperform 
the TST in low- and middle-income countries (WHO, 2011d). Lower sensitivity in the 
QuantiFERON-TB assay can be attributed to the peptide used, which is not the most immuno-
reactive for all populations (Horvati et al., 2016). A high incidence of HIV-associated TB also 
results in lower sensitivity, since the general immune response is lower (WHO, 2011d).  
The goal of latent TB diagnosis is to determine if isoniazid preventative therapy should be 
administered. In endemic settings, it is not feasible to treat everyone with latent TB as it would 
be too costly. It would be valuable if IGRAs could predict conversion to active disease. The 
potential for IGRAs to predict the risk of developing active TB has been investigated but there 
is a poor correlation between IGRA result and those that develop TB, including 
immunocompromised patients (Mandalakas et al., 2008; Rangaka et al., 2012; Sester et al., 
2014).  
Hence, IGRAs are only recommended for use in upper middle to high income countries where 
prevalence of TB is low enough to manage latent TB infections (WHO, 2011d, 2015a). 
Another strategy to diagnose certain infectious diseases is to detect the antibody response to 
the pathogen, such as the HIV serodiagnostic test which is simple and takes only a few minutes 
to perform and read. Previously Steingard et al.  explored the range of  commercial serological  
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TB diagnostics and concluded that no current serodiagnostic is robust enough for routine use 
(Steingart et al., 2011). Hence the WHO recommended against the use of  rapid serological tests 
for the diagnosis of TB (WHO, 2011a).  However, more recently, a study using highly 
immunogenic peptides from cell wall proteins has revived the possibility of a lateral flow point-
of-care  test (Gonzalez et al., 2014).  
1.8 New Diagnostics 
Improvements to current diagnostics should in principle reduce incidence, decrease the 
duration of disease and increase case detection (Keeler et al., 2006; Abu-Raddad et al., 2009).  
As discussed above, current diagnostics have shortcomings and new tools at different levels of 
the health care system are needed. There is no silver bullet to solve tuberculosis diagnosis. 
Hence several avenues need to be explored. 
A key discussion in 2014 prioritised the following point-of-care tests for diagnosis of active 
tuberculosis (WHO, 2014b; Denkinger et al., 2015): 
• The triage test: “a point-of-care triage test, which should be a simple, low-cost test that 
can be used by first-contact health-care providers to identify those who need further 
testing” 
• The biomarker test: “a point-of-care non-sputum-based test capable of detecting all 
forms of TB by identifying characteristic biomarkers or bio-signatures” 
• The smear replacement test: “a point-of-care sputum-based test to replace smear 
microscopy for detecting pulmonary TB “ 
Several studies have used the 2014 WHO meeting report above to model the effect of the 
hypothetical point-of-care tests on various markets with positive results (Denkinger et al., 
2014; Kik et al., 2015; Pantoja, Kik and Denkinger, 2015). 
A triage test with high sensitivity can be used as a rule out test which would be followed up by 
a more sensitive test. Paired with a more time- and cost-efficient system at the peripheral lab 
level, this approach would increase the detection rate of TB, allow for earlier treatment and 
reduce transmission of tuberculosis. This is predicted to ultimately reduce the burden in a 
region and contributes to the WHO’s goal of ending TB by 2030 (WHO, 2016a). A study by Van’t 
Hoog et al. explored if it would be cost effective to have a triage test before Xpert® MTB/RIF 
assay. Testing in Uganda, South Africa and India determined that the test should have the same 
sensitivity as the Xpert® MTB/RIF assay, 75% specificity and cost of 5 USD to be accepted 
(Van’t Hoog et al., 2013). 
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A non-sputum biomarker or smear replacement test with moderate sensitivity and high 
specificity would rule-in patients at the point-of care, as patients could be treated immediately. 
A non-sputum test would be beneficial for EPTB since conventional tests start off with sputum. 
Although it is important to be able to detect TB in difficult cases such as EPTB, children or HIV 
patients, a model by Denkinger et al. suggests that detecting active pulmonary cases is more 
efficient at reducing mortality than targeting difficult cases (Denkinger et al., 2014).  Hence, 
most patients would be diagnosed at the point-of-care and more difficult to diagnose patients 
would be referred for more sensitive laboratory based tests.  
Which diagnostics will be commercially viable depends on how effective they are and whether 
a particular market is ready to spend money on new diagnostics. For example, an excellent 
biomarker test could replace the need for a sputum smear replacement test (Kik et al., 2015) 
Currently there are several new diagnostics in the pipeline at different levels of the health care 
system: point-of-care, peripheral lab, and reference lab (Figure 1.5). New diagnostics typically 
go through several stages before they are released onto the market or endorsed by WHO. 
Currently, there are few point-of-care diagnostics on the market due to the challenges of 
delivering this type of diagnostic (McNerney and Daley, 2011). Some point-of-care tests in 
various stages of development include antigen detection in urine, volatile organic compound 
(VOC) detection, ß-lactamase detection and 2nd generation NAATS (Cheon et al., 2016).  
VOC detection was initially restricted to laboratories, but mobile electronic noses are being 
developed for use as point-of-care diagnostics (Kolk et al., 2010; Phillips et al., 2010; Bruins et 
al., 2013). This technique has poor performance during  validation as VOCs are produced for 
several clinical conditions and are not easily linked to a particular disease (Bruins et al., 2013). 
Global BioDiagnostics Corp, Texas, USA is developing a point-of-care diagnostic based on the 
hydrolysis of a -lactamase fluorogenic modified substrate by the BlaC enzyme expressed by 
M. tuberculosis. A LED based portable imaging set-up makes it suitable for low resource 
settings, but it needs further evaluation in the field (Xie et al., 2012). 
Loop-mediated isothermal amplification is well suited for point-of-care as a steady electricity 
supply is not essential.  LAMP products in development target various genes including IS6110, 
rpoB and REP13E12 (McNerney et al., 2015). Evaluation of these products is ongoing. 
Antigen or biomarker detection is a promising option for a non-sputum point-of-care test. 
Determine TB-LAM (Alere Inc., USA) is the only commercial test.  Currently, it is only 
recommended for severely immunocompromised HIV patients due to low sensitivity in other 
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tuberculosis patients(Peter, Theron and Dheda, 2013) 
New approaches to tuberculosis diagnostics rarely move past the initial stages of development 
and many have not been tested in clinical settings. Those that have made it into clinical settings 
have not performed well. Hence further innovation is needed in this space. 
 
1.9 Biomarkers of disease 
The Biomarkers Definitions Working Group defined a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention.”(Atkinson et al., 2001). 
Typical biological molecules that are used in diagnosis include: metabolites, lipids, proteins and 
nucleic acids.  
A key criterion for biomarkers intended for diagnostic purposes is that they should be 
detectable in patient specimens. Several promising biomarkers have been identified for 
tuberculosis diagnostics (Walzl et al., 2008; Tucci, González-Sapienza and Marin, 2014; Young 
et al., 2014).  The concentration of biomarkers in TB patient specimens is often correlated with 
bacterial load (Yanez et al., 1986; Boehme et al., 2005; Wallis et al., 2009), although Chanteau 
et al. speculated that secreted antigens cannot accumulate in sputum as they might in serum. 
 
Figure 1.5  Novel tuberculosis diagnostic pipeline 
There are innovations at different levels of the health care system. Image adapted from 
Cheon et al.  (Cheon et al., 2016). 
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Sputum is continuously expectorated,  but antigens in serum circulate for some time  (Chanteau 
et al., 2000). Diagnostics with several biomarkers or a bio-signature tend to have increased 
specificity and sensitivity. 
1.9.1 Patient Specimens  
Previous studies detecting biomarkers in sputum had poor specificity (33.3-95.6%) and 
sensitivity (9-60%) despite sputum originating at the site of disease and containing live 
mycobacteria (Yanez et al., 1986; Chanteau et al., 2000; Dheda et al., 2010; Reither et al., 2010). 
Culturing patient sputum specimens improves biomarker detection and allows for speedy 
verification of M. tuberculosis presence. However this approach does not contribute towards a 
point-of-care diagnostic (Park et al., 2009; Feng et al., 2011; Namba, 2013). Additional 
drawbacks are that collecting sputum poses a risk to health care workers and that some 
patients have difficulty producing sputum or have paucibacillary specimens, including HIV 
patients and children (Zar et al., 2005; J. G. Peter et al., 2012). Sputum could be a useful 
specimen for biomarker detection if sensitivity and specificity are improved. However, other 
patient specimens should be considered to avoid putting health care workers at risk and so as 
to diagnose patients who cannot readily produce sputum or who have extrapulmonary TB. 
 Several extrapulmonary specimens have been studied for biomarker based diagnostics 
including biopsies, cerebrospinal fluid and lymph node aspirate.  Diagnostic sensitivity and 
specificity range from 8-100% and 76-100% respectively across several types of 
extrapulmonary specimens and biomarkers, as laid out by a meta-analysis (Flores et al., 2011). 
Some of the most promising studies were in meningeal TB, which often has poor outcomes due 
to late diagnosis. However, obtaining cerebrospinal fluid or other extrapulmonary specimens 
is invasive; hence, an alternative procedure would be preferable (Wang et al., 2002; Kashyap et 
al., 2009; Flores et al., 2011).  
 Serum is a commonly used specimen for diagnosis of other diseases due to its extensive contact 
with the rest of the body. While serum collection is less invasive and dangerous than sputum 
collection, the needle prick is a risk factor when patients are HIV positive. Host protein 
bio-signatures in serum have been identified for TB; however, they have not been validated or 
are too expensive to implement as a diagnostic tool (Achkar et al., 2015; Xu et al., 2015). M. 
tuberculosis antigens have also been identified but not validated and may be sequestered into 
immuno-complexes (Chan et al., 2000; Kruh-Garcia et al., 2014). Looking for novel biomarkers 
in serum by mass spectrometry is complicated by albumin and immunoglobulins that mask less 
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abundant proteins. Moreover, depleting samples of albumin can result in loss of low abundance 
proteins. 
Urine is a particularly attractive specimen because it is easy to collect from everyone, is non-
invasive and poses little risk to health care workers. However, pathogen-derived biomarkers 
may be excluded by the glomerular basement membrane or, if antigenic they may be cleared by 
antibodies before reaching the urinary compartment. Hence the concentration of biomarkers 
in urine is usually low, resulting in poor sensitivity (Reither et al., 2009; Minion et al., 2011; 
Pollock et al., 2013), unless the urine samples are concentrated (Tessema et al., 2001; Choudhry 
et al., 2002; Savolainen et al., 2013). Despite low concentrations, several biomarkers including 
proteins, lipids and DNA have been identified in urine (Choudhry et al., 2002; Boehme et al., 
2005; Kashino et al., 2008; Napolitano et al., 2008; Alves da Cruz et al., 2011; Young et al., 2014). 
However, few have yet been validated or used in commercial test kits (WHO, 2015b; Cheon et 
al., 2016; Haas et al., 2016).  
In the context of TB, either host or pathogen-derived biomarkers may serve as indicators of 
active or latent disease. Host-derived biomarkers arise from changes in the host in response to 
the pathogen. Pathogen-derived biomarkers are cell components or products of the pathogen. 
1.9.2 Host-derived biomarkers 
Host-derived biomarkers include dysregulated human proteins or lipids, changes in gene 
expression, or immunological biomarkers (Walzl et al., 2011). Host-derived biomarkers are 
typically grouped to form a bio-signature or barcode. While serum is the typical clinical sample, 
differences in urine have been observed (Young et al., 2014). The two main drawbacks with 
host-derived biomarkers are: the changes are usually small and often it is difficult to find a 
bio-signature that is specific to one disease state. 
Gene expression studies aim to analyse the change in transcripts of microRNA or RNA between 
healthy and diseased states (Maertzdorf et al., 2012; Zhang et al., 2014). Most differentially 
expressed human genes for TB are related to inflammatory responses to disease, for example, 
IFN-γ inducible genes (Berry et al., 2010; Bloom et al., 2013; Lee et al., 2016). The caveat with 
this approach then is that the signature is not specific to TB.  To minimise this caveat, gene 
expression profiles from TB patients have been compared to other diseases that are clinically 
similar to TB or  are common co-infections (Bloom et al., 2013; Kaforou et al., 2013). However, 
these comparisons have only been performed with small cohorts. Gene expression signatures 
could be helpful in identifying individuals at risk of converting from latent to active TB or for 
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treatment monitoring.  However, it is currently an expensive and unreliable method for a point-
of-care diagnostic (Berry et al., 2010; Zak et al., 2016). 
Differentially expressed host proteins have also been identified which could be used as a 
bio-signature (Liu et al., 2010; Young et al., 2014; Xu et al., 2015). 
1.9.3 Pathogen-derived biomarkers 
Lipid, and nucleic acid based biomarkers are the most studied biomarkers for TB diagnosis, 
although small molecule and protein biomarkers are also being explored (Tucci, González-
Sapienza and Marin, 2014; McNerney et al., 2015; Pan et al., 2015). Nucleic acid based 
biomarkers typically have to be extracted from whole bacterium. Whole bacteria are usually 
acquired from sputum which is problematic as discussed above.   Small molecule biomarkers 
are currently only detectable by mass spectrometry (Pan et al., 2015) hence this discussion will 
focus on protein and lipid biomarkers. 
Pathogen-derived biomarker diagnostics have typically been aimed at cerebrospinal fluid for 
meningeal TB and severely immunocompromised HIV patients. Nevertheless, there is scope for 
diagnosis of pulmonary and other types of extrapulmonary TB with biomarkers (Flores et al., 
2011; Tucci, González-Sapienza and Marin, 2014; Shah et al., 2016). 
 Currently, most assays detect secreted protein biomarkers such as MPT64 after culturing the 
mycobacteria from patient samples  rather than directly from the samples (Parsons et al., 2011; 
Namba, 2013; Tu et al., 2015).   The secreted protein biomarkers are in low concentrations in 
patient samples and current techniques cannot detect them. Culturing the mycobacteria in large 
volumes increases the amount of secreted protein to levels that can be detected. 
As technology has developed, the ability to identify a broader set of potential protein 
biomarkers has improved. Instead of relying on mycobacterial components that are recognised 
by antibodies, proteins can be detected directly. For example, mycobacterial proteins have been 
identified in serum and urine using mass spectrometry (Kashino et al., 2008; Napolitano et al., 
2008; Kruh-Garcia et al., 2014; Young et al., 2014). A disadvantage of protein biomarkers is that, 
unlike nucleic acids, they cannot be amplified by a process such as PCR albeit, they are less 
prone to degradation than nucleic acids. 
Lipids, such as the mycolic acids and LAM can also serve as biomarkers. Mycolic acids can be 
used to distinguish between mycobacterial species and to diagnose tuberculosis. However, 
current methods require expensive equipment and highly trained personnel (Butler and 
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Guthertz, 2001; Shui et al., 2012; Szewczyk et al., 2013). 
LAM is the most well-known biomarker of TB and has been extensively studied (Flores et al., 
2011). An advantage of LAM as a biomarker is that it  can be detected while still part of an intact 
mycobacterium or as a free molecule  (Hunter, Gaylord and Brennan, 1986). Detection of LAM 
in sputum is problematic however due to current antibodies not being able to distinguish 
between LAM and glycolipids from related organisms  (Dheda et al., 2010).  While LAM  is a 
promising biomarker in urine, it is present in picomolar concentrations for pulmonary 
tuberculosis (Savolainen, 2014). Hence, new analytically sensitive assays are needed to take 
advantage of this biomarker. This biomarker will be discussed in further detail in Chapter 2. 
New biomarkers as well as new means to measure biomarkers are still needed to underpin the 
next generation TB diagnostics. 
1.10 Biosensor Assays 
In order to use non- nucleic acid biomarkers as a diagnostic indicator, they typically need to be 
captured onto a surface or bead. Once the biomarker is “fixed” on the surface, a detection 
strategy can be employed with a complementary labelled recognition element or a label-free 
method. Detection (or signal transduction) techniques for biosensors include electrochemical 
detection, fluorescence and colorimetric outputs, as well as label-free methods such as SPR and 
SERS (Zhou, Battig and Wang, 2010; Citartan et al., 2012; Ping et al., 2015).  
Point-of-care biosensors are typically either part of a handheld device or a compact benchtop 
system. Current handheld devices are mostly restricted to lateral flow systems. Although there 
have been incremental developments in lateral flow technology, features inherent to this 
technology limit sensitivity and multiplexing (Posthuma-Trumpie, Korf and Van Amerongen, 
2009; St John and Price, 2014).  Emerging lab-on-chip technology or microchips are set to 
overcome the short comings of lateral flow systems (Stedtfeld et al., 2012; Sanghavi et al., 
2015).  
Molecules can adsorb non-specifically to surfaces. However in most diagnostic assays, the 
biomarker is captured onto the surface by a molecular recognition element (Lopez and Schnaar, 
2006). Specific immobilisation onto the surface with a molecular recognition element is 
preferable for heterogeneous solutions such as patient samples. Target molecules can be 
purified from other components of a mixture that may contribute to the background signal. 
Binding affinity is a measure of how well a molecular recognition element binds to its target 
and it is usually expressed as a molar concentration such as nanomolar affinity. It is defined at 
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equilibrium by the dissociation equilibrium constant (KD) which is the quotient of the reactant 
concentrations and product concentration or the ratio of the dissociation and association rate 
constants,  𝑘𝑜𝑓𝑓 and  𝑘𝑜𝑛 respectively, at equilibrium. For fluorescent and colorimetric detection 
systems, a secondary binding agent attached to an a fluorescent molecule or enzyme is required 
(Khatkhatay and Desai, 1999). The two recognition elements must bind in two discrete 
locations on the target molecule. Hence a label free method of detection is desirable. Antibodies 
are the most common molecular recognition elements, but aptamers are now also becoming 
prominent. 
Further discussion will focus on aptamers as molecular recognition elements.  
Aptamers are short nucleic acid or peptide molecules that have binding capabilities against 
several types of molecules including proteins, lipids and carbohydrates with affinities from the 
micromolar to nanomolar range (Betat et al., 2003; Masud et al., 2004; Boese and Breaker, 
2007; Bruno et al., 2009; Low, Hill and Peccia, 2009).  Nucleic acid aptamers are typically 
selected by an in vitro selection called Systematic Evolution of Ligands by Exponential 
Enrichment (SELEX)(Tuerk and Gold, 1990), which will be discussed in more detail in 
Chapter 4.  Peptide aptamers can be selected by phage or ribosome display, where peptides are 
displayed on the exterior of  a phage or ribosome and exposed to the target of interest (Kase et 
al., 2004; Zahnd, Amstutz and Plückthun, 2007). 
Peptide aptamers have greater chemical diversity, but the number of molecules that can be 
tested or selected with phage display methods is more limited than for DNA or RNA aptamers 
with SELEX. During phage display, the diversity of the library is limited by the transformation 
efficiency of bacterial cells, but ribosome display overcomes this. Ribosome display does not 
rely on any transformation into bacterial cells.  Random mutations can also be introduced after 
each round with ribosome display (Zahnd, Amstutz and Plückthun, 2007). Peptide aptamers 
function in much the same way as binding pockets of enzymes or antibodies where the most 
favourable amino acids are selected for the ligand. Peptide interactions typically rely on 
hydrogen bonds, acid base interactions and hydrophobic pockets (Hermann and Patel, 2000).  
Nucleic acid aptamer interactions depend on deep pockets to make up for imperfect fitting, pi 
interactions with nitrogenous bases, ionic interactions with the phosphate backbone, grooves 
created by Hoogsteen pairing and other interactions depending on the target.  Hydrogen bonds 
are important because they offer short-range directionally specific interactions which often 
confers specificity.  
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DNA aptamers tend to have lower affinity for their targets compared to RNA or peptide 
aptamers (Rowe, Miller and Plaxco, 2010) due to the lack of the reactive 2’ hydroxyl group 
present on RNA and the several amino acid side chains on peptide aptamers.  Nucleic acid 
aptamers have more flexibility because each monomer has seven rotatable bonds whereas 
proteins only have two(Davies et al., 2012).  
Aptamers are well suited for biosensors for several reasons. Aptamers can be raised against 
non-immunogenic biomarkers identified by for example mass spectrometry. Synthesizing 
oligonucleotides, especially ssDNA, is more cost effective and reproducible than polyclonal 
antibody production. Since aptamers are smaller than antibodies, they can be immobilised with 
higher density on surfaces which provide a larger dynamic range for detection (Tijssen, 1985; 
Liss et al., 2002; Esteban et al., 2013). Biosensor surfaces with aptamers can be more easily 
reused by regenerating  the surfaces (Kirby et al., 2004). While antibodies need refrigeration, 
DNA aptamers are more resilient at ambient temperatures which would be beneficial for 
resource-poor settings without electricity.  
Aptamers have been used in several biosensor formats. An adaption of the antibody-based 
ELISA using aptamers is called an Enzyme Linked OligoNucleotide Assay (ELONA) or  enzyme 
linked aptamer assay (ELAA) (Drolet, Moon-McDermott and Romig, 1996).  
Aptamers have also been used in more modern technology such as label-free electrochemical 
sensors and lab-on-chip or microfluidic devices (Huh and Erickson, 2010; Rowe, Miller and 
Plaxco, 2010; Janssen et al., 2012; Larguinho et al., 2015; Liu et al., 2015; Ueno et al., 2015; 
Zheng et al., 2015)  
However, DNA aptamers have the disadvantage of being chemically limited, having a tendency 
for high off-rates. Chemical limitations are somewhat offset by the large shape repertoire in a  
oligonucleotide library (Davies et al., 2012). 
In order to expand the scope of interactions between nucleic acid aptamers and targets, the 
nucleotides may be modified. Modified aptamers have been shown to have increased affinity 
and are better at targeting challenging targets such as glycoproteins (Li et al., 2008). Drawbacks 
of modified aptamers include the variable success with modified aptamers and the time 
consuming processes needed. However, these pitfalls are being addressed with improved 
technology and certain modifications have had continued success (Diafa and Hollenstein, 
2015).  
Aptamers may be modified at the sugar base, nitrogenous base or phosphate backbone (Diafa 
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and Hollenstein, 2015). A combination of modifications can be used. For example, the aptamer 
against the hyaluronic acid binding domain of CD44 had  a modified backbone and a small drug 
like molecule attached to the nitrogenous base (He et al., 2012). 
 Base modifications are made at the C5 of pyrimidines (e.g. UTP, TTP) or the N7 of 7-deaza-
purines (ATP) (Figure 1.6). Modifications can be tailored to most likely improve binding to a 
particular molecule, for example a positive amino group, and was attached at the C5 position 
when selecting against the negatively charged sialyllactose (Masud et al., 2004). Other 
examples include a boron modified aptamer against a glycolipid molecule (Li et al., 2008) and 
attaching hydrophobic groups to facilitate hydrophobic interactions (Vaught et al., 2010). 
Aptamers modified with amino acid side chains to mimic proteins have been dubbed 
SOMAmers. Simplistically SOMAmers aim to mimic the hydrophobic pockets of 
immunoglobulins with amino acid side chains attached to the base (Figure 1.7). 
 
 
Figure 1.6 Examples of base modifications  
Several different molecules can be attached to the nucleotide base. Image adapted from 
Diafa and Hollenstein (Diafa and Hollenstein, 2015).  
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Figure 1.7 SOMAmers 
Examples of amino acid side chains attached to nucleotides to generate SOMAmers. 
Image adapted from Diafa and Hollenstein (Diafa and Hollenstein, 2015). 
 
The in vitro selection should be done with the modifications in place, as post selection 
modification has been shown  to diminish binding rather than to improve it as the whole 
structure changes (Lato et al., 2002). Modification made post-selection is sometimes tolerated 
(Mendelboum Raviv et al., 2008) 
In order to select modified aptamers against a target the modification should not disrupt the 
ability of RNA or DNA polymerase to replicate the aptamer sequence during the PCR step of the 
selection process. However, some selection processes do not require replication (Boiziau and 
Toulmé, 2001). Methodologies for aptamer selection will be discussed in a later chapter. Hence, 
modified aptamers are viable and promising molecular recognition elements for the detection 
of TB biomarkers. 
 
1.11 Aims and Objectives  
The aim of this thesis is to explore an innovative approach towards developing a point-of-care 
diagnostic tool for tuberculosis in resource-poor settings. While the focus of this thesis is 
tuberculosis, this methodology can be in principle applied to new biomarkers identified in any 
disease.  
The main objectives of the thesis are as follows: 
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• To determine if LAM can be detected in TB patient urine by concentrating the urine.  
• To use an in-house ELISA to determine if a secreted M. tuberculosis protein can be 
detected in urine.  
• To select modified aptamers against M. tuberculosis derived biomarkers. 
• To characterise aptamers selected against tuberculosis derived biomarkers. 
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2 LAM IN URINE 
2.1 Introduction 
2.1.1 LAM 
LAM is a glycolipid embedded in the cell envelope of M. tuberculosis. It is found both in the 
membrane and as a free lipid in the outer lipid layer. LAM consists of a branched arabinose 
structure with a mannan core attached to a phosphatidyl-myo-inositol mannoside (Hunter, 
Gaylord and Brennan, 1986; Hunter et al., 1990; Chatterjee et al., 1992) with two carbon chains, 
usually tuberculosteric acid (C19) and palmitic acid (C16) (Gilleron et al., 2000). The most 
abundant size of LAM is 17.4 kDa, however it can vary ± 4 kDa due to different numbers of 
glycan units or other appendages (Venisse et al., 1993; Nigou, Vercellone and Puzo, 2000).   
LAM also has various capping motifs on the tip of the arabinose branches depending on the 
species of mycobacteria (Figure 2.1). Pathogenic species such as M. tuberculosis, 
Mycobacterium bovis (including the BCG vaccine strain) (Venisse et al., 1993), 
Mycobacterium avium (Khoo, Tang and Chatterjee, 2001), Mycobacterium kansasii and 
Mycobacterium leprae have mannose caps; this type of LAM is designated manLAM. Non-
pathogenic mycobacteria may have inositol phosphate caps (piLAM) such as 
Mycobacterium smegmatis (Khoo et al., 1995) or no capping motifs (araLAM) such as 
Mycobacterium chelonae (Guerardel et al., 2002) and an avirulent strain of M. tuberculosis (H37Ra) 
(Chatterjee et al., 1991). 
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Figure 2.1 Structure of LAM across various species  
 The common structure of LAM consisting of the mannan backbone and 
phosphoinositol group is delineated by a red dotted line.  Three different capping 
motifs are delineated by a blue dotted line.  From left to right; ManLAM; piLAM 
and AraLAM. Image from Sarkar et al. (Sarkar et al., 2014).  
 
 LAM is an immunomodulator, which means it helps the bacterium to avoid destruction within 
the macrophage (Knutson et al., 1998; Nigou et al., 2001). The differing caps affect how the host 
immune response reacts; AraLAM is proinflammatory (Gilleron et al., 1997) and manLAM is 
anti-inflammatory, hence manLAM stalls the inflammatory response.  LAM vesicles are 
intentionally released by M. tuberculosis at the primary site of infection to regulate the host 
response. Therefore, LAM may serve as a good diagnostic biomarker as it is able to escape the 
macrophage phagosome and be released into the blood stream, making it more likely to be 
present in urine which is a convenient and safe specimen  (Xu et al., 1994; Beatty et al., 2000). 
 Antibodies against M. tuberculosis antigens have been previously detected in patient blood, 
which led to the investigation of serologic-based diagnostics by many researchers (Sada et al., 
1992; Steingart et al., 2011). Later, LAM was identified as a specific antigen, amongst others 
(Sada et al., 1990). Although several studies have successfully detected antibodies against 
M. tuberculosis antigens, a feasible serum-based diagnostic test has yet to be developed and 
commercialized (Steingart et al., 2007). A diagnostic test that does not require growing or 
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visualizing the mycobacterium may lead to faster and more affordable diagnosis of patients 
suspected of having tuberculosis. 
Sada et al. suggested that if there was an antibody response to LAM, it was likely that LAM would 
be present in tuberculosis patient blood and thus an antigen could be detected, rather than 
antibodies (Sada et al., 1992). Unfortunately the detection of LAM in patient blood samples is 
hampered because LAM forms complexes with anti-LAM antibodies and high density 
lipoproteins, concealing LAM amongst the immunoglobulins and micelles  (Chan et al., 2000, 
2015; Sakamuri et al., 2013).  Given this limitation, other matrices were explored, which 
included urine. 
M. tuberculosis antigens in urine were recognised  by Wildbolz in the early 20th century (Young, 
1924), and LAM is currently the most frequently studied tuberculosis antigen in urine (Flores 
et al., 2011). However the sensitivity of detection varies from 8-80% when clinical and culture-
confirmed cases are combined (Minion et al., 2011). Patients with a  high bacterial load in their 
sputum are more likely to have a positive urinary LAM ELISA (Boehme et al., 2005).   The 
sensitivity of ELISAs also increases for HIV patients, as they become more immunosuppressed. 
Increased levels of LAM detected in urine samples may be due to genitourinary TB, renal failure 
and mycobacteriuria (Dheda et al., 2010; Shah et al., 2010; Jonathan G Peter et al., 2012).  
 Up to 20% of pulmonary patients develop the urogenital  form of extrapulmonary TB (Abbara 
and Davidson, 2011), which would account for some of the LAM detected in urine (Figure 2.2). 
A report that compares Xpert MTB/RIF® to the Clearview® LAM ELISA supports the idea that 
LAM in urine originates from viable M. tuberculosis being present in the renal tract compartment 
(Wood et al., 2012). While not all LAM positive patients were Xpert MTB/RIF® positive, the 
limit of detection of the LAM ELISA is approximately 10-fold lower than that of the Xpert 
MTB/RIF® assay. A recent study showed that 10 CFUs (culture forming units) of M. tuberculosis 
is sufficient to give a signal of   ~1.5 OD, which is well above the cut-off  value for the LAM ELISA 
(Savolainen et al., 2013), while the limit of detection for Xpert MTB/RIF® is nominally about 
130 CFUs although in practice the limit of detection is closer to 1000 CFUs. Few cells are 
necessary for a positive test because LAM makes up a large proportion of the cell wall (15mg/g 
of the dry weight of mycobacteria) (Hunter, Gaylord and Brennan, 1986).  
Viable M. tuberculosis and LAM from degraded bacteria in the blood may also contribute to the 
levels of LAM in urine (Shah et al., 2010). The glomerular basement membrane (GBM) would 
have to be damaged for viable M. tuberculosis or immuno-complexed LAM to enter the urinary 
tract, however free LAM can fit through the intact glomerular membrane (Figure 2.2) (Cox et 
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al., 2015). BCG-vaccinated individuals tend to have more circulating anti-LAM antibodies, and 
therefore less free LAM is likely to be present in those individuals (Chan et al., 2015). Since most 
TB patients do not have either extrapulmonary disease or renal dysfunction, only small 
amounts of free LAM are likely to enter the urinary tract. Consequently, some studies have 
concentrated urine samples as a means to increase the likelihood of LAM detection. 
 
 
Figure 2.2 Mechanisms of LAM entry into urine  
1 and 6) M. tuberculosis is present in the urogenital organs so whole bacteria can be 
detected in urine. 2 and 3) A damaged GBM allows whole M. tuberculosis cells or 
immuno-complexed LAM to enter the urine. 4 and 5) Free LAM filters through the 
GBM into the urine and is not reabsorbed into the blood stream.  
Image from Cox et al.  (Cox et al., 2015).  
 
Tessema concentrated urine samples and achieved good sensitivity and specificity in his assays 
(Tessema et al., 2001). However this approach is impractical in a clinical setting, and others 
attempted to create assays using unprocessed urine samples instead (Boehme et al., 2005; 
Daley et al., 2009). After poor sensitivity results were obtained with unprocessed urine, a study 
concentrated urine with a 10 kDa molecular weight cut off (MWCO) filter before applying it to 
the Clearview LAM ELISA in a cohort of advanced immunosuppressed HIV patients. 
Concentrating the urine only marginally increased the mean sensitivity from 33% to 38% 
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(Lawn et al., 2009). The increase in sensitivity may have been greater if a smaller filter pore 
size had been used, as some LAM (17 kDa) could have been lost through the 10 kDa filter. 
Salvolain et al. used a cohort of HIV negative patients and concentrated urine 100-fold with a 
7.5 kDa MWCO filter, and were able to improve the assay sensitivity from 7 % to 57% 
(Savolainen et al., 2013).  These findings suggest that LAM is present in urine, however it cannot 
be detected by current tools without prior sample concentration.  
The detection of LAM in urine is very specific unless the patient has certain urinary tract or 
bladder infections, such as Candida albicans, that can cross react with the anti-LAM antibodies. 
Hence urine is preferable to sputum, as the latter has too many oral commensals that may cross 
react with the anti-LAM antibodies (Dheda et al., 2010). 
2.1.2 Aims and Objectives 
We set out to confirm the findings of Tessema et al. and others across a small sample of patients 
using the Clearview LAM ELISA and a concentration method which should reduce the likelihood 
of LAM loss.  Concentrating the urine samples increases the amount of LAM bound to antibodies 
at equilibrium, and therefore should increase the resulting absorbance reading.  
The first objective of the following experiments was to determine whether concentrating urine 
by lyophilisation or evaporation would negatively affect the ELISA assay. The second objective 
was to demonstrate that by concentrating these TB patient urine samples, and consequently 
the biomarker LAM, more patients would have a positive diagnostic test, particularly if they 
were not severely immunocompromised due to HIV. 
2.1.3 Methodology 
Enzyme linked immunosorbent assays have been used since the 1970’s as a method of 
capturing and detecting various molecules (Engvall and Perlmann, 1971). The basic principle 
of ELISAs is to measure the amount of antigen adsorbed on the surface via colorimetric 
feedback dependant on the amount of enzyme indirectly attached to the antigen via one or two 
antibodies. The antigen can be adsorbed directly to the surface or captured onto the surface by 
an antibody adsorbed onto the surface (sandwich assay). A blocking agent such as BSA or casein 
prevents molecules binding non-specifically to the surface once the antibody or antigen has 
been adsorbed to the surface (Crowther, 2009). Sandwich assays tend to be more sensitive 
probably due to better retention and presentation of the antigen (Kemeny et al., 1985). Direct 
ELISAs detect the antigen with an antibody directly conjugated with an enzyme whereas 
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indirect ELISAs have two antibodies for detection, one binds the antigen (primary antibody) 
and another  enzyme conjugated antibody binds the constant region of the first antibody 
(secondary antibody) (Crowther, 2009). While several enzymes can be used, antibodies are 
typically conjugated with Horse Radish Peroxidase (HRP). HRP is a monomeric glycoprotein 
which forms stable conjugates with antibodies and has a high substrate turnover rate 
(Khatkhatay and Desai, 1999). While several substrates are available for use in conjunction 
with HRP, 3,3',5,5'-tetramethylbenzidine (TMB) is the most sensitive and rapid.  
2.2 Methods 
2.2.1 Patient Population 
Ethical approval was obtained from the Human Research Ethics committee at the Faculty of 
Health Sciences, UCT.  HREC/REF: 787/2014 to collect and use patient urine for research 
pertaining to diagnostic research. Healthy volunteers do not require ethical approval. 
UA cohort patient samples used in these experiments were HIV positive with a CD4 count < 200 
cells/µl (Appendix A: Table A1), whereas LAMP cohort patients were either HIV negative or had 
a CD4 > 200 cells/µl (Table 2.1).   
TB disease was confirmed with culture and IGRA tests were performed to classify latent 
tuberculosis disease.  
Table 2.1 LAMP Cohort 
LAMP Study No HIV CD4 TB  status 
28 Positive 486 TB-Pos 
33 Negative  n/a TB-Pos 
44 Negative  n/a TB-Pos 
151 Positive 214 TB-Pos 
227 Negative  n/a TB-Pos 
254 Positive  n/a TB-Pos 
271 Negative  n/a TB-Pos 
275 Positive 240 TB-Pos 
298 Negative  n/a TB-Pos 
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2.2.2 Urine preparation 
Urine samples collected from healthy volunteers and patients were thawed (if needed) and 
centrifuged for 15 min at 3000 rcf to remove debris. The supernatant was concentrated either 
by lyophilisation or evaporation, and reconstituted in a smaller volume. Urine samples were 
frozen at -80 °C in volumes of 10 ml, and   were then lyophilised for ~8 h to remove most liquid. 
Samples were also concentrated by evaporation while being centrifuged to retain dried 
material. Lyophilised and evaporated samples were reconstituted in 1-1.5 ml of PBS (Sigma # 
P4417; pH 7.4).  Any particulate matter was pelleted by centrifugation for 5 min at 3000 rcf and 
the supernatant was used for the subsequent assays. Whilst the UA cohort urine samples were 
fresh, the LAMP cohort of urine samples were frozen. Additionally, neat healthy volunteer urine 
was adjusted to pH 7 with sodium hydroxide (NaOH) to approximately match the pH of PBS. 
After processing all urine samples were frozen at -80 °C. 
2.2.3 LAM ELISA 
The Clearview® ELISA was performed as per manufacturer’s instructions. Briefly, 100 µl of 
urine was incubated in a well of a 96 well plate for ~1 h. After ~1 h the urine was discarded, 
and the plate was washed three times with wash buffer (PBS, pH 7.4; 0.05% Tween 20). Anti-
LAM HRP conjugated antibody (100 µl) supplied in the kit was added to the wells and incubated 
for ~ 1 h.  Another set of three washes was performed and then 100 µl of the substrate TMB 
was added. TMB was incubated for 15 min before the reaction was stopped with 100 µl of 
1 M sulphuric acid (H2SO4), and the absorbance of each well was read at 450 nm with an iMark 
microplate reader (BioRad). A negative and positive control were included (supplied in kit) and 
samples were performed in duplicate or triplicate. The cut-off value was calculated as per the 
manufacturer’s recommendation by adding 0.1 to the negative control. Incubations with urine 
and antibody were performed at 37 ⁰C.  
Binding curves where created using purified LAM kindly donated by the Lung and Infection 
Immunity Unit, University of Cape Town or BEI Resources, NIAID, NIH (Mycobacterium 
tuberculosis, Strain H37Rv, Purified Lipoarabinomannan (LAM), NR-14848). A 2-fold dilution 
was performed in order to plot a binding curve.  
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2.3 Results 
2.3.1 Binding curves 
In order to assess if concentrating urine or adjusting the pH of the urine would change the 
performance of the ELISA, five different media based on healthy volunteer urine were spiked 
with LAM at various concentrations. The binding curves are presented in Figure 2.3. The 
different media did not change the linear nature of the curve, although the lyophilized and 
evaporated samples had slightly reduced signals overall. The concentrated samples had a signal 
~0.1 OD units lower than the PBS based sample at the highest concentration of LAM. Urine with 
a neutral pH did not change considerably compared to neat urine. 
 
 
Figure 2.3 Binding curves for concentrated, neat and pH adjusted healthy volunteer 
urine spiked with LAM.  
 PBS-Phosphate Buffered Saline (control); NEAT-unconcentrated urine; LYO-urine 
concentrated by lyophilisation; EVAP-urine concentrated by evaporation; PH-urine 
adjusted to ~pH 7.  Columns indicate the mean reading of duplicate wells.  Error bars 
indicate the minimum and maximum readings taken. 
Chapter 2: LAM in Urine  
     49 
2.3.2 Concentrated Urine Samples 
Given that concentrating the urine did not severely impact the performance of the spike-in 
assay, we concentrated patient urine samples to compare the differences in LAM detection 
using concentrated and unconcentrated samples.  
LAM ELISA - UA Cohort  
Ten random culture-confirmed TB patient’s urine from the UA cohort were concentrated via 
lyophilisation from 10 ml to 1-1.5 ml and compared to unconcentrated urine or to previous 
results of the unconcentrated sample (Figure 2.4). The results are presented in Table 2.2, and 
results from previous experiments are denoted “neat (database)”. Some neat samples were not 
tested again.  It appeared that all samples that were positive in the concentrated batch were 
also positive when neat urine was tested, with the exception of UA 133 which was negative in 
the repeat experiment but had previously tested positive. The ratio of concentrated versus neat 
urine was calculated to estimate the fold change in signal (Table 2.2).  The UA310 and UA215 
concentrated sample gave a marginally greater signal than the neat urine. 
LAM ELISA - LAMP Cohort 
Nine culture confirmed TB patients with a CD4 count >200 cells/µl or who were HIV negative 
were selected from the LAMP cohort. Urine samples were concentrated via lyophilisation from 
10 ml to 1-1.5 ml and compared to unconcentrated urine. The results are presented in Figure 
2.5. Two out of the nine patients had a positive result with neat urine. Two additional patients 
had a positive result after concentrating the urine. All patients who had a positive result had a 
higher signal after concentrating the urine. The ratio of concentrated versus neat urine was 
calculated to estimate the fold change in signal (see Table 2.3 LAMP cohort results). 
Concentrating the urine improved the signal for four of the nine TB patients. Two changed from 
negative to positive after concentrating. 
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Figure 2.4 Concentrated and Neat urine for UA cohort 
 *UA158 had absorbance >3.5 OD for concentrated and neat samples and the 
indication range of the iMark (BioRad) is 0.0-3.5 OD. Neat samples for UA122, UA137, 
UA144, UA145 and UA167 were not tested in this experiment. Cut-off was determined 
by adding 0.1 to the negative control. Columns indicate the mean reading of duplicate 
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Concentrated  - - * - + - + + + + 
Neat  - - * - + np np np np np 
Neat (database) + - + - + - + + + + 
Conc: Neat  ratio 1.06 1.03 * 1.34 1.13 np np np np np 
 * Signal >3.5 Note: Indication range of iMark (BioRad) is 0.0-3.5 OD, np: not 




Figure 2.5 Concentrated and Neat urine for LAMP cohort 
 Conc urine: Urine concentrated by lyophilisation; Neat urine; unprocessed urine 
from the same patient sample. Cut-off was determined by adding 0.1 to the negative 
control. Columns indicate the mean reading of duplicate or triplicate wells.  Error 
bars indicate the minimum and maximum readings taken. 
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2.4.1 Binding curves 
Samples concentrated by lyophilisation or evaporation were compared to PBS and neat urine.  
The concentrated urine matrix gave a slightly lower signals compared to the PBS or the neat 
samples. This could be due to the method of concentration which increased the salt 
concentrations of the samples. Solutions with a higher ionic strength are known to increase the 
disassociation between antibodies and their targets (Reverberi and Reverberi, 2007) which 
would result in a lower OD reading. In future experiments it would be beneficial to use methods 
of concentration that do not result in high salt concentrations, such as MWCO columns. 
Purification columns and MWCO filters have been used in the past, however some LAM could 
be lost during this kind of process if the filter pore sizes are too large (Tessema et al., 2001; 
Lawn et al., 2009).  
Urine adjusted to pH 7 was also compared to PBS and neat urine. Urine with a neutral pH did 
not change considerably compared to neat urine which suggests the slightly acidic pH of urine 
is not detrimental to the assay. 
Since the matrix effects due to concentration of urine did not appear to be significant, 
lyophilization of a test cohort of patient urine samples was used to explore the effect of 
concentrating urine on LAM ELISA results. 
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2.4.2 UA cohort 
In the first ELISA with concentrated patient urine, patients had culture confirmed TB and were 
HIV positive. Patients with culture confirmed TB were selected to assess if concentrating the 
urine would allow for increased detection of LAM. Eight of these patients had a CD4 count of 
< 200 cells/µl, except for patients UA144 and UA167 whose CD4 count was unknown.  In 
agreement with several publications most of these patients who were HIV positive with a CD4 
count of less than 200 cells/µl were LAM positive (Jonathan G Peter et al., 2012; Lawn et al., 
2012). In addition, patient UA310 had renal disease which could have likely led to antigenuria. 
However, patient UA215 also had renal disease and did not have a positive LAM result with 
concentrated or unconcentrated urine although the concentrated urine sample did have a 
higher OD reading than the neat sample. Hence, renal disease is not necessarily a predictor of 
whether a TB patient will be LAM positive or not. UA133 was LAM negative in this set of 
experiments however in an ELISA performed by collaborators this patient was LAM positive. 
This could be due to LAM being lost in the precipitation that sometimes forms when freezing 
urine (Mataija-Botelho et al., 2009). 
UA310’s signal did not increase dramatically after concentrating the urine, which could be due 
to the fact that the antibodies were saturated, and thus the signal could not be further increase. 
According to the binding curve performed by Savolainen et al. the maximum concentration of 
LAM is ~20 ng/ml that yields a reading of  3 OD (Savolainen et al., 2013). A limitation of this 
study is that a saturation curve of LAM spiked in urine was not performed to quantify the 
amount of LAM in each patient. 
2.4.3 LAMP cohort 
In the second set of LAM ELISA experiments patients had culture confirmed TB and were either 
HIV negative or HIV positive with a CD4 count of >200 cells /µl. Patients LAMP 28 and LAMP 
151 were positive before and after concentration, while LAMP 44 and LAMP 275 became 
positive after concentration. LAMP 44 was HIV negative and LAMP 151 was HIV positive with 
a CD4 count of 214 cells /µl.  The fold increase of the signal was not proportional to the 10-fold 
concentration of the urine, which may be partially due to the slightly dampened signal observed 
in the concentrated urine matrix in the calibration curves (Figure 2.5). 
 In this second experiment we have shown that the sensitivity of the conventional LAM ELISA 
is suboptimal, as patients may have LAM present in their urine even if they are HIV negative, 
but it is not detected by the LAM ELISA without concentrating the urine. This warrants the 
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exploration of methods which are more sensitive, while retaining specificity for detection of 
LAM in urine.  
2.5 Conclusion 
 Although concentrating urine samples caused the signal to be slightly dampened concentrating 
TB patient urine still increased the number of patients that were LAM positive.  This exploratory 
work formed the foundation for the search of a more sensitive and specific capture agent in 
order to improve the detection of LAM in unprocessed urine. In future work the BCG status of 
patients should be taken into consideration. 
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3 PROBING FOR ESAT-6 AND 
CFP-10 IN URINE AND SPUTUM 
3.1 Introduction  
3.1.1 ESAT-6 and CFP-10 
 Early secreted antigen target 6 kDa (ESAT-6) was first discovered as part of a cohort of T-cell 
antigens secreted by Mycobacterium tuberculosis (M. tuberculosis) (Andersen et al., 1991, 1995; 
Sørensen et al., 1995). Although initially estimated to have a molecular weight of 6 kDa, ESAT-
6 is in fact a ~9 kDa protein (The UniProt Consortium, 2014). It was subsequently revealed that 
culture filtrate protein 10 kDa (CFP-10) is co-expressed with ESAT-6 because they are encoded 
together in an operon (Berthet et al., 1998). Although both proteins are found in culture filtrate 
they lack classic secretion signal sequences (Vizcaíno et al., 2010). Guinn et al. identified key 
genes for the ESAT-6 secretion system 1 (ESX-1) by mutating genes flanking ESAT-6 (Rv3875) 
and CFP-10 (Rv3874) (Guinn et al., 2004). Many of the genes do not have readily predictable 
functional domains, however ATPases and transmembrane proteins have been identified 
among the key components (Digiuseppe Champion and Cox, 2007). 
ESAT-6 forms a tight 1:1 heterodimer with CFP-10 which provides thermodynamic and 
biochemical stability to both proteins (Figure 3.1) (Renshaw et al., 2002; Meher et al., 2006). 
However, they also form homodimers, and CFP-10 can interact with another protein encoded 
by gene Rv3873 (Teutschbein et al., 2009). In an acidic environment, such as inside the 
macrophage (Vandal, Nathan and Ehrt, 2009), ESAT-6 and CFP-10 dissociate and the 
monomeric ESAT-6 binds to lipid bilayers via hydrophobic helices; this may be important for 
M. tuberculosis escape from phagosomes (de Jonge et al., 2007).  
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3.1.2 Pathogenesis 
The region of difference 1 (RD-1) that encodes ESAT-6 and CFP-10 is absent in the attenuated 
BCG vaccine strain (Figure 3.2) (Harboe et al., 1996; Cole et al., 1998). M. tuberculosis with a 
RD-1 deletion imitates the attenuated BCG vaccine strain implicating this region directly in 
pathogenesis (Lewis et al., 2003). Similarly, insertion of the RD-1 region into an attenuated 
strain increases virulence (Pym et al., 2002) and decreased virulence is observed when ESAT-6 
and CFP-10 expression or secretion is halted (Wards, de Lisle and Collins, 2000; Stanley et al., 
2003; Guinn et al., 2004). Other  mycobacteria  and  Gram positive microbes have orthologs of 
ESAT-6, as well as the other genes found in the RD-1, but mycobacteria have multiple copies of 
the gene cluster containing ESAT-6 and CFP-10 in  contrast to other Gram positive bacteria (Gey 
Van Pittius et al., 2001).  
The means by which ESAT6, CFP-10 and other components of the RD-1 contribute to 
pathogenesis are unclear however several mechanisms have been proposed: modulating 
macrophages (Basu et al., 2006; Tan et al., 2006; Pathak et al., 2007; Kumar et al., 2012);  
participating in macrophage cytolysis (Hsu et al., 2003; Derrick and Morris, 2007; Guo et al., 
2012); facilitating escape from vacuoles (van der Wel et al., 2007; Smith et al., 2008); and 
driving granuloma formation (Volkman et al., 2010).  
 
Figure 3.1 ESAT-6 and CFP-10 
heterodimer   
Image adapted from Renshaw et al.  
(Renshaw et al., 2005) 
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Figure 3.2 Region of deletion 1 (RD-1)  
The RD-1  is absent in BCG  (Ganguly, Siddiqui and Sharma, 2008). 
 
3.1.3 Immunodiagnostics 
TB diagnostic assays such as IGRAs, the TST and antibody response assays measure the 
adaptive immune response against M. tuberculosis. ESAT-6 and CFP-10 induce a strong Th-1 
cell response (Ravn et al., 1999; Colangeli et al., 2000; van Pinxteren et al., 2000), accordingly 
they are used in commercially available IGRAs such as the T-SPOT®.TB (Oxford Immunotec, 
Abingdon, UK) and QuantiFERON®-TB Gold (Cellestis, VIC, Australia), and the improved TST 
(Elhay, Oettinger and Andersen, 1998). The use of RD-1 antigens in these tests differentiates 
BCG vaccinated individuals from those exposed to a mycobacterial infection (Whelan et al., 
2010). However, these tests cannot distinguish between patients exposed to M. tuberculosis, 
clinically latent TB patients and active TB patients (Janssens et al., 2007) since memory T-cells 
from previous exposures are activated when they are exposed to mycobacterial antigens. 
Nevertheless, a positive IGRA, negative culture result and no clinical signs of TB is often used 
as the definition of latent TB disease in studies (Lalvani et al., 2001; Demissie et al., 2006) since 
at present it is the best workable definition researchers can offer. The state of M. tuberculosis 
during clinical latent disease is unclear although in vitro and animal models suggest that the 
bacteria enter a persistent, non-replicating state (Wayne and Sohaskey, 2001). More recently 
TB disease has been viewed as a continuum between latent and active TB disease where M. 
tuberculosis is at varying stages of persistence, making the definition of active and latent disease 
less clear cut (Young, Gideon and Wilkinson, 2009). Hence, when patients are classified as 
“latent TB infection” the assumption should not be that the mycobacteria are in a latent or 
non-replicating state. 
Other studies have assayed the humoral immune response against ESAT-6, CFP-10 (Dillon et 
al., 2000; Silva et al., 2003; Legesse et al., 2013) and a combination of fused M. tuberculosis 
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proteins (Feng et al., 2014). However, antibody based TB diagnostic assays typically suffer from 
low sensitivity hence they are not employed in diagnosis and there are no commercial assays 
available (Steingart et al., 2011). 
3.1.4 ESAT-6 and CFP-10 as diagnostic biomarkers 
Given the caveats of measuring immune responses to M. tuberculosis proteins an alternative 
strategy is to detect proteins directly in patient samples to diagnose TB. Sputum contains whole 
mycobacteria hence secreted proteins such as ESAT-6 and CFP-10 ought to be present in the 
mucus matrix. Urine from TB patients contains mycobacterial  proteins, some of which may be 
degraded (Choudhry et al., 2002; Kashino et al., 2008; Young et al., 2014). Proteins from the 
same PE/PGRS family as ESAT-6 and CFP-10 are among the proteins detected, hence it is 
plausible that they are also present in urine (Young et al., 2014). 
ESAT-6 and CFP-10 are good candidates for diagnostic biomarkers since M. tuberculosis 
maintains a high level of ESAT-6 transcripts in a mouse model during the replicating and 
non-replicating state although expression was reduced during the non-replicating state (Shi, 
North and Gennaro, 2004; Davidow et al., 2005; Rogerson et al., 2006). Immune response 
studies in humans provide indirect evidence that ESAT-6 and CFP-10 are expressed during 
various disease states including clinically latent, mild  and extensive TB  (Ulrichs et al., 2000; 
Pathan et al., 2001; Doherty et al., 2002; Silva et al., 2003; Ravn et al., 2005). 
One caveat to keep in mind is that ESAT-6 and CFP-10 orthologs are present in other 
mycobacteria (Gey Van Pittius et al., 2001), hence using these biomarkers may be prone to cross 
reactivity in certain settings. For example, non-tuberculous mycobacteria such as 
Mycobacterium avium can be pathogenic especially in immune suppressed individuals 
(Hawkins et al., 1986), so any cross-reactivity of tests for M. tuberculosis ESAT-6 or CFP-10 with 
M. avium orthologs could be confounders to diagnosis. 
Basic tools for detecting ESAT-6, CFP-10 and other secreted proteins are available. For example, 
ESAT-6, CFP-10 and MPT-64 have been used to differentiate M. tuberculosis complex isolates 
from contaminating species in cultures in place of traditional biochemical tests or expensive 
molecular methods (Park et al., 2009; Shen et al., 2011). Additionally,  CFP-10 was detected in 
the urine of extrapulmonary TB patients (Hong et al., 2011; Kim et al., 2013, 2015), ESAT-6 in 
cerebrospinal fluid  (Kashyap et al., 2009) and both proteins in pleural fluid (Feng et al., 2011). 
The detection of ESAT-6 and/or CFP-10 in patient samples could provide a simple approach to 
diagnosing TB. However, current tools for detecting these proteins require a concentration of 
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~5 µM for a ESAT-6/CFP-10 fusion protein (Feng et al., 2011) or 105 CFU/ml for culture 
supernatants  (Park et al., 2009) while detection of biomarkers in urine and unprocessed 
sputum would require more sensitive assays. Hence, improved tools are needed for the 
detection of biomarkers in urine and sputum. 
3.1.5 Aims and Objectives 
The aim of the experiments described in this chapter was to determine if ESAT-6 and CFP-10 
could be detected in TB patient urine and sputum samples. 
First an in-house ELISA was used for the detection of ESAT-6, however following the 
observation of a high background signal in human derived samples western blot and mass 
spectrometry analysis was performed to identify a cross reactive element. 
Secondly, targeted mass spectrometry techniques were used to probe for ESAT-6 and CFP-10 
in TB patient urine samples. 
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 This method was described in the previous chapter. An in-house ELISA was developed in our 
lab to detect ESAT-6 using an indirect sandwich format (Figure 3.3). 
 
 
Figure 3.3 In house ESAT-6 indirect sandwich ELISA diagram 
Summary:  
• Immobilised anti-ESAT-6 monoclonal antibodies capture ESAT-6.  
• A polyclonal anti-ESAT-6 antibody (primary antibody) binds to immobilised ESAT-
6. 
•  HRP conjugated anti-rabbit IgG (secondary antibody) binds to the primary 
antibody.  
• TMB substrate is converted to a blue solution if HRP is present.  
• Sulphuric acid is used to stop the reaction which results in change of colour from 
blue to yellow. 
•  The absorbance of the wells is then measured at 450 nm. 
There are washes between each incubation to remove excess reagents. 
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Western Blot 
Western blots are a common molecular biology tool. Briefly, proteins separated by 
electrophoresis are transferred to a 0.45 µM nitrocellulose membrane before being incubated 
with a primary antibody and an HRP conjugated secondary antibody. An HRP substrate is 
converted into a chemiluminescent product which is used to detect proteins that bound to the 
primary antibodies (Gallagher, 2004). Diagrams of the western blots used in this study can be 
viewed in Figure 3.4 and Figure 3.5. 
 
 
Figure 3.4  Diagram of the western blot to detect ESAT-6 
Summary:  
• A monoclonal anti-ESAT-6 antibody (primary antibody) binds to protein band. 
•  HRP conjugated anti-mouse IgG (secondary antibody) binds to the primary 
antibody 
• An HRP substrate is converted to a chemiluminescent product.  
• Protein bands bound by antibodies are visualised. 
There are washes between each incubation to remove excess reagents. 
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Figure 3.5 Diagram of the western blot to test cross reactivity 
The HRP conjugated anti-mouse IgG antibody is denoted as the ‘secondary’ antibody to 
show the relationship to the previous western blot (Figure 3.4) although it is the 
primary antibody in this assay. 
Summary:  
• HRP conjugated anti-mouse IgG binds to a protein band.  
• An HRP substrate is converted to a chemiluminescent product.  
• Protein bands bound by antibodies are visualised. 
There are washes between each incubation to remove excess reagents. 
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RP-HPLC MS/MS 
 Proteins are commonly digested with trypsin, and the resulting peptides are separated by 
hydrophobicity with Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
before analysing the peptides with tandem mass spectrometry (McLafferty, 1981; Murray et al., 
2013). Peptides are ionised by electrospray ionization (ESI) to form precursor ions as they are 
eluted off the RP-HPLC column. The Q-Exactive mass spectrometer is commonly used for 
targeted mass spectrometry since molecules with a known mass to charge ratio can be 
selectively filtered and quantified (Figure 3.6)  (Miller and Denton, 1986). The Orbitrap mass 
analyser has high mass resolution, and allows for parallel reaction monitoring (PRM), where 
many product ions can be detected after fragmentation of the precursor ion in parallel 
(Makarov, 2000; Peterson et al., 2012). Product ions are generated by predictably fragmenting 
precursor ions by Higher-energy C-trap dissociation (HCD) and can be computationally 
deconvoluted for analysis  (Tang, Thibault and Boyd, 1993; Olsen et al., 2007).  
The intensity measurements of the fragment ions can be used to generate an MS2 spectrum for 
the product ions. A chromatogram can also be generated with intensity plotted against time to 
indicate when the peptides were eluted off the column. In the total ion chromatograms (TIC), 
the intensity signal contains the summed intensities for all ions of several m/z values at a 
certain time point (Figure 3.7) (Hoffmann et al., 2007). Using a database of proteins digested in 
silico, peptides can be inferred by matching MS1 and MS2 mass spectra to a database (Eng, 
McCormack and Yates, 1994). Proteins can be inferred from these peptides although unique 
peptides are necessary to distinguish proteins that contain the same peptides. A decoy 
database, usually a reverse of the real database, is used to reduce false positive identifications 
(Elias and Gygi, 2007).  
All product ions associated with a particular precursor ion are visualised together on the 
chromatogram at the retention time of the peptide (Figure 3.8). This information can be used 
to specifically detect and quantify peptides in a sample. For targeted mass spectrometry 
peptides should be consistently observed i.e. have good ionisation and at least one peptide 
should be unique for specific detection (Gallien, Duriez and Domon, 2011).  
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Figure 3.6 The Q-Exactive quadrupole-orbitrap mass spectrometer 
Note the high-energy collision dissociation (HCD) cell and the quadrupole and orbitrap 
mass analysers. Adapted from (Michalski et al., 2011) 
 
 
Figure 3.7 Mass spectra depicted on a graph  
Image from Math Works (Math Works, 2017). 
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Figure 3.8  A set of product ions on a chromatogram  
Each colour represents a different product ion.  The y-axis indicates intensity of the ion 
and the x-axis indicates the retention time. Retention time is in minutes. 
3.2 Methods  
3.2.1 Patient Population 
Ethical approval was obtained from the Human Research Ethics committee at the Faculty of 
Health Sciences, UCT. HREC/REF: 787/2014 to collect and use patient urine and sputum for 
diagnostic research purposes.  
Active TB patients are defined as having a positive sputum culture result for M. tuberculosis 
while LTBI patients had a negative culture but two positive T-SPOT®.TB results. Patients were 
classified TB negative if the culture and T-SPOT®.TB result were negative. Where indicated 
patients were tested for HIV infection. 
 UA cohort urine samples from TB positive patients were used. Healthy volunteers donated 
urine samples to be used as controls. Patient details can be viewed in Appendix A: Table A3. 
 TB-Neat (TBN) cohort patient sputum samples with active TB (TB positive), latent TB infection 
(LTBI) and no TB (TB negative) were used. Additional details about sputum samples can be 
viewed in Appendix A: Table A5. 
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OI/E cohort urine samples were grouped into 1) TB positive; HIV negative 2) TB positive; HIV 
positive 3) TB negative; HIV positive and 4) TB negative; HIV negative (Appendix A:Table A 8)  
3.2.2 Urine Sample Preparation  
Urine samples collected from healthy volunteers and patients were thawed. Debris and 
precipitant formed during freezing was removed by centrifugation at 3000 rcf for 15 min prior 
for ELISA experiments. 
For the ELISA and in-gel digestion experiments the supernatant was concentrated either by 
lyophilisation or a molecular weight cut off (MWCO) filter. For lyophilisation urine samples 
were frozen at -80 ⁰C in 10 ml aliquots and lyophilised for ~8 h to remove most liquid. 
Lyophilised samples were reconstituted in 1-1.5 ml of PBS (Sigma # P4417; pH 7.4). Another 
10 ml aliquot was filtered through a 5 kDa MWCO (Vivaspin) until the sample had been 
concentrated approximately 10-fold. Concentrated samples were stored at -20 °C. Any 
particulate matter was pelleted by centrifugation for 5 min at 3000 rcf before use in any 
subsequent assays. 
3.2.3 Sputum Sample Preparation  
Sputum was processed by the Lung Infection and Immunity Unit at the University of Cape Town. 
The sputum samples were liquefied by incubating the sputum with two volumes of 0.01% 
dithiothreitol (DTT) in PBS. Once the DTT was added the sputum was vortexed briefly and then 
placed on a roller for 30 min. After 30 min, the sputum was deemed liquefied. The liquefied 
sputum was then heat inactivated at 100 °C for 30 min. 
3.2.4 ESAT-6 ELISA 
A 96- well microplate (Corning® 96 well EIA/RIA plates; CLS3590-100EA) was coated with 
mouse anti-ESAT-6 monoclonal antibody (BioPorto) in bicarbonate/carbonate coating buffer 
(100 mM) at pH 9 overnight at 4 °C. The plate was washed once with wash buffer before 
incubating the plate with 200 µl of blocking buffer (PBS containing 1% Bovine Serum Albumin 
(BSA) and 0.02% azide) for 1-2 h. The plate was washed before adding 100 µl of samples (urine 
or sputum) and controls in duplicate or triplicate. Plates were incubated for 1-2 h. After 
washing, rabbit anti-ESAT-6 polyclonal antibody (ABR-Affinity Bioreagents), diluted 1:500 in 
PBS was added and incubated for 1-2 h. After washing, the secondary antibody, horse radish 
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HRP-conjugated anti-rabbit IgG (R&D Systems, #HAF008), was diluted 1:500 in PBS and added 
to each well and incubated for 1-2 h. The plate was washed before adding 100 µl of chromogenic 
substrate TMB and incubated at room temperature for 20 min in the dark. Stop solution (1 M 
sulphuric acid) was added to terminate the reaction. The absorbance of each well was read at 
450 nm with an iMark microplate reader (BioRad). 
PBS was used as the negative control except for the binding curve assay where each curve had 
the corresponding medium as a control. All incubations were at 37 °C with a plate sealer and 
the plate was washed four times with wash buffer (PBS containing 0.05% Tween-20) unless 
otherwise stated.  
Binding curves were generated by performing a 1:2 serial dilution of recombinant ESAT-6 
(rESAT-6) homodimer (Statens Serum Institute) starting with 10 ng/ml in the various media. 
Healthy volunteer urine was used for binding curve assays. The cut-off value was determined 
by calculating the standard deviation of the negative control and adding three times the 
standard deviation to the negative control. 
3.2.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis  
For Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) sample was 
denatured by boiling in sample loading buffer (12 mM Tris-HCl pH 6.8, 1% (v/v) β-
mercaptoethanol, 0.4% (w/v)  Sodium Dodecyl Sulphate (SDS), 5% glycerol, 0.02% (w/v) 
bromophenol blue) for 10 min. Samples were loaded onto a 16% tricine polyacrylamide gel and 
proteins were separated by electrophoresis for 30 min at 50 V (constant voltage) then at 120 V 
(constant voltage) until the dye front had reached the end of the gel (Schägger, 2006). 
Alternatively, urine samples were loaded on a pre-cast 4-20% gradient gel (BioRad, #456-
1093) and separated at 100 V (constant voltage) until the dye front reached the end of the gel 
(~1.5 h). A protein ladder (10 µl) (#26619, Thermo Scientific) was used to estimate the 
molecular weight of proteins.  
3.2.6 Western Blot 
After the proteins had been separated by electrophoresis the polyacrylamide gel was 
transferred to a western blot apparatus where the proteins were transferred to a 0.45 µm 
nitrocellulose membrane for 50 min at 300 mA or 30 min at 500 mA (constant current). The 
nitrocellulose membrane was blocked overnight with 5% (w/v) fat free milk (Elite, Clover) in 
Tris buffered saline (20 mM Tris and 150 mM NaCl) with 0.1% (v/v) Tween-20 (TBST), and 
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then probed with anti-ESAT-6 monoclonal antibody (BioPorto), diluted 1:500 or 1:1000 in 
blocking solution. Excess antibody was removed by washing with TBST three times for 5 min. 
After washing the membrane was incubated with the secondary antibody, anti-mouse IgG-HRP 
(R&D Systems, #HAF007) diluted 1:500 or 1:1000 in blocking buffer for 1.5 h. After washing 
the membrane, it was incubated with the recommended volume of SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific) for 5 min or Western Bright enhanced 
chemiluminescence substrate (Advansta #K-12045-D20) for 2 min. The membrane was then 
exposed to film for varying time periods (1-30 min) and developed with manual developer and 
fixer (AGFA Healthcare # E43HP G150 and # E43JR G354) or bands were visualised with a 
Syngene G-Box and analysed with GeneTools and GeneSnap. 
3.2.7 Proteomics 
Bicinchoninic Acid (BCA) Assay 
The concentration of the total protein in the urine samples was determined using the Pierce™ 
BCA protein assay kit (#23225; ThermoScientific). A two-fold dilution series of BSA (0.03-
2 mg/ml) was used to generate a standard curve. 25 µl of each standard and the protein 
samples was added to microtitre wells in duplicate. The BCA working reagent was prepared by 
combining 50 parts reagent A with 1 part Reagent B. 200 µl of the working reagent was added 
to each well and incubated for at 30 min at 37 ⁰C. The absorbance was read at 595 nm. The 
standard curve was used to interpolate the total protein concentration for each urine sample. 
In Gel Digestion 
Four TB culture positive patients from the UA cohort were used for this experiment. Urine 
samples were concentrated using a 5 kDa MWCO filter (Vivaspin) (Appendix A: Table A3). 
 Proteins in the urine sample were resolved on a 4-20 % pre-cast gradient gel (BioRad, #456-
1093) (see 3.2.5) and stained using AcquaStain (Bulldog-Bio; #AS001000). The gel was placed 
over the western blot image and the corresponding bands were cut from the gel. Gel slices were 
sliced into 1 mm3 cubes and transferred to glass vials (#702_283; Machery-Nagel). Two bands 
were cut out per patient namely a 25-35 kDa and 130-250 kDa band. 
The excised gel pieces were processed as previously described by (Shevchenko et al., 2007). Gel 
pieces were destained with 100 mM ammonium bicarbonate/ acetonitrile (1:1 v/v) for 
~30 min. The destaining solution was removed before 80 µl of 10 mM of DTT in 100 mM 
ammonium bicarbonate was added. The gel pieces were incubated with DTT at 60 ⁰C for 30 min 
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and cooled to room temperature before incubating for 10 min adding with 500 µl of acetonitrile. 
The acetonitrile was removed and 80 µl of 55 mM iodoacetamide (IAA) in 100 mM ammonium 
bicarbonate was added. The gel pieces were incubated for 20 min in the dark and acetonitrile 
was added to shrink the gel pieces.  
Once gel pieces were shrunk they were saturated with 13 ng/µl trypsin (Promega; #V5111) in 
ammonium bicarbonate containing 10 % (v/v) acetonitrile for 120 min on ice. Additional 
ammonium bicarbonate was added to keep the gel pieces moist. The tubes were placed in a wet 
chamber at 37 ⁰C overnight (~16 h) to digest the proteins. 
To extract the resulting peptides, 100 µl of extraction buffer (1:2 (v/v) formic acid/ acetonitrile) 
was added to each tube. The supernatant containing the peptides was transferred to glass 
inserts (#0609035; Aluglas) and dried in a vacuum centrifuge in preparation for C18 stage tips 
clean up. 
In solution Digestion 
Recombinant CFP-10 (rCFP-10) and rESAT-6 (100 ng), and urinary protein from the E/OI 
cohort samples were precipitated with methanol and chloroform, and digested with trypsin 
in-solution by Dr B. Calder.  
One volume of protein in solution was added to one volume of methanol and a three-quarter 
volume of chloroform in a glass bottle (e.g. 400 µl protein + 400 µl methanol + 300 µl 
chloroform). After mixing, the sample was centrifuged for 5 min at 13 000 rpm (~17 800 rcf). 
The upper phase was removed and discarded; proteins are present in the white interphase disc 
and in the bottom phase. An additional three-quarter volume of methanol was added to the 
bottom phase and the protein was pelleted by centrifugation for 1 min at 13 000 rpm (~17 800 
rcf). The supernatant was discarded, and the pellet was air dried. The pellet was resuspended 
in as little denaturation buffer (6 M urea, 2 M thiourea in 10 mM Tris pH 8.0) as possible (ideal 
concentration: 1- 2 µg/ml). 
The resuspended protein was quantified via a modified Bradford assay: 1 µl sample, 90 µl 0.1 M 
HCl and 150 µl Bradford reagent (BioRad).  Samples were incubated for 5 min before measuring 
the absorbance at 595 nm. 100 µg of protein was tryptically digested, except for rESAT-6 and 
rCFP-10 where ~100 ng was used. 
For the in-solution digestion reduction buffer (1 M DTT in 50 mM ammonium bicarbonate 
(ABC)) was added to the sample to a final concentration of 1 mM DTT and incubated for 1 h at 
room temperature. Next, alkylation buffer (550 mM iodoacetamide in 50 mM ABC) was added 
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to a final concentration of 5.5 mM IAA and incubated for 1 h at room temperature in the dark. 
Samples were then diluted with four volumes of 20 mM ABC buffer. If pH was not ~ pH 8 it was 
adjusted with 20 mM ABC. Trypsin was added to the sample at a 100:1 ratio (Promega; 
#V5111) overnight at room temperature (at least 16 h).  
The reaction was stopped by acidification with 1 % formic acid until pH 2 to 3 was achieved. 
Samples (10 µg) were cleaned up with in-house C18 stage, prepared by packing C18 filters 
(Empore) into pipette tips (Rappsilber, Ishihama and Mann, 2003). All stage-tip centrifugation 
was performed at 4000 rpm (~1440 rcf). C18 stage tips were activated with solvent B (80 % 
acetonitrile with 0.1 % formic acid) and then equilibrated with solvent A (2 % acetonitrile with 
0.1 % formic acid). Samples were resuspended in 100 µl of solution A and loaded onto the HPLC 
columns. The bound samples were then washed three times with solvent A. The peptides were 
eluted with solvent C (60 % acetonitrile with 0.1 % formic acid) into a glass vial and dried in a 
vacuum centrifuge. Samples were resuspended in 15 µl of solvent A for mass spectrometry 
analysis. 
LC/MS Instrumentation and Parameters 
Mass spectrometry analysis was performed with the assistance of Dr B. Calder, Mr B. Murugan 
and Dr A. Nel.  
Discovery and targeted proteomic analysis was performed on a Q-Exactive Quadrupole-
Orbitrap mass spectrometer (Thermo Scientific), coupled to a Dionex UltiMate 3500 RSLC 
nano-LC system (Thermo Scientific). Sample (400 ng) was introduced onto a 100 µm x 4 cm 
trap column packed in-house with C18 coated silica beads (5 μm Luna C18 resin, Phenomenex). 
Separation was performed by reversed phase chromatography on a nanoscale analytical 
column, also packed in-house (Aeris peptide solid bead C18 #04A-4507, 75 μm x 40 cm). 
Ionisation was attained by application of charge over a stainless-steel emitter (Thermo 
Scientific, Cat#: TFES542) affixed to the end of the analytical column. 
Discovery MS 
Mass spectrometric analysis was controlled by Xcalibur software (Thermo Scientific; v2.2). and 
acquisition parameters were developed in-house based on the work by Pirmoradian et al.  
(Pirmoradian et al., 2013). Default settings were as follows: ‘Top 10’, data-dependent and 
positive ion mode. MS1 settings included a resolution of 70000, scan range of 300-1750 m/z 
automatic gain control (AGC) target of 3E6, and an ion injection time of 250 ms. At the MS2 level 
the setting were as follows: isolation window of 4.0 m/z, a normalised collision energy (NCE) of 
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25, resolution of 17500, AGC target of 5E4 and ion injection time of 80 ms. Data dependent 
settings included an underfill ratio of 1% (which equates to an intensity threshold of 1.7x104), 
peptide match set to “preferred, isotopic exclusion, and a dynamic exclusion of 30 s. Charge 
exclusion was set to all unassigned charges, as well as all charges other than 2 or 3. 
Samples were eluted using a linear 145 min gradient at a constant flow rate of 300 nl/min. The 
sample was loaded onto the column with 2% acetonitrile (ACN, LC-MS Ultra, Sigma in UPHPLC 
grade water) for 10 min. The sample was then eluted with 8% ACN at 12 min, 40% ACN at 130 
min and finally with 80% ACN at 135 min. Washes were performed between each sample with 
80% ACN for 10 min. An additional wash was performed after four samples. 
Targeted MS 
Targeted assays were generated in Skyline for CFP-10 and ESAT-6 tryptic peptides based on a 
spectral library generated from discovery MS data. A spiked sample was included, which 
contained 100 ng of purified CFP-10 and ESAT-6 proteins as a positive control. 2-plex PRM data 
was acquired at a resolution of 35000, with the AGC target set to maximum and a 50 ms 
injection time. The normalized collision energy was set to 27 and a 2.0 m/z mass error tolerance 
was allowed. The chromatography conditions used for targeted MS were identical to those used 
for discovery MS.  
 
3.2.8 Bioinformatics 
Protein/Peptide Identification  
Data from the discovery experiments were processed by MaxQuant version 1.5.3.12 which uses 
the Andromeda search engine (Cox and Mann, 2008; Cox et al., 2011). A human  and 
M. tuberculosis proteome database  from UniProt were used (Human_UP000005640 and 
M. tuberculosis (strain ATCC 25618 / H37Rv)_ UP000001584 downloaded Feb 2016)  (The 
UniProt Consortium, 2014). Raw files from the in-gel digestion were run separately using the 
human proteome (one 25-35 kDa and 130-250 kDa gel slice per patient). Data from urine 
samples spiked with rESAT-6 or rCFP-10 were run using with the human and M. tuberculosis 
proteomes. 
The Andromeda search engine identified peptides by matching experimental MS1 and MS2 
spectra with theoretical spectra generated from an in silico tryptically digested human 
proteome. False identifications were predicted by the target-decoy approach using a reversed 
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decoy database (Elias and Gygi, 2007). PSM, peptide, and protein FDRs were set at 1% and a 
minimum of one unique peptide were required to make an identification. Unique peptides 
belong to only one protein or protein group and do not share complete sequence homology 
with any other protein or protein group. MaxQuant parameters are tabulated in Appendix 
A:Table A6.  
Analysis of protein groups from in-gel digestion  
The MaxQuant data output was assessed using the protein.groups.txt file. Contaminants, reverse 
sequence hits and trypsin (A6XMV8) were excluded from the protein groups. 
To narrow the search for the cross-reactive elements the following filters were applied to the 
proteingroups.txt file. Experiments were divided into the 25 kDa-35 kDa and 130-250 kDa 
fractions. Within each fraction, proteins or protein groups that were not present in all four 
patients and without a least one unique peptide in each patient were excluded. Protein group 
refers to a group of proteins which share peptides and unique peptides therefore they cannot 
be differentiated from each other. Unique peptides were used as a measure of confidence in the 
protein identity. The lists were sorted from largest to smallest intensity. Proteins or protein 
groups with a high intensity also having a high protein score indicating a more significant hit 
were included. The protein score in the proteingroups.txt document is derived from the 
Posterior Error Probability (PEP) which gives a significance score. 
 To simplify further analysis the majority protein in a protein group was used; this protein has 
the most peptide hits in the protein group. The majority protein of each protein group was 
searched in the UniProt database for further information including names and domain 
properties. The reduced lists for each fraction were compared using BioVenn (Hulsen, de Vlieg 
and Alkema, 2008).  
Generation of targeted proteomics isolation list 
The MaxQuant data output was assessed using the protein.groups.txt and peptide.groups.txt 
files. All detected peptides for ESAT-6 and CFP-10 were included in the isolation list for targeted 
proteomic analysis (Appendix A: Table A 9). A spectral library was generated in Skyline based 
on the MaxQuant msms.txt output, and used to select the best fragment spectra for each peptide 
in the isolation list.  
Skyline Analysis 
All spectral data was manually inspected in Skyline (64-bit version 3.6.0.10493) to confirm 
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auto-selected peak boundaries. Where the auto-selected peak boundaries did not match the 
control spike retention time the boundaries were manually corrected to within a 1-2 min 
window of the control spectra. Five to ten ions for each precursor where chosen based on 
intensity, symmetry of the peak and assigned rank. Product ions not present in both the control 
spike and the spectral library were deleted. Three peptides for each protein were chosen for 
displaying the data based on control spike dot-p values and proteotypic peptides that had 
previously been observed (Schubert et al., 2013).  
3.3 Results 
3.3.1 ESAT-6 ELISA 
An in-house ESAT-6 ELISA protocol developed by Dr Teri Roberts was used to explore the 
detection of ESAT-6 in patient samples (Figure 3.3). Previously no ESAT-6 was detected in neat 
urine samples from TB patients. To determine if ESAT-6 could be detected in urine, TB positive 
patient urine was concentrated to increase the likelihood of detection of any ESAT-6 that may 
be present.  
Binding Curves 
In order to assess the effect of concentrated urine on the performance of the ELISA and to 
determine the limit of detection of the assay, three different media were spiked with ESAT-6 at 
various concentrations (Figure 3.9 and Figure 3.10): neat urine, urine concentrated ~10 fold 
via lyophilisation and PBS, which served as the control. The cut-off for a positive result was 
defined as an absorbance signal greater than the negative control mean plus three standard 
deviations. Hence the limit of detection for each medium was the lowest absorbance reading 
above the cut-off. The approximate limit of detection for PBS, lyophilised urine and neat urine 
were 1.25 ng /ml; 0.63 ng/ml and 0.31 ng/ml of recombinant ESAT-6 (rESAT-6) respectively.  
The neat urine and lyophilised urine resulted in favourable shaped curves with good linearity 
in the lower concentration range. However, the lyophilised urine did not reach saturation at a 
similar concentration to the PBS or neat urine and the overall absorbance readings were 
greater than the PBS and neat urine readings. 
ESAT-6 ELISA with urine samples 
Patient urine samples were concentrated to compare the differences in ESAT-6 detection using 
concentrated (concentrated ~10 fold using lyophilisation or 5 kDa MWCO filter) and 
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unconcentrated samples (Figure 3.11). No neat urine samples gave a reading above the 
negative control. Concentrating with the MWCO filter resulted in greater absorbance signals 
than concentration by lyophilisation for most samples with a reading above the cut-off. 
Concentrating the urine increased the signal above the cut-off for two TB positive patients, 
however, two healthy volunteers also had a reading above the cut-off (Appendix A: Table A4). 
Of the two TB patients with a signal above the control, one had renal disease and proteinuria 
(UA215), but the other patient did not have renal disease or proteinuria (UA141). Additionally, 
patient UA310 had renal disease but did not have a signal above the negative control (Appendix 
A: Table A3). Concentrating urine with a MWCO filter generally increased the ESAT-6 ELISA 
signal more than concentration by lyophilisation.  
ESAT-6 ELISA with sputum samples 
Sputum samples were also tested in duplicate using the in-house ESAT-6 ELISA. Three groups 
of patients were tested: TB positive, latent TB infection and TB negative. Three TB positive, four 
latent TB and four TB negative patients had a signal above the cut-off (Figure 3.12 and Appendix 
A: Table A5). Most of the patients were HIV negative except for patients TBN 58 and TBN 59 
who were HIV positive and TBN 274 who was not tested for HIV. 
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Figure 3.9  Binding Curve for ESAT-6 ELISA 
 A rESAT-6 homodimer was spiked into different media namely PBS, lyophilised urine, and 
neat urine. All conditions were in triplicate except for the two highest concentrations of 
the PBS curve which were in duplicate. Points indicate the mean reading of duplicate or 
triplicate wells. Error bars indicate the minimum and maximum readings taken. 
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Figure 3.10 Binding Curve for ESAT-6 ELISA 
 A rESAT-6 homodimer was spiked into different media namely PBS, lyophilised urine, 
and neat urine. All conditions were in triplicate except for the two highest 
concentrations of the PBS curve which were in duplicate. Points indicate the mean 
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Figure 3.11 ESAT-6 ELISA with urine samples 
 UA denotes TB positive patients and H denotes healthy volunteers. Samples were 
concentrated with a 5kDa MWCO filter or by lyophilisation and compared to neat urine. PBS 
was used as a negative control. Each sample was tested in duplicate. The cut-off was 
calculated by adding 3 standard deviations of the negative control to the mean negative 
control value. Samples with a mean reading above the cut-off are marked with “*”.  Columns 
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Figure 3.12 ESAT-6 ELISA with Sputum  
 TB+:  TB positive; LTBI: clinically latent or previous TB infection; TB-: TB negative. Each 
sample was tested in duplicate. Samples with a mean reading above the negative control 
are marked with “*”. Columns indicate the mean reading of duplicate wells.  Error bars 
indicate the minimum and maximum readings taken. 
 
3.3.2  Western Blots 
To investigate the source of the positive signal in the ESAT-6 ELISA in the healthy volunteer 
urine and TB negative sputum, samples were separated by electrophoresis on a SDS-PAGE and 
probed with the monoclonal anti-ESAT-6 antibody (primary antibody) followed by the anti-
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mouse IgG-HRP antibody (secondary antibody) (Figure 3.4). A ~26 kDa band was seen in 
healthy volunteer and TB positive patient urine (
 
Figure 3.13). In some samples higher molecular weight bands were also recognised at ~26, 
~42, ~52 and >135 kDa such as in this healthy sample (Figure 3.14). The ~26 kDa band was 
also observed in sputum samples from TB positive and TB negative patients which were tested 
alongside additional urine samples from TB positive patients and healthy volunteers. The TB 
positive samples with additional higher molecular weight bands also had 1-3 mg/ml of protein 
in their urine according to clinical data (Figure 3.15; Appendix A: Table A3). ESAT-6 which is 
~9 kDa was not detected in any of the TB positive samples. 
To determine which antibody was responsible for the cross-reactive bands healthy patient 
urine was also probed with only the anti-mouse IgG-HRP antibody (Figure 3.5). When urine 
samples were probed with only the secondary antibody the ~26 kDa band was present, but the 
higher molecular weight bands were not observed (Figure 3.16).  
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Figure 3.13 Western Blot with anti-ESAT-6 antibody using urine. Healthy volunteer 





Figure 3.14 Western Blot with anti-ESAT-6 antibody 
showing high molecular weight bands.  
Faint bands at ~26 and ~52 kDa were also noted. 
H3.5: Urine from healthy volunteer 
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Figure 3.15 Western Blot with anti-ESAT-6 Antibody using urine and sputum samples.  
 A) A ~26 kDa band is visible for healthy volunteer urine samples (H1.1-1.5) and a 
faint band of the same molecular weight is present for TB negative patients (negative 
culture and negative T-SPOT®.TB). 
 B) A ~26 kDa band and some other larger bands are visible for TB positive patients 
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Figure 3.16  Western blot with only anti-mouse IgG-
HRP antibody.  
Two samples of concentrated urine from a healthy 
volunteer were probed with anti-mouse IgG-HRP 
antibody (secondary antibody). 
3.3.3 Discovery Proteomics 
SDS-PAGE and Western Blot  
To identify the proteins cross reacting with either the anti-ESAT-6 primary antibody and/or 
the anti-mouse IgG secondary antibody the appropriate molecular weight protein bands were 
cut from a SDS-PAGE gel and subjected to mass spectrometry analysis (Figure 3.17). Protein 
bands were identified by a western blot that was run in parallel and overlaid onto the gel 
(Figure 3.17). We focussed on the ~26 kDa and the >130 kDa bands which were the most 
commonly observed bands. 
BCA Assay 
The total protein concentration for each urine sample was interpolated from the BSA standard 
curve (Table 3.1). By rough approximation there are seven prominent bands on the SDS-PAGE 
(Figure 3.17) therefore each of the bands removed from the gel for mass spectrometry analysis 
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UA120 0.767 1.269 12.69 1.813 
UA127 1.040 1.732 17.32 2.474 
UA211 1.790 2.971 29.71 4.244 
UA268 2.745 4.512 45.12 6.445 
LC-MS/MS 
The raw files show the MS1 and MS2 total ion chromatograms (TICs); 1st and 2nd panel 
respectively (Figure 3.18). Product ions are derived from precursor ions selected by the top 10 
method for sequencing. Spectra had several single peaks across the gradient with no visible 
contaminants. Large single peaks may indicate abundant peptides. Peptides are well 
distributed and separated across the gradient. Raw data was further processed using 
bioinformatic tools. 
Bioinformatics analysis of MS data using Max Quant 
Protein identification by MaxQuant and Andromeda identified 546 protein groups excluding 
contaminants, reverse hits, and trypsin. A wide range of protein sizes were identified in both 
gel slices (2.2 to 856.8 kDa). The majority proteins with the highest intensities for each gel slice 
can be seen in Figure 3.19 and Figure 3.20. The overall intensity is the summed up Extracted-
ion Chromatogram (XIC) of all isotopic clusters associated with the identified amino acid 
sequence. The intensity for each protein group varies between patients. 
After protein groups were excluded as described, the list was reduced from 546 to 77 protein 
groups for the 25-35 kDa gel slice and 68 protein groups for the 130-250 kDa gel slice 
(Appendix A: Table A7). About a third of all the proteins identified had Ig-like domains; the 
number of total proteins with an immunoglobulin related domain can be seen in Table 3.2 
(MaxQuant Results). 
Several of the protein groups were identified in both fractions after sorting for at least one 
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unique peptide (Error! Reference source not found.Figure 3.21 and Appendix A: Table A7).  
 The majority protein, Ig kappa chain C region (A0A087WZW8) had the highest overall intensity 
in both gel slices and would be close to 26 kDa in a dimer form and shared several Ig-like 
domains (Table 3.2) 
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Figure 3.17 Western Blot and SDS PAGE to identify bands to be excised for mass 
spectrometry analysis.  
A) 130-250 kDa bands to be excised B) 25-35 kDa band to be excised. C) Bands 
excised from SDS PAGE. E6: Positive control rESAT-6 dimer (~18 kDa); UA:  TB 
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Figure 3.18  Representative Ion Chromatogram. 
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Figure 3.19 Protein groups identified in the 25-35 kDa gel slice. 
Protein Groups with the highest overall intensity values (top ten) and the 
corresponding intensity values for each patient. Patient identifiers: UA120, UA127, 
UA211 and UA268 
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Figure 3.20 Protein Groups with the highest overall intensity values (top ten) and the 
corresponding intensity values for each patient in the 130-250 kDa gel slice.  
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Several protein groups with at least one unique peptide were present in both gel slices 
fractions (see Appendix A: Table A7 for protein IDs). 
 
 
Table 3.2 Immunoglobulin related domains identified in Ig kappa chain C region 
(A0A087WZW8) 
ID Name 
IPR007110 Immunoglobulin-like domain 
IPR013783 Immunoglobulin-like fold 
IPR013106 Immunoglobulin V-set domain 
IPR003597 Immunoglobulin C1-set 
IPR003006 
Immunoglobulin/major histocompatibility 
complex, conserved site 
Figure 3.21 Venn diagram of protein 
groups identified in different size gel 
slices.  
Generated using BioVenn © 2007-2016 
Tim Hulsen. 
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Figure 3.22 Immunoglobulin domains associated with majority proteins identified by 
MaxQuant. 
Domain names for IDs are presented in the key below (Table 3.3). 
 
Table 3.3 Key for immunoglobulin domain names of identified proteins 
KEY  
MaxQuant All MaxQuant IDs 
IPR007110 Immunoglobulin-like domain 
IPR013783 Immunoglobulin-like fold 
IPR013106 Immunoglobulin V-set domain 
IPR003599 Immunoglobulin subtype 
IPR003597 Immunoglobulin C1-set 
IPR003006 Immunoglobulin/major histocompatibility complex, conserved site 
IPR003598 Immunoglobulin subtype 2 
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3.3.4 PRM 
Discovery proteomics was performed on rCFP-10 and rESAT-6 spiked into a healthy urine 
sample. From the discovery proteomic data peptides were selected for targeted proteomics on 
patient urine samples. The four groups of patient urine samples were 1) TB positive; HIV 
negative 2) TB positive; HIV positive 3) TB negative; HIV positive 4) TB negative; HIV negative 
(Appendix A: Table A 8). 
 
The total ion chromatogram spectra had several single peaks across the gradient with no visible 
contaminants. Large single peaks may indicate abundant peptides. Peptides are well 
distributed and separated across the gradient. Raw data was further processed using 
bioinformatic tools. (Appendix A: Figure A 3). Six peptides for ESAT-6 and eight peptides for 
CFP-10 were identified by MaxQuant and included in the isolation list (Appendix A: Table A 9). 
The library dot-product (dot-p) value shows how similar the unknown samples are to the 
spectral library, which is the reference: a value of one represents a complete match. The control 
spikes of rESAT-6 and rCFP-10 had good dot-p values in the range of 0.90 to 0.98 while most of 
the patient samples had poor dot-p values ranging from 0 to 0.69 (Figure 3.24 and Figure 3.23). 
The poor dot-p values are corroborated by the chromatographs which show no appreciable 
peaks in the expected retention window (Figure 3.25 and Figure 3.26). Additional 
chromatograms for each protein are available in Appendix A (Figure A 10 to Figure A 13). 
Sample 1275 from a TB and HIV positive patient had a dot-p of 0.90 for peptide 
TQIDQVESTAGSLQGQWR from CFP-10 (Figure 3.23- B) and although the detected peaks had a 
low intensity, their shape matched that of the control spike sample and the reference spectrum 
in the spectral library (Figure 3.27). For this reason, this should be considered a positive match.  
The peak area graphs also show that transition peaks from the spectral library and the control 
spikes of rESAT-6 and rCFP-10 were comparable in terms of the type of ions detected and the 
proportion of each ion,  while most patients samples were not similar to either the spectral 
library or the control spike sample (Appendix A: Figure A 4 to Figure A 9). Patient sample 1275 
was comparable to the spectral library for peptide TQIDQVESTAGSLQGQWR (Appendix A: 
Figure A 7). 
 
 
Chapter 3: Probing for ESAT-6 and CFP-10 in Urine and Sputum  
     92 
 
 
Figure 3.23 Dot-p value comparison between TB negative patients and the control 
spike. 
A) TB negative and HIV positive patients B) TB negative and HIV negative patients. Three peptides 
where chosen from ESAT-6 and CFP-10. E6.xxxx denotes a ESAT-6 derived peptide. C10.xxxx denotes a 
CFP-10 derived peptide 
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Figure 3.24 Dot-p value comparison between TB positive patients and the control spike 
with the spectral library. 
 A) TB positive and HIV positive patients B) TB positive and HIV negative patients. Three peptides 
where chosen from ESAT-6 and CFP-10.  E6.xxxx denotes a ESAT-6 derived peptide. C10.xxxx denotes a 
CFP-10 derived peptide 
 
Chapter 3: Probing for ESAT-6 and CFP-10 in Urine and Sputum  
     94 
 
Figure 3.25 Transition chromatogram of  peptide WDATATELNNALQNLAR 
Transition chromatogram of the rESAT-6 control spike for peptide WDATATELNNALQNLAR and four 
representative patient chromatograms from each patient group at the same retention time. 
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Figure 3.26 Transition chromatogram  for peptide TDAATLAQEAGNFER 
Transition chromatogram of the rCFP-10 control spike for peptide TDAATLAQEAGNFER and four representative 
patient chromatograms from each patient group at the same retention time. 
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Figure 3.27 Comparison between spike and TB positive patient 
Comparison of rCFP-10 spike chromatogram and patient 1275 (TB+; HIV+) for peptide 
TQIDQVESTAGSLQGQWR from CFP-10. 
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3.4 Discussion 
3.4.1 ESAT-6 ELISA 
Binding Curve 
When rESAT-6 was serially diluted and spiked into neat urine, the absorbance readings from 
the ELISA produced a concentration dependant curve similar to the PBS control (Figure 3.9). 
The curve produced by rESAT-6 spiked into lyophilised urine produced a concentration 
dependant curve but did not become saturated at a similar concentration of rESAT-6 as the PBS 
and neat urine curves (Figure 3.10). An increased saturation point and greater background 
signal is an indication that the antibodies are binding non-specifically or cross reacting to other 
proteins.  
The limit of detection of rESAT-6 in neat urine was ~0.21 ng/ml. This suggests that if ESAT-6 is 
present in urine it is at a concentration less than ~0.21 ng/ml since ESAT-6 was previously not 
detected in neat urine. Alternatively, ESAT-6 is degraded and the epitopes detected by the 
antibodies are no longer intact. In lyophilised urine the limit of detection was ~0.49 ng/ml due 
to the higher background signal. Despite the increased background, we speculated that ESAT-6 
would be detectable if urine was concentrated. The limit of detection of the PBS control was the 
highest at ~0.72 ng/ml due to the greater variance in the negative control absorbance readings 
although this was still an improvement on  a limit of detection of 1 mg/ml (125 nM) reported 
for another ESAT-6 ELISA (Mukundan et al., 2012).  
Urine and Sputum Samples 
In order to increase the likelihood of detecting ESAT-6 in patient urine samples, samples were 
concentrated. Although samples were concentrated approximately ten-fold with the MWCO 
filter and lyophilisation techniques the samples concentrated with the MWCO filters were 
found to be more likely to have a reading above the cut-off value (Figure 3.11). This perhaps 
suggests that some proteins in lyophilised samples do not solubilise when resuspended. 
Previous observations were confirmed, in this experiment with no neat urine samples giving a 
positive signal. By concentrating the urine some TB patients had a positive signal above the PBS 
control, however some healthy volunteer urine samples also gave a positive signal after 
concentration (Figure 3.11). This suggests that the cross reactivity between a human protein 
and the antibodies used in the ELISA created a background signal that masked the signal of any 
ESAT-6 that may be binding. The cross reactivity could be exacerbated when patients have 
Chapter 3: Probing for ESAT-6 and CFP-10 in Urine and Sputum  
     98 
proteinuria as with patient UA215 who had the highest absorbance reading. 
Sputum samples from TB positive, latent TB and TB negative patients were also tested with the 
ESAT-6 ELISA assay (Figure 3.12). While some TB positive and latent TB patients had a positive 
signal, patients diagnosed as TB negative also had a signal above the cut-off. Hence, a pattern 
similar to that of the urine samples was noted in the sputum samples suggesting that sputum 
also contains a cross reactive element. 
3.4.2 ESAT-6 Western Blots 
 To investigate the cause of the cross reactivity in the ELISA, sputum and concentrated urine 
samples were probed via western blot using the same anti-ESAT-6 antibody used in the ELISA. 
Several cross-reactive bands were noted in TB patients and healthy individuals however the 
most commonly observed band was approximately 26 kDa (Figure 3.13, Figure 3.14, and Figure 
3.15). Patients with several cross reactive bands tended to be positive for proteinuria for 
example UA120 and UA211 (Figure 3.15; Appendix A: Table A3).  Previously, anti-ESAT-6 
antibodies have been reported to show cross reactivity against another secreted M. tuberculosis 
protein called MTP-64  which is 24 kDa (Harboe et al., 1996), however since the cross-reactive 
band is also present in healthy urine and TB negative sputum samples, it seemed most likely 
that the cross-reactive protein is of human origin rather than from M. tuberculosis.  
Since it is unlikely that the cross-reactivity stems from a monoclonal antibody, the secondary 
antibody (anti-mouse IgG-HRP) was tested alone (Figure 3.16). The same ~26 kDa band was 
visible in the blot that was only probed with the secondary antibody but no higher molecular 
weight bands were observed suggesting that both the primary and secondary antibodies are 
binding non-specifically to proteins in the urine.  
Although cross reactive bands were seen in TB positive patients no band correlating to ESAT-6 
which is ~9 kDa was observed ( Figure 3.13 and Figure 3.15). Western blot assays are typically 
less sensitive than ELISAs hence this result does not inform about the presence of ESAT-6 in 
urine. Also, ESAT-6 may be degraded since non-tryptic M. tuberculosis peptides have previously 
been detected in urine by mass spectrometry (Young et al., 2014). 
3.4.3 Discovery Proteomics 
To investigate the cross reacting antibodies used in the ELISA and western blot, the bands 
corresponding to the proteins bound by the primary and secondary antibodies were excised 
from a SDS-PAGE gel and analysed by mass spectrometry. Initially, an immunoprecipitation 
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based approach was attempted, but the yield of recovered protein was poor (data not shown) 
therefore an alternative method was needed to identify the cross reacting protein. 
Spectra obtained had several single peaks across the gradient with no visible contaminants 
(Figure 3.18), consistent with urine typically containing less protein than other samples such 
as lysed. 
MaxQuant identified 546 protein groups of various sizes (2.2 to 856.8 kDa) across all the 
samples (Appendix A: Table A7). The protein list was narrowed down as described above in 
order to identify probable candidates for the cross-reactive protein. A cut-off of one unique 
peptide was used to increase the confidence in the identifications. The overall intensity was 
used to gauge the most abundant proteins in the gel slices. The protein groups with the highest 
intensity varied across all the samples, but the top ten for each gel slice was similar across the 
four patients (Figure 3.19 and Figure 3.20). After reducing the protein lists for each gel slice 
several proteins were identified which were present in both the 25-35 kDa fraction and the 
130-250 kDa gel fractions (Figure 3.21Error! Reference source not found.). Dimers or 
oligomers due to disulphide bonds are usually separated by β-mercaptoethanol during 
reducing SDS-PAGE protocols, however it is possible for incomplete reduction to occur 
especially with proteins rich in cysteine residues. 
 Since the secondary antibody was raised against mouse IgG (western blot) or rabbit IgG 
(ELISA) it is suspected that the antibodies were cross reacting with similar motifs in human 
proteins that are homologous to mouse IgG or rabbit IgG. Indeed, several majority proteins in 
both gel slices had Immunoglobulin (Ig) or Ig–like related polypeptides (Figure 3.22). 
Ig gamma-1 chain C region (A0A087WV47) had a high intensity and score across all samples 
(Figure 3.19 and Figure 3.20), several Ig-like domains (Table 3.2) and is ~26 kDa when it forms 
a dimer (Appendix A: Table A7). Given these factors it is plausible that is the source of the ~26 
kDa cross reactive band observed in the western blot assay and ELISAs. However, it is possible 
that several proteins cross reacted with the secondary antibodies as there were many proteins 
identified with Ig-like domains and a broad range of bands were observed in the western blot 
assays (Figure 3.22). 
3.4.4 PRM  
Since antibody based techniques were deemed not suitable for detecting ESAT-6 in patient 
samples a targeted proteomic approach was used to probe urine samples for ESAT-6 and CFP-
10. 
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ESAT-6 and CFP-10 were not observed in the majority of TB positive urine samples (Figure 
3.23). Similarly, CFP-10 and ESAT-6 were not detected in exosomes from serum (Kruh-Garcia 
et al., 2014), however free M. tuberculosis proteins were detected in urine including secreted 
proteins from the PE-PGRS family (Young et al., 2014).  
In the one patient where a CFP-10 peptide was detected the clinical data revealed that the 
patient had pyuria which indicates that the patient likely had disseminated tuberculosis in the 
genitourinary organs (Figure 3.27)(Altintepe et al., 2005). 
Factors that influence the detection of biomarkers in urine include; endogenous proteolysis, 
sample preparation and low abundance of proteins in urine. First morning urinary samples are 
more prone to have degraded proteins due to endogenous proteolysis during the night, which 
reduces detection of biomarkers (Klein et al., 2013). Non-tryptic peptides were not examined 
but proteins that are inconsistently lysed are impractical for a diagnostic test. Pre-processing 
of the sample such as freezing or removing cell debris also decreases biomarker yield in the 
sample since almost half of the total protein excreted in urine is in the sediment fraction 
(Barratt and Topham, 2007).  The yield of low abundance proteins in urine and other samples 
can be increased with methods such as combinatorial peptide ligand libraries or nanoparticle 
hydrogels as discussed by Harpole et al. (Harpole, Davis and Espina, 2016). 
These biomarkers could still be useful for accelerated characterisation of cultures and detecting 
M. tuberculosis in other patient samples such as sputum and pleural fluid (Park et al., 2009; Feng 
et al., 2011; Shen et al., 2011). 
3.5 Conclusion 
In conclusion, the ESAT-6 ELISA provided no compelling evidence for ESAT-6 in urine or 
sputum and was compromised by too low selectivity. While ESAT-6 and CFP-10 are 
undetectable in urine, molecular recognition elements which do not cross react with human 
proteins would be useful for detecting these biomarkers in other bodily fluids and cultures. 
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4  SELECTING X-APTAMERS 
AGAINST MYCOBACTERIAL 
DERIVED BIOMARKERS 
4.1 Introduction  
Detection of M. tuberculosis proteins or glycolipids in clinical samples is often plagued by poor 
specificity and/or sensitivity (Kashyap et al., 2009; Dheda et al., 2010; Rotherham et al., 2012). 
Improvements in sensitivity and specificity may be achieved by enhancing the molecular 
recognition and signal transduction phases of the binding event. 
Here we selected modified aptamers, as molecular recognition elements, against CFP-10, CFP-
10·ESAT-6, LAM and KatG as a possible means to improve the detection of M. tuberculosis 
biomarkers in patient samples. 
4.1.1 Aptamers 
Aptamers are short, single-stranded 15 mg/ml, RNA or peptide molecules that bind specifically 
to other molecules. These versatile molecules have been employed for a wide range of purposes 
including analytical applications, therapeutics and diagnostic biosensors (Keefe, Pai and 
Ellington, 2010; Radom et al., 2013; Gülbakan, 2015; Hong and Sooter, 2015).   
This discussion focuses on ssDNA aptamers, because they are more robust and affordable to 
synthesize than RNA or peptide aptamers (Keefe, Pai and Ellington, 2010). ssDNA aptamers 
have been selected against a wide range of targets including small molecules (Ellington and 
Szostak, 1992), proteins (Choi et al., 2011), and whole bacteria (Duan et al., 2013; Lamont et al., 
2014).  
DNA aptamers have also been developed against whole mycobacteria and several 
mycobacterial target molecules for diagnostic and therapeutic purposes (Bannantine et al., 
2007; Chen et al., 2007; Qin et al., 2009; Shum et al., 2011). Indeed, aptamers have been selected 
against our biomarkers of interest; LAM and the CFP-10·ESAT-6 heterodimer (Rotherham et al., 
2012; Pan et al., 2014; Tang et al., 2014).  
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While ssDNA aptamers are less likely to degrade, they have limited binding configurations, 
which impacts the affinity with which DNA aptamers can bind to their targets. High affinity 
aptamers against proteins are more common since the diversity of amino acid side chain 
moieties provide a variety of binding interactions, whereas lipids and carbohydrates are limited 
in this respect. 
It is, however, possible to take advantage of the positive attributes of ssDNA aptamers, and 
simultaneously increase the scope of binding interactions, and achieve slower off-rates by 
modifying DNA with additional chemical groups (Gold et al., 2010; Diafa and Hollenstein, 2015). 
This discussion focuses on the specific chemical modifications that could enhance the binding 
affinity and specificity of ssDNA aptamers selected against LAM, CFP-10·ESAT-6 and KatG. 
4.1.2 LAM  
LAM is a promising biomarker for diagnosing tuberculosis disease. It is an abundant component 
of the cell wall, which is released as vesicles and shed from mycobacteria into the blood stream 
(Sada et al., 1992; Beatty et al., 2000). Also, Hamasur et al. commented that LAM is less likely to 
be degraded in vivo as no known human glycosidases target the specific linkages present in LAM 
(Hamasur et al., 2001). However, LAM is typically present in low concentrations in urine 
(Savolainen et al., 2013), cannot be detected specifically in sputum with current assays (Dheda 
et al., 2010), and is mostly immunocomplexed or clumped in lipid rafts in blood (Chan et al., 
2000, 2015; Sakamuri et al., 2013). Hence, innovative and sensitive biosensors are needed to 
detect LAM in patient samples. 
The only commercial assay for detecting LAM involves anti-LAM antibodies either in an ELISA 
or lateral flow assay format produced by Alere™. Inherent limitations of these assays include, 
batch to batch variation of polyclonal antibodies and the expensive production of antibodies. 
Using these assays, LAM in urine is typically detected in patients with a high bacillary load 
(Boehme et al., 2005), a low CD4 count due to HIV (Shah et al., 2010; Peter, Theron and Dheda, 
2013), or disseminated tuberculosis (Cox et al., 2015). LAM may be detected with suitable 
sensitivity for other TB patients when the urine is concentrated, however this is impractical in 
low-resource clinical settings (Tessema et al., 2001; Savolainen et al., 2013). In sputum, the anti-
LAM antibodies cross-react with Actinobacteria and other commensal oral microorganisms 
resulting in poor specificity (Dheda et al., 2010). Other bodily fluids, such as cerebrospinal fluid, 
also contain LAM which is useful for diagnosing extrapulmonary tuberculosis (Patel et al., 
2009). So, while LAM is present in many bodily fluid compartments, its detection remains 
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suboptimal. 
Several studies have attempted to improve the detection of LAM via various techniques. One 
study developed a chimeric antibody that targets the distinctive mannose capping motifs 
present on M. tuberculosis LAM (Chan et al., 2015). Targeting the mannose caps could overcome 
the specificity problem in patient sputum, however the chimeric antibody was tested only on 
urine and serum samples. In their HIV negative cohort, the authors observed improved 
detection of smear negative and smear positive TB patients, however their intrinsic limit of 
detection (0.5 to 2 ng/ml) is within the same range of current assays (Savolainen et al., 2013). 
The authors could discriminate between M. tuberculosis and the previously cross-reactive 
Nocardia cyriacigeorgica, but not between M. tuberculosis and Tsukamurella paurometabolum 
(Venisse et al., 1993; Petzold, Stanton and Leary, 2005; Chan et al., 2015).  T. paurometabolum 
and Corynebacterium matruchotii also express terminal mannose motifs. Hence, the level of 
background signal from these organisms have to be determined before this chimeric antibody 
can be heralded as a solution to the poor specificity of the current LAM antibodies observed in 
patient sputum (Sutcliffe, 1995; Gibson et al., 2004; Dheda et al., 2010).  
Another study used a combination of monoclonal antibodies and gold coated magnetic 
nanoparticles to achieve a detection limit of 0.05 ng/ml LAM; a 20-fold improvement on the 
detection limit of 1 ng/ml observed when the same antibodies were used in an ELISA format. 
The authors used a small cohort of pulmonary and extrapulmonary TB patient urine samples 
to test their Uri-TB direct assay with promising results. However, their finding that a patient 
with urogenital extrapulmonary TB tested negative for LAM is counterintuitive, which warrants 
further investigation in a larger cohort (Hamasur et al., 2015).  
Other studies have focussed on detection platforms to improve the current ELISA limit of 
detection (~64 pM) (Savolainen et al., 2013). The use of fluorescent antibodies and single 
molecule scanners or waveguide sensors permit detection limits of 10-12 to 10-15 M for LAM 
spiked into urine or plasma. The limitations of these strategies include the poor stability of the 
fluorescent antibodies, and the cost of both the antibodies and equipment. Innovation in 
portable versions of these devices is ongoing and may present an affordable solution in the 
future (Schmidt et al., 2011; Mukundan et al., 2012).   
A label free detection platform using a quartz crystal microbalance (QCM), functionalised with 
anti-LAM antibodies, failed to improve on current methods having achieved a limit of detection 
of ~60.6 nM, however the method could be improved with better molecular recognition 
elements (Hiatt and Cliffel, 2012).  Specifically, Hiatt and Cliffel mentioned that a limitation of 
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their study was the amount of anti-LAM antibody that could be immobilised to the QCM 
cantilevers due to steric hindrance (Hiatt and Cliffel, 2012). Instead, DNA aptamers (2-3 nm in 
diameter), which are substantially smaller than antibodies (12-15 nm in diameter), can permit 
higher surface density functionalisation of the QCM cantilevers with concomitantly higher LAM 
binding capacities, thereby achieving lower detection limits for LAM. Additionally, a more 
specific molecular recognition element could overcome the challenge of poor specificity 
associated with sputum samples. 
Two previous studies claim to have selected ssDNA aptamers against LAM with a KD of 400-
670 nM (Tang et al., 2016) (Pan et al., 2014). Tang et al. reported sensitivity and specificity 
values in the 80-90% range for sputum and serum. However, the lowest LAM concentration 
noted on their standard curve is 180 ng/ml (~9 nM), which is an order of magnitude higher 
than other reported concentrations of LAM in patient serum (0.8-3.1 pM) (Sakamuri et al., 
2013; Tang et al., 2016). 
Aptamers selected against other carbohydrate and lipid molecules have modest affinities  with 
KD values ranging from 10-5 to 10-7 M (Fukusaki et al., 2000; Betat et al., 2003; Masud et al., 
2004; Boese and Breaker, 2007; Low, Hill and Peccia, 2009; Wang et al., 2014). Carbohydrates 
and lipids have limited ability to bind to ssDNA aptamers since they lack positively charged 
moieties and aromatic structures, hence it is not surprising that high affinity aptamers have not 
been previously selected against these classes of biomarkers. Additionally, the negatively 
charged phosphate group on LAM may hinder selection of an aptamer due to repulsion from 
the DNA sugar-phosphate backbone. However, aptamers can bind to unsaturated carbon chains 
by either π-interactions or shape complementarity (Betat et al., 2003; Grimme, 2008).  
Modified aptamers provide an opportunity to increase the chemical diversity of ssDNA and to 
overcome the challenges of selecting aptamers against a glycolipid. Boronic acid modified 
aptamers have been used previously to improve the binding capability of aptamers to 
carbohydrate moieties (Lato et al., 2002; Li et al., 2008). Boronic acid reacts with the diols of 
carbohydrate molecules to form stable cyclic boronate esters, which should provide an anchor 
to mediate further interactions between other parts of LAM and the ssDNA aptamer. Other 
advantageous ssDNA modifications include, hydrophobic moieties such as indole, napthyl or 
indole that facilitate binding to lipid core of LAM (Vaught et al., 2010), and positively charged 
moieties such as 5-N- (6-aminohexyl)carbamoylmethy or 5-(3′′-Aminopropynyl) that interact 
with the negatively charged phosphate group of LAM (Battersby et al., 1999; Masud et al., 2004). 
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4.1.3 ESAT-6 and CFP-10 
ESAT-6 and CFP-10 are secreted proteins that form a tight heterodimer, although CFP-10 is 
more stable than ESAT-6 as a monomer (Renshaw et al., 2002; Meher et al., 2006). 
Concentrations of these biomarkers may be high in sputum samples depending on the number 
of bacteria present. As discussed previously, ESAT-6 could not be detected with an in-house 
ELISA assay, which had a nanomolar limit of detection, so it is plausible that CFP-10 is similarly 
scarce. Hence, innovative and sensitive biosensors are needed to detect ESAT-6 and/or CFP-10.  
There are no commercial assays to detect ESAT-6 or CFP-10, however there have been several 
immunoassays using a variety of detection methods. Assays that have achieved the lowest limit 
of detection (10-60 pg/ml) used a colourimetric detection method (Feng et al., 2011; Kim et al., 
2013), while other methods, such as, waveguide optical sensors coupled with fluorescent 
antibodies or surface plasmon resonance (SPR), achieved detection limits of 100-900 ng/ml 
(Hong et al., 2011; Mukundan et al., 2012). None of these assays have been tested in urine or 
sputum from patients with pulmonary tuberculosis, however the best performing ELISA could 
detect ESAT-6 in pleural fluid with a sensitivity of 100% and specificity of  95.4%, and CFP-10 
with a sensitivity of 81.6% and specificity of 92.2% (Feng et al., 2011). Each of these methods 
used antibodies, which as previously mentioned, are expensive especially when coupled to 
fluorescent reporters. 
Two studies have explored raising ssDNA aptamers against ESAT-6 and CFP-10. The first study 
selected aptamers against the CFP-10·ESAT-6 heterodimer, however the aptamers bound 
primarily to CFP-10. They reported 100% sensitivity and 68.75% specificity when detecting 
CFP-10 in sputum with aptamer CSIR 2.11 (KD = 8 nM) (Rotherham et al., 2012). CSIR 2.11 cross-
reacts with M. smegmatis, M. bovis BCG and Pseudomonas aeruginosa, of which, two have RD1 
homologues, whereas BCG does not. The cross-reactivity of aptamer CSIR 2.11 underscores the 
poor specificity associated with assays performed on sputum samples (Rotherham, 2012). 
Another research group reported aptamers with nanomolar affinity (KD = 10-7 M) against a 
recombinant CFP-10·ESAT-6 linked heterodimer. The aptamers were used in an ELONA assay 
to detect ESAT-6 and/or CFP-10 in pulmonary TB patient sera (Tang et al., 2014). While they 
claimed 100% sensitivity and 94.1% specificity, the lowest concentration in their binding curve 
was 50 ng/ml (5 nM) which seems high given that a previous study estimated that LAM, a more 
abundant biomarker, was detectable within the picomolar range (Mukundan et al., 2012).   
While some progress has been made in detecting ESAT-6 and CFP-10 with aptamer assays, 
improvements are needed to be useful under real world conditions, especially in low resource 
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settings. Modified aptamers could provide the additional sensitivity and specificity needed for 
an affordable and effective assay to detect ESAT-6 and/or CFP-10. Modified aptamers, 
particularly thioaptamers, have been selected against several proteins (Min et al., 2008; Mann 
et al., 2010; Gandham et al., 2014), but other modifications can provide specific advantages, for 
example; ESAT-6 and CFP-10 have hydrophobic regions that could be targeted with 
hydrophobic modifications, such as the aptamers developed by Kimoto et al. (Kimoto et al., 
2013). Additionally, boronic acid can form bonds with nucleophilic amino acid side chains 
(Whyte, Vilar and Woscholski, 2013), and positively charged moieties can interact with 
negatively-charged amino acid side chains. 
4.1.4 KatG 
The M. tuberculosis catalase peroxidase has a molecular weight of ~80 kDa, and is referred to 
by its gene name, katG. Catalase converts peroxide to water and oxygen, whereas peroxidase 
generates water and an activated donor molecule. Reactive oxygen species, such as peroxide, 
are by-products of aerobic respiration, which are also used by phagocytes as a bactericide to 
defend against infections. Most bacteria have an adaptive stress response triggered by the OxyR 
transcription factor to respond to reactive oxygen species (Nathan and Shiloh, 2000). OxyR in 
M. tuberculosis appears to be non-functional due to mutations in the gene, but Sherman et al 
suggest that KatG, alkyl hydroperoxidase (AhpC), and the thick cell wall composed of oxidation 
resistant lipids, provide a constitutive oxidative stress response (Sherman et al. 1996). Later 
research showed that KatG is important for resisting the oxidative surge produced by 
phagocytes, but does not appear to have additional functions (Ng et al., 2004). 
A tuberculosis prodrug, isoniazid, is activated by KatG, however some strains have developed 
resistance to isoniazid due to mutations in the KatG gene. While KatG is important for 
counteracting reactive oxidative species in phagocytes, reciprocal mutations resulting in 
increased activity of AhpC appear to compensate for the loss of KatG functionality in isoniazid 
resistant strains (Sherman et al., 1996). 
A molecular diagnostic test called a line probe assay is available to detect the mutations that 
lead to isoniazid resistance, however it is expensive and not widely used. Line probe assays 
initially amplify the KatG gene via PCR after which, the gene products are incubated with 
mutant or wild type KatG probes. DNA that either hybridises with mutant probes, or 
alternatively does not hybridise with the wild type probe indicates a mutation in the KatG gene. 
While a particular mutant may not be present in the mutant probe library, failure of the 
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amplified KatG gene to hybridise to the wild type probe alerts to the need for further testing 
(Barnard et al., 2008). While this test is useful for detecting drug resistance, it is ill suited for 
point of care diagnostics. 
The KatG catalase-peroxidase has not been used as a biomarker in any commercial assays, 
however it was detected in exosomes retrieved from serum by mass spectrometry analysis 
(Kruh-Garcia et al., 2014). KatG is thought to be secreted as it is found in culture filtrate, 
however some cytosolic proteins were also present in the filtrate due to harvesting at the late 
log phase (Sonnenberg and Belisle, 1997). Later work argued that KatG is associated with the 
cell surface rather than actively secreted (Raynaud et al., 1998). Since it is present on the 
surface of the bacterium, and may be actively secreted in exosomes this protein could act as a 
biomarker of disease. 
While no assays have been developed to detect KatG using monoclonal antibodies, ssDNA 
aptamers have previously been generated against KatG (Sonnenberg and Belisle, 1997; 
Harroun, 2014). KatG is part of the class I peroxide catalases, which share homology across 
many bacterial species (Zámocký et al., 2014). Any diagnostic test using KatG as a biomarker 
should therefore take into consideration possible cross reaction of the molecular recognition 
element with commensal bacteria present in the mouth or associated with urinary tract 
infections. In this regard, other studies have used actinomycetes, streptococcal species, and 
other oral isolates to test the cross reactivity of their TB biomarker assays (Dheda et al., 2010; 
Rotherham et al., 2012).  
Current platforms to detect these biomarkers are costly and/or ineffective. Any assay using 
current antibodies is limited by the affinity of the antibody, and steric hindrance when 
antibodies are immobilised onto surfaces. It is therefore apparent that improvements in 
molecular recognition and signal transduction are needed to improve the specificity and 
sensitivity of TB biomarker detection assays. 
4.1.5 Methodology 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX), a term coined by Tuerk 
et al. (Tuerk and Gold, 1990), is the classic method for selecting aptamers against various 
targets. The SELEX method evolved from studying protein-DNA interactions (Oliphant and 
Struhl, 1987), and in vitro evolution of ribozymes (Green et al., 1991) with random 
oligonucleotide sequences. The next development involved selecting oligonucleotides against 
molecules that do not conventionally bind to RNA or DNA (Ellington and Szostak, 1990). The 
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SELEX methodology has been adjusted to improve the process and to customise it for a range 
of targets from whole cells to small molecules (Stoltenburg, Reinemann and Strehlitz, 2007; 
Darmostuk et al., 2015). 
Conventional SELEX has four key steps, in which the oligonucleotide sequences (from a random 
oligonucleotide pool) that bind to the target are isolated and selectively enriched with each 
successive cycle (Figure 4.1). When the aptamer pool enrichment plateaus, the oligonucleotide 




Figure 4.1 Diagram of conventional SELEX workflow 
 
While conventional SELEX requires repeated cycles, some studies have reduced the need for 
multiple cycles by adapting the SELEX process (Nitsche et al., 2007; Fan et al., 2008; Arnold et 
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al., 2012). Reduced cycles or a single cycle accelerates the selection process and reduces the 
number of PCR cycles, which would otherwise lead to the amplification of unwanted DNA 
products (Musheev and Krylov, 2006). 
Another advancement is the use of high throughput sequencing which allows monitoring of the 
selection process, and elimination of random cloning techniques where high affinity binders 
may be lost (Cho et al., 2010). 
We selected modified aptamers against our targets in collaboration with AM Biotechnologies, 
LLC (AM Biotech) who have developed a bead based method for the selection process, and use 
next generation sequencing to identify putative aptamers in the final pool (Figure 4.2) (view an 
animation of process online here) (Lokesh et al., 2017).  
 
 
Figure 4.2 Bead based X-Aptamer Selection Process.   
Negative selection: The random library, attached to polystyrene beads, is incubated with 
naked streptavidin coated magnetic beads to remove the bulk of non-specific binders. 
Primary selection: Library beads not bound during the negative selection are incubated 
with target attached to magnetic beads. Secondary Pulldown: Unbound oligonucleotides are 
removed and the bound sequences are cleaved from their polystyrene beads. Cleaved 
sequences are incubated with a fresh aliquot of target attached to magnetic beads. PCR: 
Unbound sequences are removed and putative aptamers are amplified by PCR. Next 
Generation Sequencing: PCR products are subjected to next generation sequencing and 
enriched sequences are identified. Synthesis of putative X-Aptamers: Enriched sequences 
are synthesized with original modifications for validation. 
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The pseudorandom library is generated by a split and pool scheme which has an estimated 108 
sequences. A library with modified nucleotides synthesized by the split-pool method allows for 
the positions of the various modifications to be known so that the putative aptamers can be re-
synthesized accordingly after the selection process (Gorenstein et al., 2014).   
The chemical modifications introduced to our oligonucleotide library were incorporated at 
position five of deoxyribose uracil triphosphate (dUTP) with either boronic acid, phenol, indole 
or hydroxymethyl (Figure 4.3). Indole and phenol mimic hydrophobic amino acid side chains, 
whereas hydroxymethyl mimics a polar uncharged side chain. Boronic acid interacts with diols 
and nucleophilic amino acid side chains such as serine (Whyte 2013). Boronic acid was 
specifically included to aid binding to the mannan backbone of LAM while the other 
modifications were chosen to increase the general variety of binding interactions possible.  
 
 
Figure 4.3 Base modifications to UTP by AM Biotech 
Base modifications made at position 5 of UTP with one of the four moieties on the right. 
Image adapted from Diafa and Hollenstein (Diafa and Hollenstein, 2015). 
 
After the selection process and secondary pull-down, the enriched library sequences are 
amplified by PCR in preparation for next generation sequencing (Figure 4.2). The data from the 
next generation sequencing is analysed using the Aptaligner© software.  The software typically 
reduces the number of sequences from ~5 million to ~3.5 million unique sequences by 
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reducing noise and removing sequences of the incorrect length. Enriched sequences are 
identified by comparing the primary selection and secondary pulldown sequences. It uses the 
library design file to match unmodified sequences to the original modified sequences since 
modifications are lost during the PCR process. Aptaligner© also performs clustering analysis 
using a Markov model. Sequences with similar sequences that may bind to a lesser extend are 
good aptamer candidates  (Lu et al., 2014).  Final sequences are moderated to limit hydrophobic 
groups before they are synthesized for validation experiments with the targets. 
 
4.1.6 Aim and Objective 
The aim was to select X-Aptamers against CFP-10, CFP-10·ESAT-6, LAM and KatG via a bead 
based selection method to create selective molecular recognition elements for use in a 
biosensor diagnostic platform. 
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4.2 Methods 
4.2.1 Biotinylation of targets 
KatG and CFP-10 
KatG was expressed in house by Dr Andrew Nel and CFP-10 was obtained from BEI Resources 
(NR-14869) (see Appendix B for protein sequence information). Each protein was incubated 
with biotin-N-hydroxysuccinimide ester (NHS-biotin) at a 20:1 molar ratio (biotin: protein) for 
4 h with gentle agitation in the dark at room temperature. Excess biotin was removed with the 
use of SigmaSpin™ post reaction clean-up columns (#S5059, Sigma Aldrich). The columns were 
prepared and used as per the manufacturer’s instructions. Briefly, the storage buffer was 
removed by centrifugation before the sample was applied to the column and centrifuged for 4 
min at 750 rcf. The eluate containing the protein was collected. The column was washed with 
an equal volume of PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 2 mM KH2PO4; 1 mM 
MgCl2), and the eluate was collected to determine if protein was retained on the matrix. 
Bradford Assay 
The biotinylated protein concentration was determined using a Bradford assay in a 96-well 
microplate format. A two-fold dilution series of BSA (0.06-1 mg/ml) was used to generate a 
standard curve. 10 µl of each standard and the biotinylated proteins was added to microtitre 
wells in duplicate. 200 µl of diluted Bradford dye reagent (#500-0006, BioRad) was added to 
each microtitre well containing either BSA standard or biotinylated protein, and incubated for 
at least 5 min but not more than 1 h. The absorbance was read at 595 nm. The mean absorbance 
values of the BSA dilutions were plotted against their corresponding absorbance values to 
generate a standard curve. The concentrations of biotinylated KatG and CFP-10 were 
interpolated from the BSA standard curve using their corresponding mean absorbance values. 
The mean absorbance value for the negative control (PBS only) was subtracted from all other 
absorbance values before interpolation. The two aliquots of each biotinylated protein were 
pooled for the selection process. 
LAM 
100 µg of LAM from M. tuberculosis (H37Rv) (BEI Resources; NR-14848) or M. smegmatis (BEI 
Resources; NR-14849) was oxidized in a solution of 1 mM sodium periodate dissolved in a 100 
mM sodium acetate buffer (pH 5.5) for 10 min in an ice bath (0-4 °C) in the dark. Excess 
periodate was neutralised with a solution of sodium sulphite (final concentration of 80 mM) for 
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5 min at room temperature. EZ link Hydrazide-LC-Biotin (Thermo Scientific #21340) in DMSO 
was added to the oxidised LAM to a final concentration of 3.75 mM, and the reaction was 
incubated for 1 h at room temperature. The reaction was stopped by dialysing (Slide-A lyzer 
3.5 K; Thermo Scientific #88403) against a dialysis buffer (50 mM sodium phosphate, 150 mM 
NaCl, pH 7.4) for 2 h at room temperature. The initial dialysis buffer was replaced with fresh 
buffer and placed at 4 °C overnight. Adapted from (Venisse et al., 1995). The concentration of 
biotinylated LAM was estimated based on initial concentration and final volume after dialysis. 
HABA Assay Biotinylation quantitation 
The extent of biotinylation was estimated with the HABA (4'-hydroxyazobenzene-2-carboxylic 
acid dye) displacement method (ImmunoPure HABA kit; Pierce). HABA is displaced from 
streptavidin by biotin due to the significantly higher binding affinity of biotin for streptavidin. 
180 µl aliquots of a solution of HABA and streptavidin (prepared as per the manufacturer’s 
recommendations) were pipetted into microtitre wells and the absorbance was read at 490 nm 
(500 nm filter was not available). Then 1 µg of biotinylated protein or 4 µg of LAM from 
M. smegmatis was added to each well, and the absorbance was read again. The average number 
of biotin moieties per LAM molecule was calculated from the difference in absorbance between 
the two readings using the ThermoScientific online HABA calculator. A paired two-tailed T-test 
was used to assess if the absorbance reading before and after addition of the biotinylated 
molecule was significantly different using Microsoft Excel 2013. 
Western Blot  
Biotinylation of the targets was confirmed via western blot performed with a Streptavidin-HRP 
conjugate. Amounts of each sample loaded onto the gel can be viewed in Appendix B: Table A 
13. Samples were denatured by boiling in sample loading buffer (12 mM Tris-HCl, pH 6.8, 1% 
(v/v) β-mercaptoethanol, 0.4% (w/v) SDS, 5% (v/v) glycerol, 0.02% (w/v) bromophenol blue). 
A protein ladder (#26619, Thermo Scientific) was used to estimate the molecular weights of 
proteins. Proteins were separated by electrophoresis on a 12% SDS-PAGE gel for 1-2 h at 120 
V (constant voltage), and then transferred to a 0.45 µm nitrocellulose membrane at 300 mA 
(constant current) for 50 min. The nitrocellulose membrane was blocked overnight with 5% 
(w/v) fat free milk (Elite, Clover) in Tris buffered saline (20 mM Tris and 150 mM NaCl) with 
0.1% (v/v) Tween-20 (TBST), and then probed with 0.1 µg/ml streptavidin conjugated HRP 
(KPL #14-30-00). The membrane was washed three times for 5 min with TBST with gentle 
agitation. After washing the membrane, it was incubated in the recommended volume of 
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Western Bright Chemiluminescence reagent (Advansta) for 2 min at room temperature. The 
membrane was then exposed to film for varying time periods and developed with the manual 
AGFA developer (#E43HP G150) and fixer (#E43JR G354).  
Formation of ESAT-6·CFP-10 heterodimer 
Biotinylated CFP-10 and ESAT-6 (BEI Resources; NR-14868) were incubated together in Buffer 
B (PBS and 0.05% (v/v) Tween-20) in equimolar amounts (5 µM) for 1 h at room temperature 
(Rotherham et al., 2012). 
4.2.2 X-Aptamer Selection 
A custom library (~108 members) of modified of DNA (16% Phenol and Indole, 68% Indole and 
Boronic acid, 16% Phenol and Hydroxymethyl) attached to polystyrene beads was synthesised 
by AM Biotech and provided together with forward primers and barcoded reverse primers (He 
et al., 2012; Gorenstein et al., 2014).  
• Buffer A (with BSA) [PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 2 mM KH2PO4; 
1 mM MgCl2); 0.05% (v/v) Tween20 and 0.2% (w/v) BSA] 
• Buffer B (without BSA) [PBS (137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPO4; 2 mM 
KH2PO4; 1 mM MgCl2) and 0.05% (v/v) Tween20] 
Target Coupling to Magnetic beads  
Streptavidin coated magnetic beads (Invitrogen Dynabeads M270; #11205D) were 
resuspended, and a 100 µl aliquot was transferred into a 1.5 ml microfuge tube for each target. 
The magnetic particles were pelleted with the use of a magnet and the supernatant was 
discarded. The magnetic beads were washed by initially resuspending in 250 µl Buffer B, 
followed by pelleting with a magnet to remove the supernatant. The beads were washed three 
times. The biotinylated targets were resuspended in Buffer B (Appendix B: Table A 14) and 
incubated with the magnetic beads in 100 µl of Buffer B at room temperature for 30 min with 
rotation. The magnetic bead pellets were recovered using a magnet and washed three times 
with 250 µl of Buffer B. The magnetic beads with biotinylated targets attached were 
resuspended in 100 µl of Buffer A.  
Bead library preparation 
The DNA library was resuspended in 10 ml of Buffer B, transferred to a conical tube and 
pelleted by centrifugation at 3000 rcf for 10 min at room temperature. The supernatant was 
discarded except for ~100 µl. The beads were resuspended in 3 ml of Buffer B, heated to 95 ºC 
for 5 min and allowed to cool slowly over ~30 min. Buffer A (7 ml) was added and the beads 
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were pelleted again for 10 min at 3000 rcf at room temperature. The supernatant was discarded 
leaving 100 µl of buffer. Buffer A was added to a total volume of 1.8 ml and transferred to a 2 ml 
tube. 
Negative Selection 
Streptavidin coated magnetic particles were resuspended and 300 µl was transferred to a 
1.5 ml tube. The magnetic beads were pelleted with a magnet and the supernatants were 
discarded. 500 µl of Buffer A (with BSA) was added to wash the beads. The beads were washed 
3 times as described above. After the last wash, the pellet was resuspended in 50 µl of Buffer A 
and the prepared aptamer bead library was added. The aptamer and magnetic beads were 
incubated for 1 h with rotation. Magnetic particles and any associated aptamer beads were 
pelleted with a magnet, and unbound aptamer beads were transferred into a 15 ml conical tube. 
The magnetic beads were washed repeatedly with 500 µl of Buffer A until all unbound aptamer 
beads were recovered. The magnetic beads with non-specifically bound aptamer beads were 
discarded. The remaining aptamer library beads were washed 3 times with 10 ml of Buffer A, 
and resuspended in a final volume of ~1.8 ml of Buffer A before the aptamer beads were 
transferred to a 2 ml tube.  
Positive Primary Selection 
KatG, CFP-10 and LAM were coupled to streptavidin-coated magnetic beads, and the aptamer 
beads recovered from the negative selection step were combined into one tube and incubated 
with rotation for 90 min at room temperature. About half of the mixture was transferred into a 
1.5 ml tube where the magnetic beads were pelleted and the supernatant containing the 
unbound beads removed. The remaining magnetic bead and aptamer mixture was added to the 
tube, and the supernatant was removed. The pelleted magnetic particles were washed 
repeatedly with 500 µl to1 ml of Buffer A until the supernatant became clear i.e. no remaining 
unbound aptamer beads. For the final two washes, Buffer B was used. Typically, a total wash 
volume of approx. 10 ml was used. Finally, the pellet was resuspended in 50 µl of Buffer B. 
Cleavage of Putative aptamers 
50 µl of 1 N NaOH was added to the 50 µl magnetic particle resuspension containing the 
positively selected bound library beads and incubated at 65 ºC for 30 min. The reaction was 
neutralised by adding 40 µl of 2 M Tris-HCl (pH 7.5). The magnetic particles were pelleted using 
a magnet, and the supernatant containing the cleaved oligonucleotide pool of primary selection, 
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was transferred to a 1.5 ml tube. 
Secondary Pull Down Selection: B) Multiple protein target selection 
7 µl of the cleaved oligonucleotide pool was aliquoted into each of 5 tubes (labelled 1-5). 
Biotinylated targets were added to the following tubes: KatG into tube #2, CFP-10 into tube #3   
or CFP-10·ESAT-6 heterodimer into tube #3b and LAM into tube #4 to yield final concentrations 
of ~100 nM in a total reaction volume of 140 µl with Buffer A (with BSA) (Table 4.1). Tube #1 
and #5 were controls, therefore 133 µl of Buffer A (with BSA) was added to give a total reaction 
volume of 140 µl. The cleaved oligonucleotides and targets were incubated together at room 
temp with rotation for 1 h. 
50 µl of magnetic particles were washed 3 times with 500 µl Buffer B (without BSA) and 
resuspended with 25 µl of Buffer B (without BSA). 5 µl of washed magnetic particles were 
added to tube #2, #3, #4 and #5. Note that magnetic particles were not added to tube #1, as it 
was the starting pool reference point control. All tubes were incubated with rotation at room 
temperature for 30 min to 1 h. The magnetic particles were pelleted using a magnet and the 
supernatant was removed. The magnetic particles were then washed 3 times with 150 µl of 
Buffer B (without BSA). The pellets were resuspended in 100 µl Buffer B. This putative aptamer 
pool was used as templates for PCR in the following step (10-40 µl from each tube). 
Table 4.1 Secondary Selection  
  Incubation 
#1 
   
Incubation 
#2 










#1 & #1b Start control 7 0 0 133 0 
#2 100 nM Target 1: KatG 7 0.85 19.8 114 + 
#3 100 nM Target 2: CFP-10  7 19.91 0.74 132 + 
#3b 100 nM Target 2: CFP-10·ESAT-6 7 2.75 5 128 + 
#4 100 nM Target 3: LAM H37Rv) 7 5.88 2.38 131 + 
#5 & #5b Negative control 7 0 0 133 + 
 
4.2.3 Polymerase Chain Reaction (PCR)  
PCR was performed in a G-storm thermal cycler (Gene technologies). Each tube was matched 
with the corresponding reverse primer for PCR (e.g. tube #1 with reverse primer #1). Each 
reverse primer had a unique sequence to tag the products of each tube with a ‘barcode’ for 
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differentiation during sequencing. The PCR reaction for each tube contained dNTPs (Thermo 
Scientific; R0192), reverse and forward primer (AM Biotechnologies), DreamTaq, DreamTaq 
buffer, additional MgCl2 (Thermo Scientific; EP0702) and the bead suspension containing the 
aptamer pool as a template (Table 4.2). PCR tubes were only placed in the heating block once it 
had reached 95 °C to minimise the formation of primer dimers (hot start PCR). The cycling 
conditions are presented in Table 4.3.  
 
Table 4.2 Polymerase Chain Reaction (PCR) Reaction 
Component Final concentration 
DreamTaq Buffer  1X (includes 2 mM MgCl2) 
MgCl2 2.5 mM 
dNTP Mix 0.2 mM 
Forward Primer 0.1-0.4 µM 
Reverse Primer 0.1-0.4 µM 
Template DNA 10-40 µl of aptamer pool per 50 µl reaction 
DreamTaq DNA Polymerase 2.5 U per 50 µl reaction 
PCR-grade water make up to total volume (50µl) 
 
 
Table 4.3 PCR Cycling conditions 
Step  Temperature Duration Cycles 
Initial 
denaturation 
94 °C 1 min 1 
Denaturation 94 °C 30 s 
4-25 Annealing (TA) 50 °C 30 s 
Extension 72 °C 1 min 
Final extension 72°C 1 min 1 
 
 
In order to optimise the number of cycles, 4 µl of the reaction mixture was removed for analysis 
every 4 cycles for analysis. The various fractions were analysed by separating the PCR product 
on a ~12% native polyacrylamide gel (PAGE) at 200 V for 30 min. After the optimal number of 
cycles were determined, the bulk of the PCR reaction was performed. PCR products were 
purified using the Nucleospin II kit (Machery-Nagel) as per the manufacturer’s instructions and 
eluted into water or elution buffer (3#-CFP-10 was gel purified). Putative aptamers for the 
same target were pooled and the concentration of the DNA was measured with a Nanodrop 
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spectrophotometer (Thermo Scientific; Nanodrop 2000). 
4.2.4 Next Generation Sequencing and Synthesis of X-Aptamers 
The purified PCR products were combined in one tube and shipped to AM Biotechnologies to 
be sequenced via next generation sequencing using Ion Torrent (ThermoFisher) with either an 
Ion 316™ or 318™ chip. The intensity of some bands did not correspond to the nanodrop 
readings. To ensure that enough material was shipped for sequencing, additional aliquots of #3, 
#1b #3b and #5b were sent, which equated to 200 or 300 ng as per the nanodrop reading 
(Appendix B:Table A 16). Although the first and second selection PCR products were sent 
separately, the positive controls (#1 and #1b), CFP-10 and CFP-10·ESAT6 heterodimer (#3 and 
#3b), and the negative controls (#5 and #5b) were combined for sequencing, and the 
subsequent selection of sequences.  
Aptamers were selected for re-synthesis with the aid of the Aptaligner© software (Lu et al., 
2014). Aptamers were selected based on their enrichment in the secondary pull down relative 
to the start pool, negative control, and to other targets in the selection.  Other considerations 
for selecting sequences  where: whether there were other closely related sequences that were 
also enriched and the number of hydrophobic moieties (Lokesh et al., 2017). AM 
Biotechnologies synthesized six to nine biotinylated putative aptamers with the appropriate 
phenol, indole, boronic acid or hydroxymethyl modifications for each target using a split-pool 
scheme (Gorenstein et al., 2014). 
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4.3 Results 
4.3.1 Biotinylation of targets 
In preparation for the selection of aptamers against the targets, the latter were biotinylated in 
order to couple them to the streptavidin coated magnetic beads. Biotinylation was confirmed 
by western blot, and the degree of biotinylation was estimated with the HABA assay. 
CFP-10 and KatG 
Protein targets were successfully tagged using NHS-biotin and visualised by western Blot using 
Streptavidin-HRP and a chemiluminescent substrate. CFP-10 was clearly visualised slightly 
above 10 kDa after a 5 min exposure (Figure 4.4). The expected molecular weight of Hexa-HIS 
tagged CFP-10 is ~11.8 kDa.  KatG (80 kDa) was visualised by western Blot slightly above 
70 kDa, as expected, after a 3 min exposure (Figure 4.5).  
 
 
Figure 4.4 Western blot of biotinylated CFP-10 (11.8 kDa). 
Blot probed with Streptavidin-HRP. 
 
 
Figure 4.5 Western blot of biotinylated KatG (80 kDa). 
Blot probed with Streptavidin-HRP. 
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LAM 
LAM was biotinylated by covalently linking biotin hydrazide to aldehyde groups generated by 
oxidising carbohydrate moieties on LAM. A faint band between 25 and 35 kDa, pertaining to the 
biotinylated LAM (H37Rv), was visualised by western Blot using Streptavidin-HRP (Figure 4.6). 
Although the molecular weight of LAM is ~17-19 kDa, LAM migrates to ~25-35 kDa relative to 
the bands of a protein ladder (Venisse et al., 1993). In contrast, LAM was more visible in the 
control blot of biotinylated LAM when probed with CS-40 anti-LAM antibody (Figure 4.7).  
 
 
Figure 4.6 Western Blot of Biotinylated LAM  
Blot probed with Streptavidin-HRP. Note: LAM runs at about 25-35kDa relative to a 
protein ladder (Venisse et al., 1993). 
 
 
Figure 4.7 Control Western Blot with biotinylated LAM 
Blot probed with CS-40 anti-LAM monoclonal antibody. LAM-B: biotinylated LAM 
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4.3.2 Protein Quantitation 
The concentration of the biotinylated proteins was determined to obtain optimal coverage on 
the streptavidin-coated magnetic beads, and to determine the degree of biotinylation via the 
HABA assay. 
The concentration of the biotinylated proteins was estimated by plotting the mean absorbance 
values on a BSA standard curve (Figure 4.8). The lowest dilution point produced a signal within 
the noise region, so a linear line was drawn between the origin and the second dilution point 
(0.125 mg/ml) to estimate the KatG absorbance value that fell within that region. The CFP-10 
concentration was also estimated by linear approximation between the second and third 
dilution points (0.125 mg/ml to 0.5 mg/ml) due to the lack of sufficient valid points in the 
dilution curve to perform a 4 PL curve fitting analysis. The concentration for biotinylated KatG 
and CFP-10 were estimated to be 0.048 mg/ml and 0.169 mg/ml respectively (Appendix 
B:Table A 10 and Table A 11). 
 
 
Figure 4.8 Bradford assay standard curve A. 
 Aliquot 1 of biotinylated KatG and CFP-10 plotted onto the curve. Curve determined 
using linear approximation. BSA: Bovine Serum Albumin 
 
Given the low concentration of biotinylated KatG and CFP-10 obtained from the first 
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biotinylation step, a second aliquot of both proteins was biotinylated and the concentration of 
the biotinylated proteins was determined, as before, using a Bradford assay. A standard curve 
was generated using a 4PL curve fitting formula and the absorbance readings of KatG and 
CFP-10 were plotted on the curve (Figure 4.9). The concentration for the second aliquots of 
biotinylated KatG and CFP-10 were estimated to be 0.238 mg/ml and 0.227 mg/ml, respectively 
(Appendix B:Table A 10 and Table A 11). 
 
 
Figure 4.9 Bradford assay standard curve B 
Aliquot 2 of biotinylated KatG and CFP-10 plotted onto the curve. Curve determined 
using 4-PL curve fitting.  
 
4.3.3 HABA Assay 
The HABA assay determines the extent of biotinylation based on the degree of displacement of 
HABA from streptavidin upon addition of the biotinylated target, since biotin has a significantly 
higher binding affinity than HABA for streptavidin. The displacement of HABA from 
streptavidin is observed by a proportionate decrease in absorbance at 500 nm, hence the 
change in absorbance is proportional to the quantity of biotin in the sample. It is important to 
estimate the mole-to-mole ratio of biotin to protein, because excessive biotinylation of the 
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protein target could interfere with the aptamer selection process. Aliquot 2 of KatG and CFP-10 
was used for the HABA assay (Appendix B: Table A 10 and Table A 11). 
The absorbance of the HABA solution (Streptavidin-HABA) is compared to the absorbance of 
the same solution after addition of the biotinylated molecule (Streptavidin-Biotin + HABA) in 
Figure 4.10 for all three targets. The biotinylated CFP-10 exhibited a significant decrease in 
absorbance at 490 nm, which equated to ~3 biotin molecules per CFP-10 molecule (Table 4.4). 
The biotin: KatG mole ratio could not be calculated due to an increase in background 
absorbance, which is attributed to the strong absorption of the KatG heme group at 490 nm, 
potentially masking the displacement of HABA from streptavidin (Lukat-Rodgers et al., 2000). 
LAM from M. smegmatis was used as a proof of principle in this experiment due to a limited 
supply of M. tuberculosis H37Rv LAM. A small decrease in absorbance was noted for the 
biotinylated LAM (M. smegmatis), which equated to approximately every second molecule of 
LAM being biotinylated (Table 4.4).  
Table 4.4 HABA Assay Results 
 


















0.817 0.787 0.01 11800 0.238 4 3.558 
KATG-Biotin 0.800 0.805 0.6 80000 0.227 4 * 
LAM-Biotin 0.804 0.795 0.1 17000 0.200 1 0.475 
* The biotin/mole of KatG could not be calculated 
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Figure 4.10 HABA assay  
A HABA assay was used to measure the extent of biotinylation using the second 
aliquot of biotinylated proteins and LAM from M. smegmatis. Only CFP-10 had a 
significant shift in absorbance readings *p ≤ 0.05 according to a t-test. Columns 
indicate the mean reading of duplicate wells and error bars indicate the minimum 
and maximum readings taken. 
4.3.4 X-Aptamer Selection and PCR Optimisation 
Two selections were done using the custom X-Aptamer kit supplied by AM Biotech. For the first 
selection, KatG, CFP-10 and LAM were used as targets. Due to a low yield of putative aptamers 
against CFP-10, a second selection was performed against the CFP-10·ESAT-6 heterodimer. 
The putative aptamers were amplified by PCR and analysed by separating the PCR products on 
a native polyacrylamide gel. The expected size of the putative aptamers was approximately 75 
base pairs (bp). Bands were compared to the size of the starting pool which served as a positive 
control. The negative control consisted of any starting library that bound non-specifically to the 
magnetic beads in the secondary pull-down. 
Primer concentration, template concentration and number of cycles were optimised for the PCR 
to obtain maximal product, and to minimise primer dimers or other spurious products. The 
optimisation process is summarized in Appendix B: Table A 15 and the figure key is presented 
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in Table 4.5. 
The first PCR was performed as per the AM Biotech protocol (Figure 4.11). While a single band 
of the desired size (~75 bp) was observed in the positive control, unwanted bands (~60 bp and 
<50 bp) appeared in all the other samples, including the negative control between 12 and 16 
cycles of PCR. Only #2-KatG and #4-LAM had the desired ~75 bp band, which was faint 
compared to the unwanted bands. 
In order to minimise these undesirable bands, the primer concentration was decreased and the 
template concentration was increased for PCR_1.2. Bands corresponding to the positive control 
were not observed in any of the other samples in this PCR experiment (Figure 4.12). 
A drastic decrease in primer concentration was tested in PCR 1.3, however in this instance, 
there was insufficient primer to amplify the product, hence no bands were observed on the gel 
(image not included).   
The PCR conditions in PCR_1.4, comprising a primer concentration of 0.1 µM, and 20 µl of 
template, were found to eliminate the formation of primer dimers (Figure 4.13). However, the 
yields of the desired PCR products for #2-KatG and #4-LAM were low and barely visible on the 
gel, and completely absent for #3-CFP-10. Since the quantity of template DNA was limited, 
which prevented higher starting concentrations of the DNA template being used in the 
reactions, the number of PCR cycles was instead increased to improve the yield of PCR products. 
In PCR_1.5, the PCR product yield improved despite the reappearance of primer dimer products 
at high cycle numbers (Figure 4.14). At 25 cycles, most targets reached sufficient product yield 
with minimal or no additional bands. The purified PCR product concentrations were low; 
therefore an additional PCR was performed to increase the yield of the desired sequences 
(PCR_1.6: Figure 4.15).  
The PCR products were purified as noted in Figure 4.14 and Figure 4.15. The samples with the 
most product, but least unwanted bands, were purified and putative aptamers for the same 
target were pooled. The PCR product of #3 CFP-10 was gel purified to minimise the primer 
dimer contamination since the yield of the true product and the primer dimers were similar. 
The PCR yield for the #3-CFP-10 was poor, hence the selection was repeated with the 
CFP-10·ESAT-6 heterodimer. The optimised conditions were used for PCR_2.1 and resulted in 
favourable bands (Figure 4.16), however the product yield was suboptimal. Thus, the template 
concentration and cycle number for PCR_2.2 was increased accordingly (Figure 4.17). The 
control band in the positive control was faint, which warranted a repeat of the PCR.  In the 
Chapter 4: Selecting X-Aptamers Against Mycobacterial Derived Biomarkers  
     126 
repeat PCR, a ~75 bp band was observed in all the lanes. A no template control exhibited primer 
dimers, but not the 75 bp band (Figure 4.17). Since sequences in the #5b tube (negative control) 
could be excluded after sequencing, the putative aptamers (PCR products) were purified and 
prepared for shipping (PCR_2.3: Figure 4.18). Each pooled product (50 ng) was separated by 
PAGE (Figure 4.19), before shipping the DNA to AM Biotech, to ensure that the PCR products 
were of the correct size, and relatively free of unwanted sequences. 
 
Table 4.5  PCR PAGE Figure Key 
Number Name Description 
#1 Positive control Starting pool for secondary pull down 
amplified by PCR 
#2 KatG Putative aptamers that bound in 
secondary pulldown to biotinylated KatG 
amplified by PCR 
#3 CFP-10 Putative aptamers that bound in 
secondary pulldown to biotinylated CFP-
10 amplified by PCR 
#4 LAM Putative aptamers that bound in 
secondary pulldown to biotinylated LAM 
amplified by PCR 
#5 Negative control DNA that bound in secondary pulldown 
to magnetic beads amplified by PCR 
#1b Positive control Starting pool for secondary pull down of 
second selection. 
#3b CFP-10·ESAT-6 Putative aptamers that bound in 
secondary pulldown to the CFP-
10·ESAT-6 heterodimer amplified by 
PCR (Only CFP-10 biotinylated) 
#5b Negative control DNA that bound in secondary pulldown 
to magnetic beads amplified by PCR 
C No template  
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Figure 4.11 PCR _1.1  
Parameters: 0.4 µM primer, 10 µl template, and 4-20 PCR cycles. See key above (Table 
4.5). M: DNA ladder (bp). Lane numbers indicate number of cycles of PCR.   
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Figure 4.12 PCR_1.2  
Parameters: 0.2µM Primer, 20µl template and 16 cycles. See key above (Table 4.5). M: 
DNA ladder (bp). 
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Figure 4.13 PCR_1.4  
Parameters: 0.1 µM Primer, 20 µl template, and 16 and 20 cycles. See key above (Table 
4.5). Lane numbers indicate number of cycles of PCR. M: DNA ladder (bp). 
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Figure 4.14 PCR_1.5  
Parameters: 0.1 µM primer, 20 µl template, and 25 and 30 cycles. See key above (Table 
4.5). Lane numbers indicate number of cycles of PCR. PCR products from 25 cycle lanes 
were purified. #3- CFP-10 products were cut from the gel for purification. 
 
Chapter 4: Selecting X-Aptamers Against Mycobacterial Derived Biomarkers  
     131 
 
Figure 4.15 PCR 1.6  
Parameters: 0.1 µM primer, 1 µl of template, and 15 cycles. See key above (Table 4.5). PCR 
products from circled lanes were purified. #3- CFP-10 products were cut from the gel for 
purification. Concentrations of each template used in the PCR is indicated in the table for each 
lane. 
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Figure 4.16 PCR 2.1  
Parameters: 0.1 µM primer, 20 µl template and 16-24 cycles. See key above (Table 4.5). Lane 
numbers indicate number of cycles of PCR. 
 
Figure 4.17 PCR 2.2  
Parameters: 0.1 µM, 40 µl template, and 20 and 24 cycles. See key above (Table 4.5). Lane 
numbers indicate number of cycles of PCR.  
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Figure 4.18 PCR_2.3  
Parameters: 0.1 µM primer, 20 µl template, and 20 and 24 cycles. See key above (Table 4.5). 
Lane numbers indicate number of cycles of PCR. PCR products from all lanes were purified.  
C- No template control, 24 cycles 
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Figure 4.19 Final Gel before shipping putative X-Aptamers.  
50 ng of each product was loaded on to the gel as calculated from the nanodrop readings. 
100bp band of ladder = 14 ng (7% of 0.2 µg).  Expected size is 75 bp. See key above (Table 
4.5). 
 
4.3.5 Next Generation Sequencing and Putative X-Aptamer Synthesis 
Next generation sequencing, analysis with Aptaligner© and putative X-Aptamers synthesis as 
described in the Methodology section (4.1.5) was performed by Dr N. Ward at AM Biotech. 
Aptamers were selected for re-synthesis based on their enrichment in the secondary pull down 
relative to the start pool, negative control, and to other targets in the selection. Sequences 
corresponding to the bands in the negative control were removed from the aptamer pool before 
synthesis of the putative aptamers. 
AM Biotechnologies synthesized six to nine biotinylated putative aptamers (Appendix B: 
Putative X-Aptamer sequences) with the appropriate phenol, indole, boronic acid or 
hydroxymethyl modifications for each target using a split-pool scheme (Gorenstein et al., 2014). 
The most common modifications were boronic acid and indole (Figure 4.20).   
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Figure 4.20 Type and number of modifications on each sequence synthesised 
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4.4 Discussion 
The various targets were biotinylated to facilitate their immobilisation onto the streptavidin 
coated beads. While other forms of immobilisation are possible, the biotin-streptavidin 
interaction is exceptionally strong (KD = 4x10-14 M), and biotinylation is conveniently optimised 
since it is widely used in molecular biology applications.  
Biotinylation of all three targets was confirmed via western blot performed with a 
Streptavidin-HRP conjugate. Distinct bands were observed at the correct molecular weights for 
KatG and CFP-10 (Figure 4.4 and Figure 4.5 respectively). The western blot for biotinylated 
LAM appeared as a weak band suggesting that either the number of biotin molecules per LAM 
molecule was low, the biotinylation efficiency was low or that there was a loss of material 
during biotinylation (Figure 4.6). However, a control blot performed with anti-LAM antibodies 
revealed that biotinylated LAM could be detected with significantly higher sensitivity than 
observed with streptavidin-HRP, which suggests that the weak signal intensity in the 
streptavidin-HRP blot was due to low levels of biotinylation (Figure 4.7). The band smearing 
observed in the control blot is indicative of the heterogeneous nature of the LAM produced by 
M. tuberculosis (Venisse et al., 1993).  
When selecting aptamers against biotinylated targets, it is preferable to maintain a low biotin: 
target molar ratio, since the aim is to select aptamers that recognise native epitopes of the 
target molecules, and not any excess biotin molecules that may have not bound to streptavidin. 
Keeping this in mind, a HABA assay was performed to estimate the number of biotin molecules 
per biomarker target. The HABA assay was performed on the two protein targets, but not on 
LAM (H37Rv) due to limited stocks of LAM. However, a proof of principle experiment was 
performed with LAM from M. smegmatis. CFP-10 had a favourable biotin-to-target ratio of ~ 
3:1, while approximately every second molecule of LAM (M. smegmatis) was biotinylated, 
which is a plausible reason for the low signal intensity observed in the western blot of LAM 
(H37Rv). The extent of biotinylation for KatG could not be calculated since the heme group of 
KatG absorbs in the same range as the HABA solution resulting in a high background signal 
(Table 4.4). Nonetheless, this property of KatG is particularly advantageous for the label-free 
detection of KatG (Lukat-Rodgers et al., 2000; Kapetanaki et al., 2003).  
After the selection process, putative aptamers were amplified by PCR in preparation for 
sequencing. Various PCR parameters, i.e. cycle number, primer concentration and template 
amount were optimised to reduce primer dimers and obtain maximal yield (Figure 4.11 to 
Figure 4.18) (Roux, 1995). Due to a low yield of putative aptamers against CFP-10, we repeated 
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the selection process using the CFP-10·ESAT-6 heterodimer, which is more stable than either 
of the monomers on their own (Renshaw et al., 2002) (Figure 4.16 to Figure 4.18). It is therefore 
plausible that an aptamer, which recognises epitopes of either CFP-10, ESAT-6 or some 
interface of the heterodimer could have been selected.  
Initially, it appeared that the concentration of template, which was unknown, was less than the 
suggested primer concentration of 0.4 µM as primer dimer products (<50 bp) dominated the 
first PCR (Figure 4.11). Due to limited DNA template available from the selection process, the 
starting template volume could only be doubled. The primer concentration was reduced to 
0.1 µM before primer dimer products were eliminated, or reduced so that the aptamers 
dominated the final PCR products (Figure 4.13 and Figure 4.14). Except for putative aptamers 
selected against CFP-10, primer dimers continued to be of similar or greater concentrations 
than the desired product (Figure 4.14 and Figure 4.15). 
The number of PCR cycles was increased to improve the yield of PCR products. However, this 
should be done with caution when amplifying aptamers as by-products also increase 
exponentially. Short random DNA sequences are prone to generating spurious by-products due 
to product-product hybridisation. These by-products can overshadow real products resulting 
in the original library being lost within five PCR cycles despite ample primers being available 
for primer-template hybridisation (Musheev and Krylov, 2006). 
Stable secondary structures, which are key for aptamer binding ability (Fischer, Tok and 
Tarasow, 2008) and usually associated with a higher GC content, can be responsible for by-
products via deletion events. For example, a hairpin-loop that persists during extension results 
in the polymerase “jumping” over a section of sequence. The outcome is by-products that are 
shorter than the original template (McDowell, Burns and Parkes, 1998; Viswanathan, Krcmarik 
and Cianciotto, 1999). This mechanism is a plausible explanation for the ~60 bp band observed 
in Figure 4.11, Figure 4.13 and Figure 4.16. Agents, such as DMSO or betaine, can be used to 
minimize stable secondary structures, however they can also destabilise priming during PCR 
(Kang, Lee and Gorenstein, 2005; Musso et al., 2006). 
Enrichment of by-products is minimised in the bead based method (He et al., 2012) as only one 
round of PCR needs to be performed, whereas in traditional SELEX methods, repeated rounds 
of PCR expand spurious products to the point that real binders can be lost (Musheev and Krylov, 
2006). Another method of preventing product-product hybridisation is emulsion PCR. Each 
template is amplified in its own compartment, which eliminates the opportunity for 
complementary random sequences to anneal and produce spurious products. However, the 
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clean-up process is more tedious and yield is effected with this method (Shao et al., 2011). 
The final concern was a 75 bp band that appeared in the #5 tube (negative control) (Figure 
4.11, Figure 4.14, Figure 4.17 and Figure 4.18). The source of this 75 bp band could be 
contamination incurred while preparing the PCR reactions, despite precautions such as, 
preparing PCR reactions with filter-plugged tips, wearing gloves and preparing reactions in a 
different location from the thermocycler and electrophoresis apparatus. PCR reactions were 
performed with a no template control and in these reactions, the 75 bp band was not present 
(Figure 4.17 and Figure 4.18). It was an oversight to not include this control in all the PCR 
experiments. An alternative source of the 75 bp sequences is DNA that bound non- specifically 
in the secondary selection, despite the initial negative selection, which should have excluded 
most non-specific binders. Sequences from tube #5 were compared to other tubes and excluded 
from the pool of putative aptamers selected for re-synthesis. If these sequences were a result 
of contamination rather than non-specific binding, putative aptamers would have been lost in 
this process. 
Although the first and second selections were sent separately for sequencing, the positive 
controls (#1 and #1b), the CFP-10 and CFP-10·ESAT-6 heterodimer (#3 and #3b) and the 
negative controls (#5 and #5b) were combined for sequencing, and the subsequent selection of 
aptamers.  
After selecting putative aptamers that were unique to each target and were not present in the 
negative control (i.e. non-specific binders), these sequences were synthesized with the 
appropriate modifications (Appendix B: Table A 17) (Gorenstein et al., 2014). Boronic acid and 
indole were the most common modifications since they compromised 68% of the starting 
library (Figure 4.20). 
The putative aptamers against CFP-10 and the CFP-10·ESAT-6 heterodimer had mostly indole 
and boronic acid modifications. The indole moiety likely interacts with the hydrophobic regions 
of these proteins. Boronic acid can also interact with hydrophobic amino acids, and any amino 
acid side chain that can donate a pair of electrons, such as serine (Whyte, Vilar and Woscholski, 
2013). The putative aptamers against LAM contained mostly boronic acid and indole moieties, 
which probably bind to the carbohydrate and lipid parts of LAM, respectively. KatG was the 
only target to bind putative X-Aptamers containing a hydroxymethyl group, which also 
contained several boronic acid groups. The active site of KatG contains histidine, which may be 
one of the epitopes to which a boronic acid aptamer could bind. KatG, being a large protein with 
several different types of amino acids, probably offers more opportunity for binding aptamers. 
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4.5 Conclusion 
The bead-based SELEX method provides an accelerated means of selecting aptamers against 
several targets concurrently.  Novel modified sequences were selected against KatG, LAM and 
the CFP-10.ESAT-6 dimer.  These putative aptamers could form the basis of a new biosensor for 
the detection of biomarkers in TB patient samples.  Sequences selected after analysis with the 
Aptaligner® softer were synthesized and will be discussed in the following chapter. 
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5 CHARACTERISING X-APTAMERS 
AGAINST TB BIOMARKERS 
5.1 Introduction 
It is essential to characterise aptamers in order to identify the best candidates for use in a 
diagnostic biosensor.  Diagnostic biosensors should have high analytical sensitivity and 
specificity to enable detection of biomarkers in complex clinical samples where biomarkers 
may be in low concentrations.  Determining the binding affinities and interrogating the 
secondary structure of the selected aptamers are two methods to calibrate and optimise a 
diagnostic platform. 
5.1.1 Analytical Sensitivity and Specificity 
Analytical sensitivity is determined by measuring the lowest concentration of the biomarker 
that can be detected by an assay i.e. the limit of detection (Ekins and Chu, 1991).  “Analytical 
specificity is the ability of an assay to exclusively identify a target substance or organism … in a 
sample or specimen.” Note analytical sensitivity and specificity should not be confused with 
diagnostic sensitivity and specificity (Saah and Hoover, 1997). Binding affinity is a key 
contributor to the analytical sensitivity and specificity of an assay (Eaton, Gold and Zichi, 1995).  
Ionic strength and pH of buffers can alter aptamer binding affinity hence buffers should be 
taken into consideration when designing assays (Baldrich, Restrepo and O’Sullivan, 2004; 
Hianik et al., 2007).  Analyte concentration, assay volume, and complexity of the patient 
samples will also affect the overall sensitivity and specificity of an assay (Pesce and Michael, 
1992). Hence diagnostic assays should be validated with complex samples similar to real 
samples to determine realistic sensitivity and specificity metrics.  
Binding Affinity 
Binding affinity is defined at equilibrium by the dissociation equilibrium constant (KD) which is 
the quotient of the reactant concentrations and product concentration or the ratio of the 
dissociation and association rate constants,  𝑘𝑜𝑓𝑓 and  𝑘𝑜𝑛  respectively, at equilibrium (See 
Equations 1). For the purpose of this discussion, when one molecule is immobilised onto a 
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surface that molecule will be referred to as the ligand, while the molecule in solution will be 
referred to as the analyte and reactants will be used as a collective term.  The smaller the value 
of the KD the stronger the binding between a ligand and analyte as the formation of the ligand-
analyte complex is favoured ((Pollard, 2010).   
 
Equations 1 
𝐿 + 𝐴 ↔  𝐿A  ( 1)  
Where L is the ligand and A is the analyte and LA is the analyte bound to the ligand. 
This equation assumes 1:1 stoichiometry 
Forward Reaction:  𝑅𝑎𝑡𝑒 = 𝑘𝑜𝑛 [𝐿][𝐴] ( 2) 
Reverse Reaction:  𝑅𝑎𝑡𝑒 = 𝑘𝑜𝑓𝑓 [𝐿𝐴] (3) 
Where  𝑘𝑜𝑛is the association rate constant and  𝑘𝑜𝑓𝑓is the dissociation rate constant. 
[L] is the density of ligand on the surface (mol/m2) and [A] is the concentration of the 
analyte in solution (mol/litre), while [LA] is the density of analyte bound to ligand on 
the surface (mol/m2).  
At Equililbrium:  𝑘𝑜𝑛[𝐿][𝐴] = 𝑘𝑜𝑓𝑓[𝐿𝐴] (4) 









Concentrations of ligand and analyte need to be optimised to determine the binding affinity. 
Firstly, the fraction bound at equilibrium only varies significantly if the concentration of analyte 
is within two orders of magnitude from the KD value (Kuriyan, Konforti and Wemmer, 2009). 
Secondly, in order to simplify calculations binding should occur under pseudo-first order 
conditions where either the analyte or ligand is in excess of the other. Pseudo-first order 
conditions allow for easy calculation of the rate of the reaction since the rate is proportional to 
the concentration of one of the reactants under these conditions. Lastly, when surface 
immobilisation became popular there were concerns about the validity of calculating the KD 
when a reactant was immobilised on the surface (Goldberg and Djavadi-Ohaniance, 1993).  
Edwards et al. found that KD values obtained when molecules were immobilised were 
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comparable to KD values obtained in solution assays as long as the ligand was not impeded by 
steric hindrance i.e. crowding on the surface (Edwards, Lowe and Leatherbarrow, 1997). In the 
context of designing a biosensor the immobilised KD value is more relevant than an in-solution 
KD value and the concentration of immobilised ligand can be optimised to increase analytical 
sensitivity and specificity.  
There are two types of assays to determine the KD: equilibrium and kinetic assays. Equilibrium 
assays may be used to determine the KD but not the rate constants (𝑘𝑜𝑓𝑓 and 𝑘𝑜𝑛). Kinetic assays 
are more expensive and complicated, but they yield more useful information including the 𝑘𝑜𝑓𝑓 
and 𝑘𝑜𝑛  rate constants  (Pollard, 2010). 
Equilibrium Assays 
During an equilibrium assay the two reactants are allowed to reach equilibrium in solution and  
the concentration of unbound reactant, typically the reactant in excess, is measured without 
disrupting the equilibrium unless there is a method to remove unbound reactant from the 
solution (Pollard, 2010). An ELISA or ELONA is an example of an equilibrium assay. An ELONA 
is similar to an ELISA except antibodies are replaced with aptamers  (Drolet, Moon-McDermott 
and Romig, 1996).  When an ELISA is used to measure unbound reactant, a separate aliquot of 
the other reactant or another molecule becomes the ligand and is immobilised on the surface.  
This type of assay is often  referred to as a “competition assay” since the ligand reactant in 
solution is “in competition” with itself or another molecule on the surface (Ekins, 1989; 
Baldrich, Restrepo and O’Sullivan, 2004; Papamichael, Kreuzer and Guilbault, 2007; Martineau, 
2010). To maintain the equilibrium less than 10% of the analyte reactant being measured 
should be involved in the measurement assay. The ELISA (or ELONA) should also be optimised 
to give a response which is proportional to the  total unbound reactant concentration (Friguet 
et al., 1985, 1995).   
ELISAs (or ELONAs) should not be used for determining binding affinity when the equilibrium 
is between an immobilised ligand and an analyte in solution where there are wash steps before 
detection of the bound analyte. New equilibria may occur with each subsequent step after the 
primary ligand-analyte complex formation hence the  concentration of  the ligand-analyte 
complex at the initial equilibrium cannot be measured  with this method (Venkatesh and 
Murthy, 1996).  However, ELONAs or ELISA-ELONA hybrid assays can be used to screen 
putative aptamers to find good binders which can be further characterised with kinetic assays.  
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Kinetic Assays 
Kinetic assays yield more information than equilibrium assays including the thermodynamic 
parameter, the equilibrium constant and the rate constants. (Pollard, 2010). The downfall of 
kinetic experiments is that they often require more reagents. However, some techniques have 
become more advanced and minute amounts of a molecule can be detected. A few techniques 
that have been used to characterise aptamer binding will be highlighted here.  
Isothermal titration calorimetry (ITC) has been used in several aptamer studies. The major 
advantage of this technique is that it does not require immobilisation. However micromolar 
concentrations are required to perform the analysis (Cooper, 2004). Despite this drawback, 
studies characterising aptamers and modified aptamers have used this technique (Shum et al., 
2011; Wang et al., 2014; Zandarashvili et al., 2015).  
Thermophoresis has also been used to characterise binding affinity of aptamers with tweaks 
such as microscale thermophoresis and optical thermophoresis (Baaske et al., 2010; Reineck, 
Wienken and Braun, 2010; Wienken et al., 2010). The limitations of this technique is that the 
thermophoresis of  proteins is usually weak and small molecules do not significantly change 
the charge or size of a molecule (Wienken et al., 2010). 
Surface Plasmon Resonance (SPR) is a common method for determining binding affinity and 
has been used to characterise several aptamers (Murphy et al., 2003; Ostatná et al., 2008; Gong 
et al., 2012; Miodek et al., 2013). In the Biacore system the ligand is immobilised onto a gold 
surface via streptavidin, Ni-NTA or liposomal mono- or bi-layers. The analyte, at various 
dilutions, flows over the immobilised ligand which creates an environment where the analyte 
is effectively at a constant concentration (Hodnik et al., 2010). The drawbacks of this method 
are the high maintenance requirements of the equipment and a sensitivity to interfering effects 
(Homola, 2003; Abdiche et al., 2008). 
Biolayer interferometry (BLI) is an “optical analytical technique that measures interference 
patterns between waves of light” (Figure 5.1). BLI is used by systems such as the Octet® system 
(ForteBio®) to characterise binding between unlabelled molecules (Tobias and 
Kumaraswamy, 2013). 
The OCTET system has only recently become sensitive enough to detect small molecules such 
as aptamers as the signal is proportional to the mass of the molecules in the biolayer (Abdiche 
et al., 2008; Shah and Duncan, 2014). However, recently BLI has been used to characterise RNA 
aptamers against VEGF and thrombin, and a method has been published in Current Protocols in 
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Nucleic Acid Chemistry (Abeydeera et al., 2016; Lou et al., 2016). 
 
 
Figure 5.1 Forte Bio OCTET System  
[Adapted from (Tobias and Kumaraswamy, 2013)] 
White light shines through an optic fibre to which a ligand has been immobilised (left). 
The light reflects and produces constructive and destructive interference depending on 
the thickness of the biolayer on the optic fiber. Hence as the ligand binds analyte the 
interference pattern changes and binding can be monitored by a spectrometer (right). 
 
5.1.2 In Silico Sequence Analysis 
Once the binding affinities of the aptamers have been determined they may be optimised by 
truncating the sequence. Minimising aptamers has several advantages including reducing the 
cost of synthesis, improving affinity for the target and understanding aptamer-target 
interactions. Truncation may be performed empirically or guided by in silico secondary 
structure predictions (Fischer, Tok and Tarasow, 2008; Keefe, Pai and Ellington, 2010; 
Berezhnoy et al., 2012; Kaur and Yung, 2012). 
Secondary structures are associated with key binding regions for example the guanine 
quadruplex or hairpin structures (Fischer, Tok and Tarasow, 2008; Russo Krauss et al., 2011; 
Cheung et al., 2013). Constant primer regions do not usually form part of the secondary 
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structure (Cowperthwaite and Ellington, 2008) whereas consensus sequences may be located 
within secondary structures (Wilson and Szostak, 1998; Fischer, Tok and Tarasow, 2008; Cho 
et al., 2013). Some studies have taken advantage of the knowledge that secondary structure 
plays a key role in selecting high affinity aptamers by designing libraries with built-in secondary 
structure such as hairpin loops and found better aptamers were selected (Davis and Szostak, 
2002; Ruff, Snyder and Liu, 2010).  
There are several algorithms available to predict secondary structure (Zuker, 2003, 2010; 
Mathews, 2004; Afzal et al., 2012). Experimental data assists algorithms in making more 
accurate predictions (Patel, 1997; Cheung et al., 2013; Tatarinova et al., 2014). Experimental 
data for modified nucleotides is scarce. Thus, secondary structure prediction for aptamers with 
modified nucleotides is not commonly supported. An exception is DNA Software Inc. that 
revealed the Modifieds™ package in a press release which can reportedly include  nucleic acid 
analogues, deoxyribose uracil, purine isomers and deaminated adenosine (DNA Software, 
2009).  Even without modified nucleotides most software is ill equipped to deal with aptamers. 
For example Mfold fails to take tertiary interactions into account and neglects kinetically 
trapped structures i.e. assumes a minimum free energy is the most probable (Zuker, 2010). 
Despite these limitations a few studies with modified aptamers have used Mfold to predict 
secondary structures (Kato et al., 2005; He et al., 2012; Gandham et al., 2014). None of these 
studies discuss the limitations of using Mfold for secondary structure prediction.  
5.1.3 Aims and Objectives 
Here, modified aptamers against the CFP-10·ESAT-6 dimer, CFP-10 and LAM (H37Rv) were 
characterised with ELONA-ELISA hybrid assays, BLI and in silico structure prediction software. 
The X-Aptamers selected against KatG were not characterised due to time constraints. 
5.2 Methods 
5.2.1 ELONA-ELISA Hybrid 
Various in-house ELONA-ELISA hybrid assays were developed in our lab to test the ability of 
putative aptamers to detect CFP-10, ESAT-6 or LAM based on methods described in the 
following papers (Baldrich, Restrepo and O’Sullivan, 2004; Pan et al., 2014; Tang et al., 2014). 
Chapter 5: Characterising X-Aptamers Against TB Biomarkers  
     146 
ESAT-6 and CFP-10 
 
Figure 5.2 CFP-10 and ESAT-6 ELONA-ELISA Hybrid Assay 
 Workflows: CE_A, CE_B and CE_C 
 
Two different versions of the ELONA-ELISA hybrid assay were used to test the binding of 
putative X-Aptamers to ESAT-6 and CFP-10 (Figure 5.2). All reagents were resuspended in PBS 
(Sigma; P4417 or 137 mM NaCl, 2.7 mM KCl, 10 mM NaHPO4 ·7 H2O, 1.8 mM KH2PO4) at pH 7.4 
and this buffer was used as a negative control.  All incubations were performed at 37 °C with a 
plate sealer and the plate was washed three times with wash buffer (PBS containing 0.05% 
Tween-20) unless otherwise noted.  Biotinylated X-Aptamers were immobilised via 
streptavidin onto the surface. 
Binding curves was generated by performing a 1:2 serial dilution of the respective X-Aptamers 
starting with 0.5 µM. H37Rv cultures were cultured in 7H9 Middlebrook broth (BD Difco™ 
#271310) and heat killed at 80 ⁰C for 30 min by Dr Z. Mlamla. Cultures were pelleted by 
centrifugation at 3300 xg for 15-30 min at 4 ⁰C. The culture filtrate was removed and stored at 
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-20 ⁰C.  
Recombinant ESAT-6 and CFP-10 were detected via their HIS-tags with HRP conjugated Anti-
HIS antibodies (Figure 5.2: CE_A and CE_B)  (Baldrich, Restrepo and O’Sullivan, 2004).  A 96-
well plate (Corning® 96-well EIA/RIA plates; CLS3590-100EA) was coated with streptavidin 
(10 µg/ml) (Prospec; PRO-283) overnight at 4 °C. The plate was washed one to three times with 
wash buffer before incubating the plate with 200 µl of blocking buffer (PBS containing 1% BSA) 
for 1-2 h. The plate was washed before adding 75-100 µl of X-Aptamers (0.5 µM) which had 
been incubated at 95 °C for 10 min and then renatured on ice for 5 min. After washing 75-100 
µl of rCFP-10-HIS (5.9 nM) (BEI Resources; NR-14869), rESAT-HIS (5.9 nM) (BEI Resources; 
NR-14868) or controls in duplicate was added to the plate. Plates were incubated for 1-2 h. 
After washing HRP-conjugated Anti-HIS (Sigma; A7058-1VL), diluted 1:10000 was added and 
incubated for 1-2 h. The plate was washed before adding 100 µl of chromogenic substrate TMB 
(R&D; DY999) and incubated at room temperature for 20 min in the dark. Stop solution (1 M 
sulphuric acid) was added to terminate the reaction. The absorbance of each well was read at 
450 nm with an iMark microplate reader (Bio-Rad). 
Native ESAT-6 was detected in H37Rv culture filtrate with anti-ESAT-6 antibodies and HRP 
conjugated anti-rabbit IgG antibodies (Figure 5.2: CE_C). Pre-coated streptavidin plates 
(Thermo Scientific Nunc Immobilizer Streptavidin; 436014) were washed before adding 100 µl 
of X-Aptamers (0.5 µM) which had been incubated at 95 °C for 10 min and then renatured on 
ice for 5 min. The plate was washed before adding culture filtrate from H37Rv and controls in 
triplicate. Plates were incubated for 1-2 h. After washing, 100 µl of polyclonal anti-ESAT-6 
antibody (BEI resources; NR-13803) diluted 1:5000 was added to the wells. After washing 
twice, HRP-conjugated Anti-rabbit IgG (R&D systems; HAF008), diluted 1:10000 was added and 
incubated for 1-2 h. The plate was washed before adding 100 µl of chromogenic substrate TMB 
and incubated at room temperature for 20 min in the dark. Stop solution (1 M sulphuric acid) 
was added to terminate the reaction. The absorbance of each well was read at 450 nm with an 
iMark microplate reader. 
 
Chapter 5: Characterising X-Aptamers Against TB Biomarkers  
     148 
LAM  
 
Figure 5.3 LAM ELONA-ELISA Hybrid Assay  
Workflows: LAM_A, LAM_B and LAM_C 
 
Three different versions of the ELONA-ELISA hybrid assay were used to test the binding of 
putative X-Aptamers to LAM (Figure 5.3). All reagents were resuspended in PBS (Sigma; P4417) 
at pH 7.4 and this buffer was used as a negative control.  All incubations were at 37 °C with a 
plate sealer and the plate was washed three times with wash buffer (PBS containing 0.05% 
Tween-20) unless otherwise noted.  Corning® 96-well EIA/RIA plates (CLS3590-100EA) were 
used for all the following experiments. 
For the first version LAM was immobilised onto the surface via anti-LAM antibodies and 
detected via the biotinylated X-Aptamers and HRP conjugated streptavidin (Figure 5.3: LAM_A). 
A 96-well plate was coated with polyclonal Anti-LAM antibodies (BEI Resources; NR-13821) 
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overnight at 4 °C. The plate was washed once with wash buffer before incubating the plate with 
200 µl of blocking buffer (PBS containing 1% BSA) for 1-2 h. The plate was washed before 
adding 100 µl of LAM (H37Rv) (100 ng/ml or 5.9 nM) (BEI Resources NR-14848) and controls 
in duplicate. The plate was washed before adding 100 µl of X-Aptamers (0.5 µM) which had 
been incubated at 95 °C for 10 min and then renatured on ice for 5 min. Plates were incubated 
for 1-2 h. X-Aptamers were removed but the plate was not washed before adding HRP 
conjugated streptavidin (#14-20-00 KPL), diluted 1:10000 was added and incubated for 1-2 h. 
The plate was washed and 100 µl of chromogenic substrate TMB was added and incubated at 
room temperature for 20 min in the dark. Stop solution (1 M sulphuric acid) was added to 
terminate the reaction. The absorbance of each well was read at 450 nm with an iMark 
microplate reader. 
A second version of the ELONA-ELISA hybrid, where the biotinylated X-Aptamers were 
immobilised via streptavidin and the LAM (H37Rv) was detected with antibodies, was also 
performed (Figure 5.3: LAM_B). A 96-well plate was coated with streptavidin (10 µg/ml) 
overnight at 4 °C. The plate was washed once with wash buffer before incubating the plate with 
200 µl of blocking buffer (PBS containing 1% BSA) for 1-2 h. The plate was washed before 
adding 100 µl of X-Aptamers (0.5 µM or 5 µM) which had been incubated at 95 °C for 10 min 
and then renatured on ice for 5 min. The plate was washed before adding 100 µl of LAM 
(H37RV) (5.9 nM or 1 µM) and controls in duplicate. Plates were incubated for 1-2 h.  After 
washing 100 µl of monoclonal anti-LAM antibody (BEI resources; NR-13812), diluted 1:1000, 
was added to the wells. After washing, HRP conjugated anti-mouse IgG (R&D systems; HAF007), 
diluted 1:1000 was added and incubated for 1-2 h. The plate was washed and 100 µl of 
chromogenic substrate TMB was added and incubated at room temperature for 20 min in the 
dark. Stop solution (1 M sulphuric acid) was added to terminate the reaction. The absorbance 
of each well was read at 450 nm with an iMark microplate reader. 
Finally, a third assay was performed based on the method described by Pan et al.  (Figure 5.3: 
LAM_C) (Pan et al., 2014). LAM was adsorbed directly onto the surface and detected with 
X-Aptamer and HRP conjugated streptavidin. A 96-well plate was coated with LAM (H37Rv) (20 
µg/ml or 1 µM) overnight at 4 °C in triplicate. The plate was washed once with wash buffer 
before incubating the plate with 200 µl of blocking buffer (100 µg/ml salmon sperm ssDNA 
(Sigma; D9156-1ML) or salmon sperm ssDNA in 1% BSA) for 1-2 h. The plate was washed 
before adding 100 µl of X-Aptamers (5 µM) which had been incubated at 95 °C for 10 min and 
then renatured on ice for 5 min. Plates were incubated for 1-2 h. After washing once, HRP 
Chapter 5: Characterising X-Aptamers Against TB Biomarkers  
     150 
conjugated streptavidin (#14-20-00 KPL), diluted 1:10000, was added and incubated for 1-2 h. 
The plate was washed and 100 µl of chromogenic substrate TMB was added and incubated at 
room temperature for 20 min in the dark. Stop solution (1 M sulphuric acid) was added to 
terminate the reaction. The absorbance of each well was read at 450 nm with an iMark 
microplate reader. 
5.2.2 Biolayer Interferometry  
OCTET RED 
Initial BLI analysis of the putative X-Aptamers was done on the OCTET Red system by 
AmBioTech. Biotinylated X-Aptamers were loaded onto streptavidin coated tips at 500 nM in 
PBS-TMB buffer (PBS with 0.02% Tween-20, 2 mM MgCl2, 0.1% BSA). X-Aptamers were 
incubated at 95 °C for 10 min and then renatured on ice for 5 min before loading. The 
concentration of LAM and rESAT-6 was 500 nM. Tips were loaded with X-Aptamer for 60 s 
followed by a 30 s wash with PBSTMB buffer for LAM X-Aptamers and a 120 s blocking step for 
CE X-Aptamers. X-Aptamers were allowed to associate with the target for 300 s before the tips 
were moved to buffer for a dissociation for 300 s.  
Data were processed and analysed using the Octet data analysis software (ForteBio®) using 
the 1:1 stoichiometric model.  Due to poor fitting a custom analysis was performed. The error 
created by the baseline drift was corrected by subtracting the baseline data from the binding 
data.  
The initial association and dissociation curves were used to estimate the rate constant of the 
binding reaction between immobilised X-Aptamer and LAM using the initial association and 
initial dissociation slope expressions. These expressions are derived below. 
• The initial slope of association curve is 𝑘𝑜𝑛[𝐴]0[𝐿]0 𝜑⁄ . 
• The initial slope of the dissociation curve is −𝑅𝑠𝑎𝑡𝑘𝑜𝑓𝑓. 
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Definitions 
• A: concentration in solution [mol/m3] 
• L: density immobilised on surface [ mol/m2] 
• [LA]: analyte-ligand complex on the surface [mol/m2] 
• V: volume of microtitre plate well [m3] 
• S: surface area of microtitre plate well [m2] 
• 𝑘𝑜𝑓𝑓:  Dissociation rate constant [1/s] 
• 𝑘𝑜𝑛: Association rate constant [m3/(mol·s)] 
• R: BLI signal [nm shift] 
 
Consider the reversible reaction 





Where the forward reaction rate is given by: 
 
𝑟𝑜𝑛 = 𝑘𝑜𝑛[L] ⋅ [A] (2) 
And the reverse reaction rate is: 
𝑟𝑜𝑓𝑓 = 𝑘𝑜𝑓𝑓[LA] (3) 
Where concentration [A] is defined per unit of volume and concentrations [L]  and [LA]  are 
defined per unit of surface area.  The dynamic mass balance of all the components results in 
this set of ordinary differential equations: 
𝑑[A]
𝑑𝑡
= (−𝑘𝑜𝑛 𝐶 ∙ [L] ∙ [A]) + (𝑘𝑜𝑓𝑓𝐶 ∙ [LA]) (4) 
𝑑[LA]
𝑑𝑡
= (k𝑜𝑛[L] ∙ [A]) − (𝑘𝑜𝑓𝑓[LA]) (5) 
𝑑[L]
𝑑𝑡
= (−𝑘𝑜𝑛[L] ∙ [A]) + (𝑘𝑜𝑓𝑓[LA]) (6) 
Where, 𝐶 is the ratio of total surface area to the volume. 
Since signal 𝑅 is proportional to the concentration [LA], [LA] can be expressed as [LA] = 𝜑𝑅, 
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where 𝜑  is a constant. According to equation (1) stoichiometry, concentrations [L] and [LA] 
are related via the expression: 
[𝐿] = [𝐿]0 − [𝐿𝐴] = [𝐿]0 − 𝜑𝑅 (7) 
Where [𝐿]0  is initial concentration of L. Substituting this expression into the differential 
equations (4) and (5) results in the following two equations: 
𝑑[𝐴]
𝑑𝑡






 ∙ [𝐴] ([𝐿]0 −  𝜑𝑅 ) − 𝑘𝑜𝑓𝑓𝑅 (9) 
Equation (6)  was excluded as it is not required. 
Curve fitting 
At initial association (Δta), where the curve is almost a straight line the following can be 
assumed. 
Initially, R is small thus assuming R ≈ 0: substitute into equation (8): 
𝑑[A]
𝑑𝑡
= (−𝑘𝑜𝑛 [A]𝐶 ∙ [L]0) (10) 
This equation can be solved directly, where [A]0 is the initial concentration of A: 
[𝐴] = [𝐴]0 exp(−𝑘𝑜𝑛𝐶[𝐿]0 𝑡) (11) 






 ([𝐴]0 exp(−𝑘𝑜𝑛𝐶[𝐿]0 𝑡)) ∙ [𝐿]0 (12) 
Integrate equation (12): 
R =  
[A]0
𝜑𝐶
 (1 − exp(−𝑘𝑜𝑛𝐶[𝐿]0 𝑡)) (13) 
Since 0 < 𝑡 < Δ𝑡𝑎   and Δ𝑡𝑎 is small, the exponent can be approximated by a linear expression, 





Thus, the initial slope of the association curve is 𝑘𝑜𝑛[𝐴]0[𝐿]0 𝜑⁄ . 
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Similarly, for initial stage of dissociation, [𝐴] ≈ 0 and equation (6) becomes 
𝑑𝑅
𝑑𝑡
= −𝑘𝑑𝑅 (15) 
Its integration results in 
𝑅 = 𝑅𝑠𝑎𝑡 exp (−𝑘𝑜𝑓𝑓(𝑡 − 𝑡𝑑)) (16) 
Where 𝑡𝑑 is the time at the beginning of dissociation curve and  𝑅𝑠𝑎𝑡  is the signal at time 𝑡𝑑 . For 
small time increments 𝑡 − 𝑡𝑑 < Δ𝑡𝑑, this simplifies to 
𝑅 ≈ 𝑅𝑠𝑎𝑡 (1 − 𝑘𝑜𝑓𝑓(𝑡 − 𝑡𝑑)) (17) 
Thus, the initial slope of the dissociation curve is −𝑅𝑠𝑎𝑡𝑘𝑜𝑓𝑓. 
 
OCTET K2 
At a later date an OCTET K2 system became available for use. Due to limited reagents only one 
aptamer was tested. Previously CE 3.8 had encouraging binding with ELONAs hence it was 
further characterised. A 2-fold dilution series of rESAT-6 was prepared (1000 to 62.5 nM) in 
PBS-TM (PBS with 0.05% Tween-20, 1 mM MgCl2). Streptavidin coated tips were equilibrated 
for 180s in PBS-TM before loading biotinylated X-Aptamers at 100 nM in PBS-TM buffer for 
150 s. X-Aptamers were incubated at 95 °C for 10 min and then renatured on ice for 5 min 
before loading. X-Aptamer coated tips were allowed to associate with the target for 300 s before 
the tips were moved to PBS-TM buffer for 300 s to dissociate. Reference tips were coated with 
X-Aptamer but not incubated with rESAT-6. LAM 4.1 was used as an irrelevant aptamer control 
to assess the analytical specificity of binding.  
Data were processed and analysed using the Octet data analysis software (ForteBio®). Curves 
were fitted using a 1:1 stoichiometric model. Reference traces were subtracted before analysis. 
5.2.3 In silico Sequence Analysis 
The Mfold web server was used to secondary structure analysis of X-Aptamer sequences 
(http://unafold.rna.albany.edu/?q=mfold/DNA-Folding-Form). All settings were left as default 
except for folding temperature and sodium concentration ([Na+]). Folding temperature was set 
at 25 ⁰C and [Na+] was set at 137 mM since aptamer were suspended in PBS pH ~7.5. 
Modified bases were converted from uracil to thymidine since Mfold does not have functionality 
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for deoxyribose uracil (dUTP) nucleotides. 
5.3 Results 
5.3.1 ELONA-ELISA Hybrid 
In-house ELONA-ELISA hybrid assays were used to screen the binding ability of putative 
aptamers selected against the CFP-10·ESAT-6 dimer, CFP-10 and LAM. Up to three controls 
were used in these assays. The aptamer only control assessed non-specific binding of the HRP 
conjugated antibody to the surface with aptamer. The ESAT-6, CFP-10 or LAM only control 
assessed non-specific binding of the molecules to the surface without being specifically 
immobilised by an aptamer or antibody. Lastly, the no aptamer or biomarker assessed baseline 
non-specific binding of the HRP conjugated antibody to the surface. 
ESAT-6 and CFP-10 
 To screen the aptamers against ESAT-6 and CFP-10, the biotinylated X-Aptamers were 
immobilised via streptavidin and the recombinant proteins were detected via their HIS-tags 
with HRP conjugated Anti-HIS antibodies.   
X-Aptamer CE 3.8 (Figure 5.4) produced the highest absorbance readings when binding to 
rESAT-6 and rCFP-10. CE 3.6 and CE 3.9 also had absorbance readings above the pooled X-
Aptamer only control for rCFP-10 and control two and three for rESAT-6.  There was no 
detectable binding of rESAT-6 or rCFP-10 for the other X-Aptamers as the absorbance reading 
was equal to or less than the control for these aptamers (Figure 5.5 and Figure 5.6).  
CE 3.8 TTTTT CA TCGT AGCCTAGCCTGWCCCZWAATACTTAZCGGZ TCGT TTTTT 
W=INDOLE; Z=BORON 
 
Figure 5.4 X-Aptamer CE 3.8 sequence.  
The CE 3.8 sequence was modified at three positions with indole and boron. 
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Figure 5.5 CFP-10 ELONA-ELISA Hybrid.  
CE 3.1-3.9 were assessed for binding to HIS tagged rCFP-10 (5.9 nM). All wells were 
performed in duplicate. Columns indicate the mean reading of duplicate or triplicate 
wells.  Error bars indicate the minimum and maximum readings taken. 
CE_A: Streptavidin BSAX-AptamerrCFP-10-HISAnti-HIS-HRP (rCFP-10-HIS) 
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Figure 5.6 ESAT-6 ELONA-ELISA Hybrid.  
CE 3.1 to 3.9 were assessed for binding to HIS tagged rESAT-6 (5.9 nM).  All wells were 
in duplicate. Columns indicate the mean reading of duplicate wells.  Error bars indicate 
the minimum and maximum readings taken. 
CE_B: Strep BSAX-Aptamer rESAT-6-HIS Anti-HIS-HRP (rESAT-6-HIS) 
Control 1: StreptavidinBSA PBS rESAT-6  Anti-HIS-HRP (Ctrl 1: rESAT-6 no HIS tag) 
Control 2: StreptavidinBSA X-Aptamer (CE 3.9)  PBS Anti-HIS-HRP (Ctrl 2: X-Apt only) 
Control 3: StreptavidinBSA PBS PBS Anti-HIS-HRP (Ctrl 3: No X-Apt; No ESAT-6) 
Chapter 5: Characterising X-Aptamers Against TB Biomarkers  
     157 
 
Binding curves were constructed where rESAT-6 and rCFP-10 concentrations were fixed at 
1 nM and the X-Aptamers were diluted in a two-fold serial dilution (0.004-0.5 µM). When the 
concentration of X-Aptamer incubated with the surface was increased the amount of CFP-10 
bound at equilibrium did not increase for any of the X-Aptamers tested (Appendix C: Figure A 
14 and Figure A 15).  Similarly, the amount of rESAT-6 bound did not increase with increasing 
X-Aptamer immobilised on the surface for X-Aptamers CE3.6 and CE 3.9 (Appendix C: Figure A 
16). However, the amount of rESAT-6 bound at equilibrium increased with increasing 
concentration of X-Aptamer CE 3.8 incubated with the surface which produced a binding curve 
(Figure 5.7). As little as 4 nM of CE 3.8 could detect 1 nM of rESAT-6. Further experiments were 
conducted with rESAT-6 and CE 3.8. 
 
Figure 5.7 Binding Curve with rESAT-6 and CE 3.8. 
HIS tagged rESAT-6 (1 nM) and two-fold serial dilutions of X-Aptamer CE 3.8 (0.5-
0.004 µM). All wells were performed in duplicate.  Columns indicate the mean 
reading of duplicate wells.  Error bars indicate the minimum and maximum 
readings taken. 
CE_B: Streptavidin BSAX-AptamerrESAT-6-HISAnti-HIS-HRP 
Control 1: StreptavidinBSA X-Aptamer (CE 3.9) PBS Anti-HIS-HRP (Ctrl 1: X-Apt Only) 
Control 2: StreptavidinBSA PBS PBS Anti-HIS-HRP (Ctrl 2: No X-Apt; No ESAT-6) 
 
 
Chapter 5: Characterising X-Aptamers Against TB Biomarkers  
     158 
 
To detect native ESAT-6 an alternative ELONA-ELISA hybrid was optimised, namely using 
polyclonal antibodies against ESAT-6 and a secondary HRP conjugated antibody against rabbit 
IgG. ESAT-6 was detected in H37Rv culture filtrate during mid-log and log phase but not 
stationary phase (Figure 5.8). Note the X-Aptamer only control gave a high background signal 
compared to the other controls. 
 
 
Figure 5.8 ESAT-6 detection in H37Rv Culture Filtrate with CE 3.8. 
All wells were performed in triplicate. Columns indicate the mean reading of triplicate 
wells.  Error bars indicate the minimum and maximum readings taken. 
ELONA/ELISA: Streptavidin X-AptamerCulture Filtrate Anti-ESAT-6 Anti-Rabbit IgG-HRP 
(H37Rv Culture Filtrate) 
Control 1: Streptavidin PBSCulture Filtrate Anti-ESAT-6 Anti-Rabbit IgG-HRP 
Control 2: Streptavidin X-Aptamer PBS Anti-ESAT-6 Anti-Rabbit IgG-HRP (Ctrl 2: X-Apt Only) 
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LAM 
To screen aptamers selected against LAM several LAM ELONA-ELISA hybrid assays were 
performed. For the first experiment LAM was captured onto the surface via anti-LAM antibodies 
and detected via the biotinylated X-Aptamers and HRP conjugated streptavidin (Figure 5.9 A). 
Each aptamer was tested with and without LAM present. All wells containing LAM had 
absorbance readings above the LAM only control, but only LAM 4.3 had an absorbance reading 
above the respective X-Aptamer only control. When a dilution series of the LAM only control 
was performed, it appeared that the lower the concentration of LAM the higher the background 
absorbance reading (Figure 5.9 B). 
In the second version of the ELONA-ELISA hybrid assay, biotinylated X-Aptamers were 
immobilised via streptavidin and the LAM (H37Rv) was detected with a monoclonal anti-LAM 
antibody and an HRP conjugated anti-mouse IgG. The first experiment was performed with 
0.5 µM X-Aptamer and 5.9 nM LAM (Figure 5.10 A). None of the wells had a signal above the 
controls, thus the concentration of X-Aptamer and LAM were increased to 5 µM and 1 µM 
respectively in the following experiment (Figure 5.10 B). While the overall signal was low, there 
were three X-Aptamers (LAM 4.1, 4.4 and 4.7) that had a signal above both the controls.  
Finally, a third assay was performed based on the method described by Pan et. al (Pan et al., 
2014). LAM (1 µM) was adsorbed directly onto the surface and detected with X-Aptamer and 
HRP conjugated streptavidin. Salmon sperm ssDNA was used to block the surface in the first 
version of this assay as reported by Pan et al. None of the aptamers binding LAM gave an 
absorbance reading above the LAM only control (Figure 5.11 A). To improve blocking 1 % BSA 
was added to the blocking buffer and the previously reported ZXL 1 aptamer was included to 
test the repeatability of the paper’s results. The absorbance readings had low values and the 
control absorbance reading remained higher than the wells where X-Aptamer was present 
(Figure 5.11 B). 
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Figure 5.9 LAM ELONA-ELISA hybrid with streptavidin-HRP detection. 
 A) LAM 4.1-4.9 were assessed for binding to LAM (5.9 nM). B) Serial dilution of LAM 
only control. All wells were in duplicate.  Columns indicate the mean reading of 
duplicate wells.  Error bars indicate the minimum and maximum readings taken. 
LAM_A: Anti-LAM (polyclonal)  BSALAM  X-AptamerStreptavidin-HRP 
Control 1: Anti-LAM (polyclonal) BSAPBS X-AptamerStreptavidin-HRP (Ctrl 1: X-Apt only) 
Control 2: Anti-LAM (polyclonal) BSALAM PBSStreptavidin-HRP (Ctrl 2: LAM only) 
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Figure 5.10 ELONA-ELISA Hybrid MAB detection.  
A) 0.5 µM X-Aptamer and 5.9 nM LAM B) 5 µM X-Aptamer and 1 µM LAM. All wells were 
in duplicate.  Columns indicate the mean reading of duplicate or triplicate wells.  Error 
bars indicate the minimum and maximum readings taken. 
LAM_B: StreptavidinBSA X-Aptamer LAM  Anti-LAM (monoclonal)Anti-mouse IgG-HRP 
Control 1: StreptavidinBSA X-Aptamer PBS Anti-LAM Anti-mouse IgG-HRP (Ctrl 1: X-Apt 
only) 
Control 2: StreptavidinBSA PBS LAM Anti-LAM Anti-mouse IgG-HRP (Ctrl 2: LAM only) 
Control 3: StreptavidinBSA PBS Anti-LAM Anti-mouse IgG-HRP (Ctrl 3: No X-Apt; no LAM) 
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Figure 5.11 LAM ELONA with ssDNA or ssDNA + BSA blocking.  
A) Wells blocked with Salmon sperm ssDNA. B) Wells blocked with salmon sperm ssDNA. All 
wells were in triplicate.  Columns indicate the mean reading of duplicate or triplicate wells.  
Error bars indicate the minimum and maximum readings taken. 
LAM_C: LAM(BSA +) ssDNA X-AptamerStreptavidin-HRP 
Control 1: LAM(BSA +) ssDNA PBSStreptavidin-HRP (Ctrl 1: LAM only) 
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5.3.2 Biolayer Interferometry  
OCTET RED 
For analysis with the Octet RED most X-Aptamers did not display binding (Appendix C: Figure 
A 17 and Figure A 18). Binding to CFP-10 was not tested since ELONA-ELISA assay screening 
had shown the best binding to ESAT-6. 
 The exception was LAM 4.1 binding to LAM. ForteBio® Octet software was used to fit a curve 
to the data assuming 1:1 stoichiometry (Figure 5.12). However, the curve did not fit well with 
a poor R2 score (< 0.9).  The negative trace of the baseline and dissociation phase is due to 
alignment artefacts from the software. Equilibrium appears to be reached by 100 s. 
Custom curve fitting after correcting the baseline drift was performed using the expressions: 
• The initial slope of association curve is 𝑘𝑜𝑛[𝐴]0[𝐿]0 𝜑⁄ . 
• The initial slope of the dissociation curve is −𝑅𝑠𝑎𝑡𝑘𝑜𝑓𝑓. 
The rate constant value 𝑘𝑜𝑓𝑓 = 0.064 s-1 was found to minimise the error between predicted 
initial dissociation curve and the experimental data (Figure 5.13).  The data from initial stage 
of association is insufficient to determine rate coefficient 𝑘𝑜𝑛, since it can only determine the 
value of the expression (𝑘𝑜𝑛[L]0)/𝜑 and values [L]0 and ϕ are unknown. 
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Figure 5.12 BLI data for X-Aptamer LAM 4.1  
 ForteBio® software fitted curves 
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Figure 5.13 Initial dissociation curve of X-Aptamer LAM 4.1 and LAM.  
Calculated 𝑘𝑜𝑓𝑓 = 0.064 (1/s) 
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OCTET K2 
After optimisation of the ESAT-6 concentration range, X-Aptamer concentration and loading 
time (Appendix C: Figure A 1) the final experiment was performed as stated in the methods. 
While signal was weak, it was sufficient. Signal should ideally be > 0.7 nm, but higher signals 
could not be obtained. Using the ForteBio® software a 1:1 stoichiometric model was used to 
determine the binding constants.  The three highest concentrations of ESAT-6 produced curves 
that fitted well with a 1:1 model (Figure 5.14 A) X-Aptamer 3.8) and had good R2 values (> 0.9) 
(Table 5.1). Small 2   values are also desirable.  The two lowest concentrations did not have 
good R2 values, signal was very low and curves almost appeared flat.  
The calculated KD values for binding between X-Aptamer CE 3.8 and rESAT-6 were between 187 
nM and 400 nM. The 𝑘𝑜𝑓𝑓 values ranged from 10-4 to 10-3 (s-1). 
An unrelated X-Aptamer was also associated with rESAT-6 to assess non-specific binding. The 
poor fit to the 1:1 model and (Table 5.2) the sharp dip in signal at the start of dissociation 
indicates non-specific binding which is most evident at the highest concentration of rESAT-6 
(Figure 5.14 B) Unrelated X-Aptamer).  Non-specific binding had lower signal than real binding 
between X-Aptamer CE 3.8 and rESAT-6. 
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Figure 5.14 Association and Dissociation of rESAT-6 with 
 A) X-Aptamer CE 3.8 and B) Unrelated X-Aptamer Control (LAM 4.1). rESAT-6 
concentrations: Blue- 1000 nM; Red- 500 nM; Light blue- 250 nM; Lime green- 125 nM; 
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Table 5.1 X-Aptamer CE 3.8 Curve fitting results 
 rESAT-6 conc. 
(nM) 
KD(M) 𝒌𝒐𝒏 (1/Ms) 𝒌𝒐𝒇𝒇 (1/s) 𝒌𝒐𝒃𝒔 (1/s) Full X2 Full R2 
1000 2.04E-07 3.13E+03 6.39E-04 3.77E-03 0.0076 0.992 
500 1.87E-07 4.12E+03 7.72E-04 2.83E-03 0.0055 0.985 
250 4.06E-07 3.75E+03 1.52E-03 2.46E-03 0.0042 0.951 
125 6.73E-08 2.48E+04 1.67E-03 4.76E-03 0.0044 0.886 
62.5 <1.0E-12 2.08E+04 <1.0E-07 1.30E-03 0.0093 0.707 
 
Table 5.2 Unrelated X-Aptamer Control Curve fitting results 
rESAT-6 conc. 
(nM) 
KD (M) 𝒌𝒐𝒏 (1/Ms) 𝒌𝒐𝒇𝒇 (1/s) 𝒌𝒐𝒃𝒔 (1/s) Full X2 Full R2 
1000 1.76E-07 8.54E+03 1.50E-03 1.00E-02 0.0248 0.810 
500 9.57E-08 1.99E+04 1.91E-03 1.19E-02 0.0083 0.7493 
250 2.25E-08 4.47E+04 1.01E-03 1.22E-02 0.0058 0.7543 
125 <1.0E-12 3.17E+04 <1.0E-07 3.96E-03 0.0094 0.7192 
62.5 <1.0E-12 2.01E+05 <1.0E-07 1.26E-02 0.0071 0.3196 
 
5.3.3 Secondary Structure Analysis 
The two aptamers that showed the most promising binding were subject to in silico secondary 
structure analysis with Mfold software (Zuker, 2003). CE 3.8 produced three structures with 
hairpin-loops with short stems and minimum free energy (ΔG) values ranging from 0.08 to 1.06 
kcal/mol (Figure 5.15 A, B and C). LAM 4.1 had structures with hairpin-loop structures with 
longer stems and ΔG values from -2.66 to -1.34 kcal/mol (Figure 5.16).  
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Figure 5.15 X-Aptamer CE 3.8 secondary Structures predicted by Mfold. A) Structure 1; 
B) Structure 2; C) Structure 3; D) Structure 4. 
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Figure 5.16 X-Aptamer LAM 4.1 secondary structures predicted by Mfold. 
 A) Structure 1; B) Structure 2; C) Structure 3; D) Structure 4. 
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5.4 Discussion 
5.4.1 ELONA-ELISA hybrid 
ESAT-6 and CFP-10 
During the initial screening of the X-Aptamers selected against rESAT-6 and rCFP-10 three 
aptamers were found to bind to rCFP-10 and rESAT-6 with absorbance readings above one or 
more of the controls (Figure 5.5 and Figure 5.6). The sequence with the best absorbance 
readings, CE 3.8, had indole and boron modifications which indicate that binding was facilitated 
by interactions with hydrophobic  and nucleophilic amino acid side chains on ESAT-6 (Figure 
5.4) (Whyte, Vilar and Woscholski, 2013). CE3.6 and CE 3.9 were included for further 
investigation with rESAT-6 despite absorbance readings being below the X-Aptamer only 
control since only X-Aptamer CE 3.9 was used as a control and rCFP-10 had bound to these two 
aptamers. 
In this first experiment X-Aptamers were pooled for the X-Aptamer only control in the assay 
(Figure 5.5), but since the non-specific binding of the antibodies to the X-Aptamers was not 
expected to vary greatly from aptamer to aptamer only one X-Aptamer was used as a control in 
the following experiment to save X-Aptamer stocks (Figure 5.6). This assumption was later 
withdrawn hence in later experiments, each X-Aptamer investigated had a control well with the 
respective X-Aptamer only control (Figure 5.7 and Figure A 14 to Figure A 16). The X-Aptamer 
only control produced a particularly high absorbance reading for the assay with the H37Rv 
culture filtrate (Figure 5.8) which is likely due to the available antibodies binding non-
specifically to the X-Aptamer when there is no protein present, which reiterates the need for 
better molecular recognition reagents for diagnostic assays. 
To explore the parameters of the assay a dilution series of the X-Aptamers was incubated with 
streptavidin coated surfaces. Streptavidin can bind up to four molecules of biotin with 
femtomolar affinity (KD ~ 10-14). The density of X-Aptamer on the surface is proportional to the 
concentration of X-Aptamer incubated with the streptavidin surface until the surface is 
saturated. Hence the amount of rESAT-6 or rCFP-10 bound should also increase with increasing 
density of X-Aptamer on the surface. 
The dilution series of X-Aptamer CE 3.8 revealed a concentration-dependent binding curve 
when binding 1 nM of rESAT-6 (Figure 5.7). The other aptamers did not produce a similar curve 
when binding to rCFP-10 or rESAT-6. The absorbance readings for these aptamers remained 
constant and low irrespective of the concentration of X-Aptamer immobilised on the surface 
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(Appendix C: Figure A 14 to Figure A 16).  The lack of concentration-dependent binding 
indicates that the binding observed could be non-specific for these aptamers.  
Lastly, the ability of X-Aptamer CE 3.8 to detect ESAT-6 in H37Rv culture filtrate was tested. A 
common misconception is that ESAT-6 is only present in early stages of growth however it is 
rather one of the earliest proteins secreted into the culture filtrate (Andersen et al., 1991; 
Sørensen et al., 1995; Målen et al., 2007). Despite a high background signal from the X-Aptamer 
only control ESAT-6 was detected in the mid-log and log phase whereas it could not be detected 
above background, in the stationary phase (Figure 5.8).  This assay demonstrates that the CE 
3.8 can detect native ESAT-6 in a complex media. Future work would include testing this 
aptamer in more complex media such as patient samples and testing cross-reactivity with 
commensal bacteria found in patient samples. 
LAM 
Since LAM did not have a HIS tag like rESAT-6 and rCFP-10, alternative ELONA-ELISA hybrid 
assays were explored to assess binding of the putative X-Aptamers against LAM. The first 
alternative assay captured LAM onto the surface via anti-LAM antibodies and bound 
X-Aptamers were detected with HRP-conjugated streptavidin (LAM_A: Figure 5.3).  
 The absorbance values for the X-Aptamer only control wells were higher than wells containing 
LAM and X-Aptamer, and covered a broad range (0.14 to 0.26) (Figure 5.9 A). This background 
signal is likely due to the streptavidin-HRP binding non-specifically to the other components of 
the assay as X-Aptamers used in the control were likely removed during wash steps since no 
LAM was present for the X-Aptamers to bind. The absorbance readings for this assay were also 
low which indicates a low concentration of LAM is being retained on the surface. The 
combination of high background and low assay signal impeded analysis of this assay as it is not 
clear if binding is due to non-specific binding or if real binding is occurring.  
When a dilution series was performed, it was evident that the LAM was acting as a blocking 
agent; the more LAM that was bound the less non-specific binding there was by the HRP 
conjugated streptavidin (Figure 5.9 B). When the concentration of LAM is sufficient to block 
non-specific binding the absorbance values are valid for screening binding. Values should be 
above the LAM only control. 
Given the caveats of the previous assay format another ELONA-ELISA hybrid assay was 
performed where biotinylated X-Aptamers were immobilised via streptavidin and LAM was 
detected with a monoclonal anti-LAM antibody and an HRP conjugated anti-mouse IgG (LAM_B: 
Chapter 5: Characterising X-Aptamers Against TB Biomarkers  
     173 
Figure 5.3).  An advantage of this assay format is that the X-Aptamer binds to LAM first. Hence 
binding is unhindered by a bulky antibody that may obstruct the epitope that the X-Aptamer 
binds. 
Initially the assay was performed with 0.5 µM X-Aptamer and 5.9 nM LAM (Figure 5.10 A) 
however no binding above the controls was observed. Hence the concentration of X-Aptamer 
and LAM were increased to 5 µM and 1 µM respectively in the following experiment (Figure 
5.10 B).  Despite increasing concentrations of LAM and X-Aptamer incubated with the surface, 
absorbance readings did not increase considerably. The surface could be saturated with 0.5 µM 
of X-Aptamer hence the amplitude of the signal could not be increased by increasing the 
concentration to 5 µM. Nevertheless, there were three X-Aptamers (LAM 4.1, LAM 4.4 and LAM 
4.7) that had absorbance readings above the controls (Figure 5.10 B).  
The last strategy to improve signal was to use different blocking agents to decrease the 
background absorbance. The third assay was performed based on the method described by Pan 
et. al; LAM was adsorbed directly onto the surface and detected with X-Aptamer and HRP 
conjugated streptavidin (LAM_C: Figure 5.3)(Pan et al., 2014). Salmon sperm ssDNA was used 
to block the surface in the first version of this assay as reported by Pan et al., however it was 
not effective at blocking the surface as there were no absorbance readings above the controls 
(Figure 5.11 A). BSA was added to reduce non-specific binding and one of the aptamers from 
the Pan et al. study (ZXL 1) was synthesized to use as a control (Figure 5.11 B). Overall 
background binding was reduced 10-fold from 0.6 to 0.06 absorbance units, however  the 
sample signals  remained below the background signal including ZXL 1 which had previously 
been reported to bind to LAM above a LAM only control in a similar experiment (Pan et al., 
2014).  
In summary, all the X-Aptamers selected against LAM appear to have bound LAM  as per the 
first ELONA-ELISA hybrid assay (Figure 5.9) and LAM 4.1, LAM 4.4, and LAM 4.7 appear to bind 
more tightly according to the second assay when the concentrations of LAM and X-Aptamer are 
increased (Figure 5.10).  
5.4.2 Biolayer Interferometry 
X-Aptamers, LAM and rESAT-6 where sent for analysis by the Octet RED system which employs 
BLI to measure binding. Poor binding was observed for most the aptamers (Appendix C: Figure 
A 17 and Figure A 18). The ESAT-6 assays appeared to suffer from non-specific binding of 
rESAT-6 to the streptavidin tips and blocking strategies did not overcome this.  
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 X-Aptamer LAM 4.1 data showed a clear binding curve, but the Octet software could not fit a 
curve to the data. Hence a customised approach was used where the initial slope of the 
dissociation curve was used to estimate 𝑘𝑜𝑓𝑓 . The 𝑘𝑜𝑓𝑓  value was estimated at 0.064 𝑠
−1 . 
Pollard commented that association rate constants for typically sized proteins are often in a 
narrow range (106 to 107𝑀−1𝑠−1) hence the dissociation rate constant often determines the 
affinity. Hence micromolar affinity binding reactions have 𝑘𝑜𝑓𝑓  values around 1 𝑠
−1  while 
nanomolar affinity reactions have 𝑘𝑜𝑓𝑓  values around 0.001 𝑠
−1  (Pollard, 2010). Thus a 𝑘𝑜𝑓𝑓 
value of 0.064 𝑠−1  is an improvement  of typical  aptamers selected against lipid or 
carbohydrate moieties which tend to have low micromolar affinity (10−5 to 10−7 𝑀) (Fukusaki 
et al., 2000; Betat et al., 2003; Masud et al., 2004; Boese and Breaker, 2007; Low, Hill and Peccia, 
2009; Wang et al., 2014). 
At a later date a local OCTET K2 system became available. Additional analyses were performed 
between rESAT-6 and X-Aptamer CE 3.8.  
 During initial experiments concentrations of rESAT-6 were between 0.7 nM and 250 nM and 
X-Aptamer concentration was 50 nM. The final rESAT-6 range was 62.5 nM to 1000 nM given 
the poor signal obtained at lower ranges (data not shown). The concentration of aptamer was 
also increased to 100 nM to maximise the surface coverage of X-Aptamer on the streptavidin 
coated surface. ForteBio® recommends concentrations between 50 nM and 100 nM (Tobias 
and Kumaraswamy, 2013). The loading time of aptamers was increased from 150 s to 300 s in 
an effort to increase signal. However, increased loading time did not improve signal and 
excessive loading time or high ligand concentrations can result in steric hindrance (Appendix 
C: Figure A 2) (Edwards et al., 1995). 
 BSA and detergents are typical agents used to minimise non-specific binding. BSA is not 
recommended when characterising aptamers since there is a heating step during aptamer 
preparation. Hence, Tween-20 or other detergents should be used to mitigate non-specific 
binding. The ForteBio® Kinetics buffer contains BSA but this is not stated on the data sheet 
which impeded initial trouble-shooting. 
Fitted curves generated KD values from ~180 to 400 nM (Table 5.1). While this binding affinity 
is in a modest range the benefits of aptamers coupled with label-free detection could still 
warrant the use of aptamers over antibodies. Additionally, given the novel method of selection 
it is bound to improve with time. Hence better aptamers could be selected with more advanced 
selection methods.  
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DNA aptamers previously selected against ESAT-6 had a similar KD value of 160 nM but they 
did not report 𝑘𝑜𝑓𝑓  values (Tang et al., 2014). The 𝑘𝑜𝑓𝑓  values for X-Aptamer CE 3.8 ranged 
from 10-3 to 10-4 (s-1). This equates to a half-time between ~8-18 min i.e. the amount of time for 
50% dissociation. While a KD value may indicate nano –or micromolar affinity it does not 
indicate the on- and off-rate. Since the KD value is the quotient of the rate constants, a reaction 
with a fast on- and off- rate may have the same KD value as a reaction with a slower, more 
favourable off-rate.  
Lower concentrations of rESAT-6 had poorly fitted curves and thus poor estimation of the KD.  
Lower analyte concentrations may suffer from mass transport issues where binding is 
dependent on access to the surface rather than affinity between the two molecules. If mass 
transport is an issue curves tend to be flatter and may appear as flat lines such as observed for 
the lowest concentration of rESAT-6 (Figure 5.14) (Tobias and Kumaraswamy, 2013). 
An unrelated X-Aptamer was also associated with rESAT-6 to assess non-specific binding. The 
poor fit to the 1:1 model and (Table 5.2) the sharp dip in signal at the start of dissociation 
indicates non-specific binding which is most evident at the highest concentration of ESAT-6 
(Figure 5.14).  Non-specific binding had lower signal than real binding between X-Aptamer CE 
3.8 and rESAT-6 but should be kept in mind when designing assays. 
5.4.3 Secondary Structure Analysis 
Despite the caveats discussed above secondary structure analysis was performed on the two 
best performing X-Aptamers CE 3.8 and LAM 4.1 (Figure 5.15 and Figure 5.16) 
CE 3.8 produced three structures with poor ΔG values ranging from 0.08 to 1.06 kcal/mol with 
short stemmed hairpin loops; hence these predicated structures are unstable and not useful for 
predicting key binding epitopes of this aptamer (Figure 5.15). LAM 4.1 had more promising 
predicted structures with ΔG values from -2.66 to -1.34 kcal/mol and longer stems on the 
hairpin loops which indicates better stability (Figure 5.16). These structures could be used to 
guide truncation of the X-Aptamer LAM 4.1 for reducing the cost of synthesis, possibly 
improving affinity for the target and understanding  the aptamer-target interaction (Fischer, 
Tok and Tarasow, 2008; Keefe, Pai and Ellington, 2010; Berezhnoy et al., 2012; Kaur and Yung, 
2012). 
5.4.4 Conclusion 
X-Aptamer CE 3.8 was identified as a good candidate as a molecular recognition unit in a 
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biosensor to detect ESAT-6 in patient samples. In order to be a viable option for diagnosing 
tuberculosis, aptamers require further optimisation to improve analytical sensitivity and 
specificity. Availability and concentration of individual biomarkers is key to the choice of 
specimen in which to make diagnostic measurements. 
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6  CONCLUSION 
The first aim of this thesis was to determine if LAM could be detected in TB patient urine with 
conventional methods by concentrating the urine. Concentration of TB patient urine increased 
the number of patient samples that were LAM positive, including an HIV negative patient. This 
illustrates that conventional methods are not sensitive enough to detect the low concentration 
of LAM present in TB patients. 
Secondly, urine and sputum were probed for secreted mycobacterial proteins. Initial 
experiments used an in-house ELISA to detect ESAT-6, but due to cross-reactivity issues an 
alternative method was employed, namely mass spectrometry. Neither ESAT-6 nor CFP-10 
could be detected in urine. Future work should focus on detecting ESAT-6 or CFP-10 in other 
patient specimens such as sputum. 
Lastly, novel X-Aptamers were selected against KatG, ESAT-6 and LAM. A detailed kinetic 
characterization was carried out for the best aptamer selected against ESAT-6, X-Aptamer 
CE 3.8. Additionally, this aptamer binds to native ESAT-6 in culture filtrate in a growth state 
dependent manner. The ability of this aptamer to bind to native ESAT-6 highlights its potential 
utility in future diagnostic or other assays. 
Given that neither CFP-10 nor ESAT-6 were detected in urine by targeted mass spectrometry 
future work with the selected aptamers should include development of assays for the detection 
of native biomarkers in biological specimens such as culture filtrate and other patient samples 
which may contain these biomarkers such as sputum. 
The use of aptamers as capture agents for detecting biomarkers in biological specimens thus 
appears to be a viable option for diagnosing tuberculosis, although availability and 
concentration of individual biomarkers seems likely to remain key to the choice of specimen in 
which to make diagnostic measurements. 
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APPENDIX A 
Binding curve results 
Table A2  Mean absorbance readings for ESAT-6 ELISA binding curves. Each point is the mean 
of triplicate wells except for rESAT-6 10 ng/ml and 5 ng/ml in PBS which were in duplicate. The 








10.00 0.420 0.694 0.414 
5.00 0.397 0.566 0.367 
2.50 0.331 0.478 0.286 
1.25 0.272 0.418 0.211 
0.63 0.199 0.380 0.177 
0.31 0.168 0.373 0.168 
0.15 0.151 0.355 0.157 
Negative Control 0.140 0.347 0.131 
Cut-off 0.206 0.377 0.159 
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ELISA Patient Sample Information and Results 
Table A3 Urine sample patient details 










UA133 Positive 17 TB + No * ELISA 
UA141 Positive 54 TB + No * ELISA 
UA158 Positive 6 TB + No * ELISA 
UA215 Positive 84 TB + Yes 1+ ELISA 
UA310 Positive 164 TB + Yes * ELISA 
UA120 Positive 112 TB + No trace MS; WB 
UA127 Positive 146 TB + No 1+ MS; WB 
UA211 Positive 5 TB + No trace MS; WB 
UA268 Negative * TB + No * MS; WB 
UA137 Positive 17 TB + No * WB 
UA144 Positive * TB + No * WB 
UA167 Positive * TB + No * WB 
*Data not available; M. tuberculosis detected by culturing sputum (TB +); Protein in urine 
grading: negative (less than 10 mg per dL), trace (10 to 20 mg per dL), 1+ (30 mg per dL), 2+ 
(100 mg per dL), 3+ (300 mg per dL) or 4+ (1,000 mg per dL); Western Blot (WB); Enzyme 
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Table A4 Mean absorbance readings from in-house ESAT 6 ELISA using urine samples 
Sample numbers 
5 kDa MWCO 
filter 
Lyophilised Neat 
UA133 0.105 0.122 0.089 
UA141 0.387* 0.146 0.078 
UA158 0.116 0.081 0.094 
UA215 0.548* 0.144 0.087 
UA310 0.108 0.092 0.084 
H1 0.096 0.094 0.084 
H2 0.171 0.150 0.085 
H3 0.111 0.312* 0.098 
H4 0.106 0.098 0.089 
H5 0.315* 0.153 0.094 
Negative Control 0.125 0.125 0.125 
Cut-off 0.258 0.258 0.258 
*Absorbance reading above the cut-off 
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Table A5 Sputum sample patient details and absorbance readings from in-house ESAT-6 ELISA 
Patient  #Absorbance TB Status Culture 
T-SPOT®. 
TB 
TBN58 0.111 TB+ + * 
TBN59 0.108 TB+ + * 
TBN141 0.125 TB+ + * 
TBN145 0.113 TB+ + * 
TBN162 0.143 TB+ + * 
TBN274 0.148 TB+ + * 
TBN73 0.170 LTBI - + 
TBN113 0.210 LTBI - + 
TBN146 0.115 LTBI - + 
TBN164 0.260 LTBI - + 
TBN282 0.548 LTBI - + 
TBN35 0.106 TB- - - 
TBN397 0.155 TB- - - 
TBN399 0.140 TB- - - 
TBN465 0.317 TB- - - 
TBN468 0.270 TB- - - 
Negative 
control 
0,117 n/a n/a n/a 
*Data not available or test not performed; M. tuberculosis detected by culturing 
sputum (TB +); positive T-SPOT®.TB and negative culture (LTBI); negative T-
SPOT®.TB and negative culture (TB -).  
 
  
Appendix A  
     221 
Max Quant  
MaxQuant Settings 
 
Table A6 MaxQuant Parameters 
Parameter Value 
Version 1.5.3.12 
Fixed modifications Carbamidomethyl (C) 
Decoy mode revert 
Special AAs KR 
Include contaminants TRUE 
MS/MS toll. (FTMS) 20 ppm 
Top MS/MS peaks per 100 Da. (FTMS) 12 
MS/MS deisotoping (FTMS) TRUE 
MS/MS tol. (ITMS) 0.5 Da 
Top MS/MS peaks per 100 Da. (ITMS) 8 
MS/MS deisotoping (ITMS) FALSE 
MS/MS tol. (TOF) 40 ppm 
Top MS/MS peaks per 100 Da. (TOF) 10 
MS/MS deisotoping (TOF) TRUE 
MS/MS tol. (Unknown) 0.5 Da 
Top MS/MS peaks per 100 Da. (Unknown) 8 
MS/MS deisotoping (Unknown) FALSE 
PSM FDR 0.01 
Protein FDR 0.01 
Site FDR 0.01 
Use Normalized Ratios For Occupancy TRUE 
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Parameter Value 
Min. peptide Length 7 
Min. score for unmodified peptides 0 
Min. score for modified peptides 40 
Min. delta score for unmodified peptides 0 
Min. delta score for modified peptides 6 
Min. unique peptides 0 
Min. razor peptides 1 
Min. peptides 1 
Use only unmodified peptides and TRUE 
Modifications included in protein 
quantification 
Oxidation (M); Acetyl (Protein N-term) 
Peptides used for protein quantification Razor 
Discard unmodified counterpart peptides TRUE 
Min. ratio count 2 
Use delta score FALSE 
iBAQ FALSE 
iBAQ log fit FALSE 
Match between runs FALSE 




M. tuberculosis (strain ATCC 25618 / 
H37Rv) _ UP000001584_Feb2016.fasta 
Labelled amino acid filtering TRUE 
Site tables Oxidation (M)Sites.txt 
Decoy mode revert 
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Parameter Value 
Special AAs KR 
Include contaminants TRUE 
RT shift FALSE 
Advanced ratios TRUE 
AIF correlation 0 
First pass AIF correlation 0 
AIF topx 0 
AIF min mass 0 
AIF SIL weight 0 
AIF ISO weight 0 
AIF iterative FALSE 
AIF threshold FDR 0 
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MaxQuant Results 
Table A7 MaxQuant Results (majority protein IDs are displayed for simplicity). Protein IDs which had at least one unique peptide in each 
patient for each gel slice respectively is indicated by 25-35 kDa and 130-250 kDa unique peptides. Majority proteins with one or more Ig 
or Ig-like domain are indicated in the last column. Decimal separator in this table are commas. 
 Majority 
protein IDs 












A0A087WV47 Ig gamma-1 chain C region 323,31 3,13E+11 51,154 No No No 
P02760 Protein AMBP [Cleaved into: Alpha-1-microglobulin (Protein HC) (Alpha-1 
microglycoprotein) (Complex-forming glycoprotein heterogeneous in 
charge); Inter-alpha-trypsin inhibitor light chain (ITI-LC) (Bikunin) 
(EDC1) (HI-30) (Uronic-acid-rich protein); Trypstatin] 
323,31 1,58E+11 38,999 Yes Yes No 
A0A087WZW8 Ig kappa chain C region 323,31 1,30E+11 12,997 Yes Yes Yes 
A0A024R6I7 Alpha-1-antitrypsin (Serpin peptidase inhibitor, clade A (Alpha-1 
antiproteinase, antitrypsin), member 1, isoform CRA_a) 
323,31 6,76E+10 46,708 Yes Yes No 
P01876 Ig alpha-1 chain C region 323,31 3,56E+10 37,655 No Yes Yes 
A0A0G2JN06 Ig gamma-2 chain C region (Fragment) 323,31 2,82E+10 35,901 No Yes Yes 
A0A087WXL8 Ig gamma-3 chain C region 323,31 2,42E+10 56,89 No No No 
P00915 Carbonic anhydrase 1 (EC 4.2.1.1) (Carbonate dehydratase I) (Carbonic 
anhydrase B) (CAB) (Carbonic anhydrase I) (CA-I) 
323,31 1,96E+10 28,87 No No No 
E9PFZ2 Ceruloplasmin 323,31 1,83E+10 108,82 No No No 
P01011 Alpha-1-antichymotrypsin (ACT) (Cell growth-inhibiting gene 24/25 
protein) (Serpin A3) [Cleaved into: Alpha-1-antichymotrypsin His-Pro-
less] 
323,31 1,82E+10 47,651 Yes Yes No 
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 Majority 
protein IDs 












P02750 Leucine-rich alpha-2-glycoprotein (LRG) 323,31 1,62E+10 38,178 Yes Yes Yes 
B4E1Z4 Uncharacterized protein (cDNA FLJ55673, highly similar to Complement 
factor B (EC 3.4.21.47)) 
323,31 1,57E+10 140,943 Yes No No 
A0A075B6L0 Ig lambda-3 chain C regions (Fragment) 142,05 1,35E+10 11,32 No No No 
P01024 Complement C3 (C3 and PZP-like alpha-2-macroglobulin domain-
containing protein 1) [Cleaved into: Complement C3 beta chain; C3-beta-c 
(C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation 
stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; 
Complement C3c alpha' chain fragment 1; Complement C3dg fragment; 
Complement C3g fragment; Complement C3d fragment; Complement C3f 
fragment; Complement C3c alpha' chain fragment 2] 
323,31 1,27E+10 187,148 Yes Yes No 
P0C0L5 Complement C4-B (Basic complement C4) (C3 and PZP-like alpha-2-
macroglobulin domain-containing protein 3) [Cleaved into: Complement 
C4 beta chain; Complement C4-B alpha chain; C4a anaphylatoxin; C4b-B; 
C4d-B; Complement C4 gamma chain] 
323,31 1,23E+10 192,751 No No No 
P01623 Ig kappa chain V-III region WOL 323,31 1,17E+10 11,746 No No No 
P02763 Alpha-1-acid glycoprotein 1 (AGP 1) (Orosomucoid-1) (OMD 1) 323,31 8,76E+09 23,512 Yes Yes No 
P00738 Haptoglobin (Zonulin) [Cleaved into: Haptoglobin alpha chain; 
Haptoglobin beta chain] 
295,10 8,14E+09 45,205 Yes Yes No 
P18135 Ig kappa chain V-III region HAH 287,23 7,16E+09 14,073 No No No 
A0A0G2JPD4 Ig gamma-4 chain C region (Fragment) 233,96 6,92E+09 35,941 No Yes Yes 
A0A0A0MS51 Gelsolin 323,31 6,82E+09 82,526 Yes No No 
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 Majority 
protein IDs 












P08571 Monocyte differentiation antigen CD14 (Myeloid cell-specific leucine-rich 
glycoprotein) (CD antigen CD14) [Cleaved into: Monocyte differentiation 
antigen CD14, urinary form; Monocyte differentiation antigen CD14, 
membrane-bound form] 
323,31 6,48E+09 40,076 Yes No No 
B7ZKJ8 ITIH4 protein (Inter-alpha-trypsin inhibitor heavy chain H4) 323,31 6,41E+09 103,881 Yes No No 
P01019 Angiotensinogen (Serpin A8) [Cleaved into: Angiotensin-1 (Angiotensin 1-
10) (Angiotensin I) (Ang I); Angiotensin-2 (Angiotensin 1-8) (Angiotensin 
II) (Ang II); Angiotensin-3 (Angiotensin 2-8) (Angiotensin III) (Ang III) 
(Des-Asp[1]-angiotensin II); Angiotensin-4 (Angiotensin 3-8) 
(Angiotensin IV) (Ang IV); Angiotensin 1-9; Angiotensin 1-7; Angiotensin 
1-5; Angiotensin 1-4] 
323,31 5,91E+09 53,154 Yes Yes No 
C9JF17 Apolipoprotein D (Fragment) 323,31 5,55E+09 24,158 Yes No No 
P41222 Prostaglandin-H2 D-isomerase (EC 5.3.99.2) (Beta-trace protein) 
(Cerebrin-28) (Glutathione-independent PGD synthase) (Lipocalin-type 
prostaglandin-D synthase) (Prostaglandin-D2 synthase) (PGD2 synthase) 
(PGDS) (PGDS2) 
148,96 5,11E+09 21,029 Yes No No 
P80748 Ig lambda chain V-III region LOI 266,75 4,84E+09 11,935 Yes Yes Yes 
P02790 Hemopexin (Beta-1B-glycoprotein) 323,31 4,71E+09 51,676 Yes Yes No 
P04264 Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-1) (CK-1) 
(Hair alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1) 
323,31 4,21E+09 66,039 Yes Yes No 
A0A087WW89 Protein IGHV3-72 225,05 4,19E+09 11,167 No No No 
P01625 Ig kappa chain V-IV region Len 188,03 3,54E+09 12,64 No Yes Yes 
D6RBV2 Vesicular integral-membrane protein VIP36 323,31 3,36E+09 36,543 Yes No No 
P01621 Ig kappa chain V-III region NG9 (Fragment) 43,04 3,33E+09 10,729 Yes Yes Yes 
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protein IDs 












P25311 Zinc-alpha-2-glycoprotein (Zn-alpha-2-GP) (Zn-alpha-2-glycoprotein) 323,31 3,05E+09 34,259 Yes No Yes 
Q9UBR2 Cathepsin Z (EC 3.4.18.1) (Cathepsin P) (Cathepsin X) 155,70 2,93E+09 33,868 Yes No No 
P02787 Serotransferrin (Transferrin) (Beta-1 metal-binding globulin) 
(Siderophilin) 
323,31 2,89E+09 77,064 Yes Yes No 
P01779 Ig heavy chain V-III region TUR 151,70 2,32E+09 12,431 No No No 
A0A0A0MTQ6 Protein IGKV2D-28 112,62 2,24E+09 11,043 No Yes Yes 
P05155 Plasma protease C1 inhibitor (C1 Inh) (C1Inh) (C1 esterase inhibitor) (C1-
inhibiting factor) (Serpin G1) 
257,37 2,19E+09 55,154 Yes Yes No 
P01714 Ig lambda chain V-III region SH 112,04 1,95E+09 11,393 Yes Yes Yes 
P59666 Neutrophil defensin 3 (Defensin, alpha 3) (HNP-3) (HP-3) (HP3) [Cleaved 
into: HP 3-56; Neutrophil defensin 2 (HNP-2) (HP-2) (HP2)] 
79,60 1,72E+09 10,245 Yes Yes No 
A0A0C4DH40 Protein IGHV4-59 (Fragment) 268,56 1,60E+09 12,936 No No No 
A0A087WYJ9 Ig mu chain C region 12,78 1,56E+09 65,701 No Yes Yes 
P60709 Actin, cytoplasmic 1 (Beta-actin) [Cleaved into: Actin, cytoplasmic 1, N-
terminally processed] 
237,36 1,41E+09 41,737 Yes Yes No 
P01610 Ig kappa chain V-I region WEA 264,72 1,34E+09 11,84 No No No 
X6RBG4 Uromodulin 214,33 1,29E+09 75,663 No Yes No 
A0A087X130 Ig kappa chain C region (Fragment) 208,02 1,24E+09 11,72 No No No 
A0A0J9YY99 Uncharacterized protein (Fragment) 262,75 1,24E+09 12,965 No No No 
A0A075B6I5 Protein IGLV1-51 (Fragment) 62,63 1,23E+09 12,619 Yes No Yes 
P07339 Cathepsin D (EC 3.4.23.5) [Cleaved into: Cathepsin D light chain; Cathepsin 
D heavy chain] 
130,56 1,22E+09 44,552 Yes No No 
P01598 Ig kappa chain V-I region EU 201,84 1,08E+09 11,788 No No No 
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protein IDs 












A0A087X0S5 Collagen alpha-1(VI) chain 309,35 1,05E+09 108,339 Yes Yes No 
P01008 Antithrombin-III (ATIII) (Serpin C1) 281,12 1,02E+09 52,602 Yes Yes No 
P15144 Aminopeptidase N (AP-N) (hAPN) (EC 3.4.11.2) (Alanyl aminopeptidase) 
(Aminopeptidase M) (AP-M) (Microsomal aminopeptidase) (Myeloid 
plasma membrane glycoprotein CD13) (gp150) (CD antigen CD13) 
246,64 9,98E+08 109,54 No Yes No 
A0A075B6I0 Protein IGLV8-61 (Fragment) 37,45 9,26E+08 12,901 No Yes Yes 
A0A087WTX5 Ig kappa chain C region 46,12 9,13E+08 26,096 No No No 
Q99459 Cell division cycle 5-like protein (Cdc5-like protein) (Pombe cdc5-related 
protein) 
6,84 9,11E+08 92,251 No Yes No 
A0A087X2C0 Ig mu chain C region 238,99 8,38E+08 64,106 No No No 
O95336 6-phosphogluconolactonase (6PGL) (EC 3.1.1.31) 188,66 7,93E+08 27,547 No No No 
P05543 Thyroxine-binding globulin (Serpin A7) (T4-binding globulin) 284,31 7,89E+08 46,325 No No No 
Q9BYE9 Cadherin-related family member 2 (Protocadherin LKC) (PC-LKC) 
(Protocadherin-24) 
293,74 7,67E+08 141,543 No Yes No 
A0A087WYC5 Ig gamma-1 chain C region 93,90 7,67E+08 52,426 No No No 
P04004 Vitronectin (VN) (S-protein) (Serum-spreading factor) (V75) [Cleaved 
into: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin-B] 
167,04 7,31E+08 54,306 No No No 
P35908 Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e) (CK-2e) 
(Epithelial keratin-2e) (Keratin-2 epidermis) (Keratin-2e) (K2e) (Type-II 
keratin Kb2) 
185,59 7,25E+08 65,433 Yes Yes No 
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P06702 Protein S100-A9 (Calgranulin-B) (Calprotectin L1H subunit) (Leukocyte 
L1 complex heavy chain) (Migration inhibitory factor-related protein 14) 
(MRP-14) (p14) (S100 calcium-binding protein A9) 
127,12 7,09E+08 13,242 Yes Yes No 
P36955 Pigment epithelium-derived factor (PEDF) (Cell proliferation-inducing 
gene 35 protein) (EPC-1) (Serpin F1) 
148,04 6,95E+08 46,312 No No No 
P69905 Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain) 48,07 6,91E+08 15,258 Yes Yes No 
P19320 Vascular cell adhesion protein 1 (V-CAM 1) (VCAM-1) (INCAM-100) (CD 
antigen CD106) 
130,17 6,84E+08 81,276 Yes No Yes 
A0A0B4J1Z4 Protein IGKV1-17 (Fragment) 195,52 6,74E+08 12,779 No Yes Yes 
E9PIT3 Prothrombin 323,31 6,63E+08 65,409 No No No 
D6RF35 Vitamin D-binding protein 271,65 6,41E+08 53,021 Yes No No 
A0A0C4DH25 Protein IGKV3D-20 (Fragment) 23,93 6,40E+08 12,515 No No No 
Q92820 Gamma-glutamyl hydrolase (EC 3.4.19.9) (Conjugase) (GH) (Gamma-Glu-X 
carboxypeptidase) 
136,15 6,09E+08 35,964 Yes No No 
Q12805 EGF-containing fibulin-like extracellular matrix protein 1 (Extracellular 
protein S1-5) (Fibrillin-like protein) (Fibulin-3) (FIBL-3) 
226,84 6,03E+08 54,641 No No No 
A0A087WZH9 Protein IGKV1-33 (Protein IGKV1D-33) 85,51 6,03E+08 11,842 No No No 
P98164 Low-density lipoprotein receptor-related protein 2 (LRP-2) (Glycoprotein 
330) (gp330) (Megalin) 
323,31 6,01E+08 521,958 No Yes No 
P07195 L-lactate dehydrogenase B chain (LDH-B) (EC 1.1.1.27) (LDH heart 
subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46) 
120,22 5,89E+08 36,638 No No No 
P04217 Alpha-1B-glycoprotein (Alpha-1-B glycoprotein) 170,74 5,77E+08 54,254 Yes Yes Yes 
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P00747 Plasminogen (EC 3.4.21.7) [Cleaved into: Plasmin heavy chain A; 
Activation peptide; Angiostatin; Plasmin heavy chain A, short form; 
Plasmin light chain B] 
171,62 5,65E+08 90,569 Yes No No 
P68871 Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved 
into: LVV-hemorphin-7; Spinorphin] 
176,21 5,64E+08 15,998 Yes Yes No 
P01042 Kininogen-1 (Alpha-2-thiol proteinase inhibitor) (Fitzgerald factor) (High 
molecular weight kininogen) (HMWK) (Williams-Fitzgerald-Flaujeac 
factor) [Cleaved into: Kininogen-1 heavy chain; T-kinin (Ile-Ser-
Bradykinin); Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); 
Kininogen-1 light chain; Low molecular weight growth-promoting factor] 
152,29 5,61E+08 71,957 Yes Yes No 
P06331 Ig heavy chain V-II region ARH-77 21,35 5,48E+08 16,228 No Yes Yes 
C9JEU5 Fibrinogen gamma chain 279,84 5,46E+08 50,322 No No No 
A0A0C4DH38 Protein IGHV5-51 (Fragment) 51,23 5,32E+08 12,675 No No No 
P02748 Complement component C9 [Cleaved into: Complement component C9a; 
Complement component C9b] 
108,12 5,17E+08 63,173 No No No 
A0A0C4DGN4 Uncharacterized protein (Zymogen granule protein 16 homolog B) 292,24 5,06E+08 19,6 Yes No No 
P02671 Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha 
chain] 
298,28 5,05E+08 94,973 Yes Yes No 
P13473 Lysosome-associated membrane glycoprotein 2 (LAMP-2) (Lysosome-
associated membrane protein 2) (CD107 antigen-like family member B) 
(CD antigen CD107b) 
33,07 5,03E+08 44,961 Yes No No 
P01767 Ig heavy chain V-III region BUT 32,06 4,85E+08 12,379 No No No 
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P01009 Alpha-1-antitrypsin (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase) 
(Serpin A1) [Cleaved into: Short peptide from AAT (SPAAT)] 
206,14 4,82E+08 46,737 Yes Yes No 
P01717 Ig lambda chain V-IV region Hil 54,79 4,81E+08 11,517 No Yes Yes 
A0A0B4J1X5 Protein IGHV3-74 (Fragment) 18,47 4,72E+08 12,84 No Yes Yes 
P08697 Alpha-2-antiplasmin (Alpha-2-AP) (Alpha-2-plasmin inhibitor) (Alpha-2-
PI) (Serpin F2) 
135,93 4,72E+08 54,566 No No No 
P18428 Lipopolysaccharide-binding protein (LBP) 132,36 4,58E+08 53,384 No No No 
P02751 Fibronectin (FN) (Cold-insoluble globulin) (CIG) [Cleaved into: Anastellin; 
Ugl-Y1; Ugl-Y2; Ugl-Y3] 
160,37 4,51E+08 262,625 Yes Yes Yes 
P04208 Ig lambda chain V-I region WAH 28,62 4,43E+08 11,725 No No No 
P00748 Coagulation factor XII (EC 3.4.21.38) (Hageman factor) (HAF) [Cleaved 
into: Coagulation factor XIIa heavy chain; Beta-factor XIIa part 1; 
Coagulation factor XIIa light chain (Beta-factor XIIa part 2)] 
148,16 4,41E+08 67,792 No No No 
A0A087X0D5 Pro-cathepsin H 91,03 4,35E+08 36,269 Yes No No 
P00450 Ceruloplasmin (EC 1.16.3.1) (Ferroxidase) 104,45 4,27E+08 122,205 No No No 
P19652 Alpha-1-acid glycoprotein 2 (AGP 2) (Orosomucoid-2) (OMD 2) 251,21 4,17E+08 23,603 Yes No No 
P01602 Ig heavy chain V-I region 5 (Ig kappa chain V-I region HK102) 
(Immunoglobulin kappa variable 1-5) (Fragment) 
35,57 4,13E+08 12,782 No No No 
P01824 Ig heavy chain V-II region WAH 28,30 4,13E+08 14,117 No Yes Yes 
Q08380 Galectin-3-binding protein (Basement membrane autoantigen p105) 
(Lectin galactoside-binding soluble 3-binding protein) (Mac-2-binding 
protein) (MAC2BP) (Mac-2 BP) (Tumor-associated antigen 90K) 
108,52 4,11E+08 65,331 No Yes No 
A0A087WU91 Protein IGHV3-49 42,83 4,07E+08 12,332 No No No 
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P08758 Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) 
(CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) 
(PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin 
inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha) 
233,40 4,06E+08 35,937 No No No 
Q5VY30 Retinol binding protein 4, plasma, isoform CRA_b (Retinol-binding protein 
4) 
163,69 4,02E+08 22,974 No Yes No 
A0A087WSY6 Protein IGKV3D-15 (Fragment) 8,17 3,99E+08 12,631 No No No 
P62805 Histone H4 40,11 3,93E+08 11,367 Yes Yes No 
P05109 Protein S100-A8 (Calgranulin-A) (Calprotectin L1L subunit) (Cystic 
fibrosis antigen) (CFAG) (Leukocyte L1 complex light chain) (Migration 
inhibitory factor-related protein 8) (MRP-8) (p8) (S100 calcium-binding 
protein A8) (Urinary stone protein band A) [Cleaved into: Protein S100-
A8, N-terminally processed] 
72,12 3,79E+08 10,835 Yes Yes No 
P01608 Ig kappa chain V-I region Roy -2,00 3,73E+08 11,782 No Yes Yes 
Q13228 Selenium-binding protein 1 (56 kDa selenium-binding protein) (SBP56) 
(SP56) 
158,48 3,72E+08 52,391 Yes No No 
P02766 Transthyretin (ATTR) (Prealbumin) (TBPA) 125,99 3,63E+08 15,887 No No No 
A0A0A0MTL4 Neuron navigator 2 6,51 3,62E+08 261,862 No No No 
A0A0J9YVU5 Protein IGHV2-70 (Fragment) 6,77 3,61E+08 13,359 No No No 
A0A075B6J0 Protein IGLV1-40 (Fragment) 45,06 3,51E+08 12,389 Yes No Yes 
H7C3P4 N-acetylglucosamine-6-sulfatase (EC 3.1.6.14) (Glucosamine-6-sulfatase) 74,56 3,46E+08 56,374 Yes No No 
A0A0C4DH68 Protein IGKV2-24 (Fragment) 101,61 3,32E+08 13,079 No No No 
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P04207 Ig kappa chain V-III region CLL (Rheumatoid factor) 85,29 3,27E+08 14,275 Yes No Yes 
A0A0G2JMB2 Ig alpha-2 chain C region (Fragment) 161,33 3,26E+08 36,508 No No No 
Q5T985 Inter-alpha-trypsin inhibitor heavy chain H2 91,67 3,20E+08 105,216 No No No 
A0A075B6J8 Protein IGLV3-19 (Fragment) 28,82 3,15E+08 12,042 No No No 
A0A087WW43 Inter-alpha-trypsin inhibitor heavy chain H3 93,99 3,14E+08 75,078 No No No 
P10153 Non-secretory ribonuclease (EC 3.1.27.5) (Eosinophil-derived neurotoxin) 
(RNase UpI-2) (Ribonuclease 2) (RNase 2) (Ribonuclease US) 
40,88 3,13E+08 18,354 Yes No No 
O96009 Napsin-A (EC 3.4.23.-) (Aspartyl protease 4) (ASP4) (Asp 4) (Napsin-1) 
(TA01/TA02) 
58,46 3,12E+08 45,387 No No No 
P24387 Corticotropin-releasing factor-binding protein (CRF-BP) (CRF-binding 
protein) (Corticotropin-releasing hormone-binding protein) (CRH-BP) 
137,37 3,02E+08 36,144 No No No 
Q9HCU0 Endosialin (Tumor endothelial marker 1) (CD antigen CD248) 86,23 3,01E+08 80,859 Yes No No 
A0A075B6J4 Protein IGLV3-25 (Fragment) 24,02 2,98E+08 12,011 No No No 
Q16270 Insulin-like growth factor-binding protein 7 (IBP-7) (IGF-binding protein 
7) (IGFBP-7) (IGFBP-rP1) (MAC25 protein) (PGI2-stimulating factor) 
(Prostacyclin-stimulating factor) (Tumor-derived adhesion factor) (TAF) 
100,63 2,97E+08 29,13 Yes No Yes 
P61769 Beta-2-microglobulin [Cleaved into: Beta-2-microglobulin form pI 5.3] 55,03 2,87E+08 13,715 No Yes Yes 
A0A075B7B8 Protein IGHV3OR16-12 (Fragment) 67,70 2,86E+08 12,875 No No No 
P01699 Ig lambda chain V-I region VOR 6,96 2,84E+08 11,515 No Yes Yes 
A0A075B6S3 Protein IGKV2-30 (Fragment) 58,40 2,82E+08 13,185 No No No 
P15085 Carboxypeptidase A1 (EC 3.4.17.1) 202,59 2,80E+08 47,14 No No No 
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P01612 Ig kappa chain V-I region Mev 6,56 2,73E+08 11,87 No No No 
P0C0L4 Complement C4-A (Acidic complement C4) (C3 and PZP-like alpha-2-
macroglobulin domain-containing protein 2) [Cleaved into: Complement 
C4 beta chain; Complement C4-A alpha chain; C4a anaphylatoxin; C4b-A; 
C4d-A; Complement C4 gamma chain] 
26,66 2,71E+08 192,785 No No No 
P01133 Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth 
factor (Urogastrone)] 
112,62 2,67E+08 133,994 No No No 
Q99972 Myocilin (Myocilin 55 kDa subunit) (Trabecular meshwork-induced 
glucocorticoid response protein) [Cleaved into: Myocilin, N-terminal 
fragment (Myocilin 20 kDa N-terminal fragment); Myocilin, C-terminal 
fragment (Myocilin 35 kDa N-terminal fragment)] 
107,89 2,64E+08 56,972 No No No 
P01597 Ig kappa chain V-I region DEE 14,58 2,57E+08 11,661 No No No 
P23083 Ig heavy chain V-I region V35 10,18 2,56E+08 13,009 No No No 
E7EQB2 Lactotransferrin (Fragment) 119,24 2,53E+08 76,626 Yes No No 
A0A0A0MT74 Protein IGKV1-16 (Fragment) 66,92 2,52E+08 12,618 No Yes Yes 
O75882 Attractin (DPPT-L) (Mahogany homolog) 197,82 2,51E+08 158,537 No Yes No 
Q07075 Glutamyl aminopeptidase (EAP) (EC 3.4.11.7) (Aminopeptidase A) (AP-A) 
(Differentiation antigen gp160) (CD antigen CD249) 
123,51 2,48E+08 109,244 No No No 
P01781 Ig heavy chain V-III region GAL 56,63 2,47E+08 12,731 No No No 
A0A075B6N7 Ig alpha-2 chain C region (Fragment) 108,98 2,46E+08 36,591 No No No 
Q9NUQ9 Protein FAM49B (L1) 132,20 2,39E+08 36,748 No No No 
P01619 Ig kappa chain V-III region B6 47,72 2,33E+08 11,636 No No No 
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O60494 Cubilin (460 kDa receptor) (Intestinal intrinsic factor receptor) (Intrinsic 
factor-cobalamin receptor) (Intrinsic factor-vitamin B12 receptor) 
169,71 2,26E+08 398,736 No Yes No 
A0A0C4DGZ9 Tripeptidyl-peptidase 1 46,61 2,25E+08 60,458 No No No 
C9J0D1 Histone H2A 18,29 2,24E+08 13,163 Yes Yes No 
P04746 Pancreatic alpha-amylase (PA) (EC 3.2.1.1) (1,4-alpha-D-glucan 
glucanohydrolase) 
118,41 2,10E+08 57,707 No No No 
P01620 Ig kappa chain V-III region SIE 55,56 2,07E+08 11,775 No No No 
P12111 Collagen alpha-3(VI) chain 173,33 2,05E+08 343,669 No No No 
A0A087X0K0 Collagen alpha-1(XV) chain 36,39 1,99E+08 140,059 No No No 
E7ESB3 NAD(P)(+)--arginine ADP-ribosyltransferase (EC 2.4.2.31) (Mono(ADP-
ribosyl)transferase) (Fragment) 
85,66 1,89E+08 23,179 No No No 
P01703 Ig lambda chain V-I region NEWM 8,65 1,85E+08 10,904 No No No 
P02743 Serum amyloid P-component (SAP) (9.5S alpha-1-glycoprotein) [Cleaved 
into: Serum amyloid P-component(1-203)] 
118,42 1,84E+08 25,387 No No No 
A0A0B4J2D9 Protein IGKV1D-13 (Fragment) 61,39 1,82E+08 12,569 No Yes Yes 
O94919 Endonuclease domain-containing 1 protein (EC 3.1.30.-) 100,54 1,80E+08 55,017 No No No 
Q16651 Prostasin (EC 3.4.21.-) (Channel-activating protease 1) (CAP1) (Serine 
protease 8) [Cleaved into: Prostasin light chain; Prostasin heavy chain] 
100,13 1,79E+08 36,431 No No No 
P24855 Deoxyribonuclease-1 (EC 3.1.21.1) (Deoxyribonuclease I) (DNase I) 
(Dornase alfa) 
71,28 1,75E+08 31,434 No No No 
P04430 Ig kappa chain V-I region BAN 141,93 1,74E+08 11,84 No No No 
A0A075B6I8 Protein IGLV1-47 (Fragment) 30,34 1,72E+08 12,284 No No No 
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P29508 Serpin B3 (Protein T4-A) (Squamous cell carcinoma antigen 1) (SCCA-1) 117,69 1,69E+08 44,565 No No No 
O00560 Syntenin-1 (Melanoma differentiation-associated protein 9) (MDA-9) 
(Pro-TGF-alpha cytoplasmic domain-interacting protein 18) (TACIP18) 
(Scaffold protein Pbp1) (Syndecan-binding protein 1) 
81,79 1,69E+08 32,444 Yes No No 
P01772 Ig heavy chain V-III region KOL 30,56 1,69E+08 13,718 No Yes Yes 
X6R8F3 Neutrophil gelatinase-associated lipocalin 186,51 1,69E+08 22,788 Yes No No 
A0A087WUS7 Ig delta chain C region 84,41 1,63E+08 42,353 No No No 
P0DJD9 Pepsin A-5 (EC 3.4.23.1) (Pepsinogen-5) 31,19 1,63E+08 41,993 No No No 
U3KPS2 Myeloblastin 30,66 1,61E+08 23,611 No No No 
A0A0B4J1X8 Protein IGHV3-43 (Fragment) 60,48 1,60E+08 13,077 No No No 
A0A075B6I9 Protein IGLV7-46 (Fragment) 16,29 1,56E+08 12,468 No No No 
A0A0B4J1Z7 Protein IGKV1-39 (Fragment) 10,60 1,52E+08 12,737 No No No 
P10451 Osteopontin (Bone sialoprotein 1) (Nephropontin) (Secreted 
phosphoprotein 1) (SPP-1) (Urinary stone protein) (Uropontin) 
201,11 1,49E+08 35,423 No No No 
A0A0G2JRQ6 Uncharacterized protein (Fragment) 17,41 1,49E+08 12,846 No No No 
P08185 Corticosteroid-binding globulin (CBG) (Serpin A6) (Transcortin) 36,42 1,48E+08 45,141 No No No 
B2R4S9 Histone H2B 6,52 1,46E+08 13,906 Yes Yes No 
E7ER45 Maltase-glucoamylase, intestinal 122,72 1,44E+08 312,022 No Yes No 
Q16769 Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) 
(QC) (sQC) (Glutaminyl-tRNA cyclotransferase) (Glutamyl cyclase) (EC) 
98,44 1,43E+08 40,877 No No No 
A0A0A0MT36 Protein IGKV6D-21 (Fragment) 42,39 1,42E+08 12,34 No No No 
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P07355 Annexin A2 (Annexin II) (Annexin-2) (Calpactin I heavy chain) (Calpactin-
1 heavy chain) (Chromobindin-8) (Lipocortin II) (Placental anticoagulant 
protein IV) (PAP-IV) (Protein I) (p36) 
158,50 1,41E+08 38,604 No No No 
P46952 3-hydroxyanthranilate 3,4-dioxygenase (EC 1.13.11.6) (3-
hydroxyanthranilate oxygenase) (3-HAO) (3-hydroxyanthranilic acid 
dioxygenase) (HAD) 
89,38 1,40E+08 32,556 No No No 
P10253 Lysosomal alpha-glucosidase (EC 3.2.1.20) (Acid maltase) (Aglucosidase 
alfa) [Cleaved into: 76 kDa lysosomal alpha-glucosidase; 70 kDa lysosomal 
alpha-glucosidase] 
93,34 1,39E+08 105,324 No No No 
P04209 Ig lambda chain V-II region NIG-84 16,87 1,38E+08 11,581 No No No 
H0YD13 CD44 antigen 31,70 1,38E+08 22,683 Yes Yes No 
X6R3L3 MOB kinase activator 3C 6,41 1,37E+08 31,726 No No No 
A0A0G2JMI3 Uncharacterized protein (Fragment) 40,31 1,35E+08 12,871 No No No 
P09525 Annexin A4 (35-beta calcimedin) (Annexin IV) (Annexin-4) 
(Carbohydrate-binding protein p33/p41) (Chromobindin-4) (Endonexin 
I) (Lipocortin IV) (P32.5) (PP4-X) (Placental anticoagulant protein II) 
(PAP-II) (Protein II) 
89,02 1,35E+08 35,883 No No No 
A0A0C4DGZ8 Glycoprotein Ib (Platelet), alpha polypeptide (Platelet glycoprotein Ib 
alpha chain) 
41,29 1,33E+08 68,955 No No No 
P01023 Alpha-2-macroglobulin (Alpha-2-M) (C3 and PZP-like alpha-2-
macroglobulin domain-containing protein 5) 
94,37 1,32E+08 163,291 No No No 
Q14573 Inositol 1,4,5-trisphosphate receptor type 3 (IP3 receptor isoform 3) 
(IP3R 3) (InsP3R3) (Type 3 inositol 1,4,5-trisphosphate receptor) (Type 3 
InsP3 receptor) 
6,62 1,31E+08 304,106 No No No 
A0A0C4DH34 Protein IGHV4-28 (Fragment) 15,65 1,29E+08 13,124 No No No 
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Q15848 Adiponectin (30 kDa adipocyte complement-related protein) (Adipocyte 
complement-related 30 kDa protein) (ACRP30) (Adipocyte, C1q and 
collagen domain-containing protein) (Adipose most abundant gene 
transcript 1 protein) (apM-1) (Gelatin-binding protein) 
22,17 1,25E+08 26,414 No No No 
P04083 Annexin A1 (Annexin I) (Annexin-1) (Calpactin II) (Calpactin-2) 
(Chromobindin-9) (Lipocortin I) (Phospholipase A2 inhibitory protein) 
(p35) 
200,48 1,23E+08 38,714 No No No 
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein 
(HSPG) (Perlecan) (PLC) [Cleaved into: Endorepellin; LG3 peptide] 
62,92 1,23E+08 468,83 No No No 
F8WE04 Heat shock protein beta-1 38,50 1,22E+08 20,406 No No No 
P01833 Polymeric immunoglobulin receptor (PIgR) (Poly-Ig receptor) 
(Hepatocellular carcinoma-associated protein TB6) [Cleaved into: 
Secretory component] 
79,55 1,20E+08 83,284 No No No 
P01613 Ig kappa chain V-I region Ni 32,16 1,19E+08 12,246 No No No 
P07737 Profilin-1 (Epididymis tissue protein Li 184a) (Profilin I) 42,80 1,17E+08 15,054 No No No 
A0A075B6H9 Protein IGLV4-69 (Fragment) 21,55 1,11E+08 12,773 No No No 
C9J6H2 Insulin-like growth factor-binding protein 1 31,85 1,10E+08 22,886 No No No 
A0A075B6S5 Protein IGKV1-27 (Fragment) 19,60 1,09E+08 12,712 No No No 
P01034 Cystatin-C (Cystatin-3) (Gamma-trace) (Neuroendocrine basic 
polypeptide) (Post-gamma-globulin) 
67,24 1,08E+08 15,799 No No No 
A0A0A0MS11 Protein IGHV3-13 (Fragment) 36,10 1,08E+08 12,506 No No No 
P05062 Fructose-bisphosphate aldolase B (EC 4.1.2.13) (Liver-type aldolase) 90,87 1,08E+08 39,473 No No No 
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Q5JS37 NHL repeat-containing protein 3 34,73 1,07E+08 38,283 Yes No No 
C9JR67 Epsilon-sarcoglycan (Sarcoglycan epsilon isoform 2) 74,18 1,05E+08 48,751 No No No 
P62258 14-3-3 protein epsilon (14-3-3E) 44,04 1,05E+08 29,174 No No No 
P01742 Ig heavy chain V-I region EU 7,69 1,05E+08 12,472 No Yes Yes 
P63104 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) 103,64 1,04E+08 27,745 No No No 
I3L145 Sex hormone-binding globulin (Sex hormone-binding globulin, isoform 
CRA_a) 
76,01 1,04E+08 37,488 No No No 
P14543 Nidogen-1 (NID-1) (Entactin) 139,74 1,02E+08 136,377 No No No 
Q5TEC6 Histone H3 26,68 1,01E+08 15,43 Yes Yes No 
Q14165 Malectin 62,21 9,90E+07 32,234 No No No 
P04431 Ig kappa chain V-I region Walker 45,70 9,89E+07 14,069 No No No 
O75594 Peptidoglycan recognition protein 1 (Peptidoglycan recognition protein 
short) (PGRP-S) 
149,79 9,78E+07 21,731 No No No 
P83593 Ig kappa chain V-IV region STH (Fragment) 7,89 9,78E+07 12,06 No No No 
P05154 Plasma serine protease inhibitor (Acrosomal serine protease inhibitor) 
(Plasminogen activator inhibitor 3) (PAI-3) (PAI3) (Protein C inhibitor) 
(PCI) (Serpin A5) 
64,25 9,62E+07 45,675 No No No 
E9PIM6 Thy-1 membrane glycoprotein (Fragment) 31,82 9,50E+07 17,041 Yes No Yes 
C9JV77 Alpha-2-HS-glycoprotein 73,42 9,48E+07 39,412 No No No 
A0A0G2JM94 Leukocyte-associated immunoglobulin-like receptor 1 162,85 9,47E+07 15,143 Yes No Yes 
Q9Y5Z4 Heme-binding protein 2 (Placental protein 23) (PP23) (Protein SOUL) 178,52 9,39E+07 22,875 No No No 
P01611 Ig kappa chain V-I region Wes 76,73 9,20E+07 11,608 No No No 
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A0A0B4J2H0 Protein IGHV1-69-2 (Fragment) 8,28 9,15E+07 12,66 No No No 
P00441 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) (Superoxide dismutase 1) 
(hSod1) 
52,72 9,01E+07 15,936 No No No 
P01594 Ig kappa chain V-I region AU 45,89 8,96E+07 11,939 No No No 
O15230 Laminin subunit alpha-5 (Laminin-10 subunit alpha) (Laminin-11 subunit 
alpha) (Laminin-15 subunit alpha) 
6,80 8,94E+07 399,737 No No No 
A0A0C4DH31 Protein IGHV1-18 (Fragment) 35,90 8,92E+07 12,82 No No No 
Q14118 Dystroglycan (Dystrophin-associated glycoprotein 1) [Cleaved into: 
Alpha-dystroglycan (Alpha-DG); Beta-dystroglycan (Beta-DG)] 
33,93 8,89E+07 97,441 No No No 
P53634 Dipeptidyl peptidase 1 (EC 3.4.14.1) (Cathepsin C) (Cathepsin J) 
(Dipeptidyl peptidase I) (DPP-I) (DPPI) (Dipeptidyl transferase) [Cleaved 
into: Dipeptidyl peptidase 1 exclusion domain chain (Dipeptidyl peptidase 
I exclusion domain chain); Dipeptidyl peptidase 1 heavy chain (Dipeptidyl 
peptidase I heavy chain); Dipeptidyl peptidase 1 light chain (Dipeptidyl 
peptidase I light chain)] 
47,51 8,85E+07 51,854 No No No 
P00338 L-lactate dehydrogenase A chain (LDH-A) (EC 1.1.1.27) (Cell proliferation-
inducing gene 19 protein) (LDH muscle subunit) (LDH-M) (Renal 
carcinoma antigen NY-REN-59) 
55,93 8,81E+07 36,689 No No No 
A0A087WXI5 Cadherin-1 65,02 8,73E+07 100,027 No No No 
P00491 Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) (Inosine 
phosphorylase) (Inosine-guanosine phosphorylase) 
67,36 8,71E+07 32,118 No No No 
J3QS39 Polyubiquitin-B (Fragment) 81,70 8,65E+07 10,469 Yes Yes No 
A0A087WVJ0 Mucin-1 (Fragment) 37,23 8,57E+07 25,566 Yes No No 
Q6EMK4 Vasorin (Protein slit-like 2) 97,09 8,48E+07 71,713 No No No 
F8VYK9 Insulin-like growth factor-binding protein 6 275,61 8,38E+07 25,152 No No No 
Appendix A  
     241 
 Majority 
protein IDs 












P10909 Clusterin (Aging-associated gene 4 protein) (Apolipoprotein J) (Apo-J) 
(Complement cytolysis inhibitor) (CLI) (Complement-associated protein 
SP-40,40) (Ku70-binding protein 1) (NA1/NA2) (Testosterone-repressed 
prostate message 2) (TRPM-2) [Cleaved into: Clusterin beta chain 
(ApoJalpha) (Complement cytolysis inhibitor a chain); Clusterin alpha 
chain (ApoJbeta) (Complement cytolysis inhibitor b chain)] 
51,21 8,32E+07 52,495 No No No 
E9PHH3 Syndecan-1 56,05 8,14E+07 17,782 No No No 
A0A024QZX5 Serpin B6 (Serpin peptidase inhibitor, clade B (Ovalbumin), member 6, 
isoform CRA_d) 
29,52 8,14E+07 43,024 No No No 
A0A0C4DH35 Protein IGHV3-35 (Fragment) 18,51 8,00E+07 12,81 No No No 
P27487 Dipeptidyl peptidase 4 (EC 3.4.14.5) (ADABP) (Adenosine deaminase 
complexing protein 2) (ADCP-2) (Dipeptidyl peptidase IV) (DPP IV) (T-cell 
activation antigen CD26) (TP103) (CD antigen CD26) [Cleaved into: 
Dipeptidyl peptidase 4 membrane form (Dipeptidyl peptidase IV 
membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl 
peptidase IV soluble form)] 
59,74 7,92E+07 88,279 No No No 
Q9UKU9 Angiopoietin-related protein 2 (Angiopoietin-like protein 2) 54,33 7,65E+07 57,104 No No No 
A4UGR9 Xin actin-binding repeat-containing protein 2 (Beta-xin) 
(Cardiomyopathy-associated protein 3) (Xeplin) 
10,59 7,50E+07 382,3 No No No 
Q96S96 Phosphatidylethanolamine-binding protein 4 (PEBP-4) (hPEBP4) (Protein 
cousin-of-RKIP 1) 
29,00 7,37E+07 25,733 No No No 
Q9Y490 Talin-1 58,15 7,33E+07 269,767 No No No 
A0A075B6J9 HCG1782423 (Protein IGLV2-18) (Fragment) 13,53 7,28E+07 12,705 No No No 
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Q96FE7 Phosphoinositide-3-kinase-interacting protein 1 (Kringle domain-
containing protein HGFL) 
19,34 7,16E+07 28,248 Yes No No 
P98172 Ephrin-B1 (EFL-3) (ELK ligand) (ELK-L) (EPH-related receptor tyrosine 
kinase ligand 2) (LERK-2) 
48,30 7,12E+07 38,007 No No No 
Q6PK18 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 
3 (EC 1.14.11.-) 
75,57 7,07E+07 35,646 No No No 
B0QYF8 Myoglobin (Fragment) 29,67 7,07E+07 15,989 No No No 
Q71U36 Tubulin alpha-1A chain (Alpha-tubulin 3) (Tubulin B-alpha-1) (Tubulin 
alpha-3 chain) 
69,52 7,06E+07 50,136 No No No 
P56537 Eukaryotic translation initiation factor 6 (eIF-6) (B(2)GCN homolog) (B4 
integrin interactor) (CAB) (p27(BBP)) 
30,72 7,02E+07 26,599 No No No 
A0A0C4DH33 Protein IGHV1-24 (Fragment) 10,71 6,96E+07 12,824 No No No 
G3XAM2 Complement factor I (Complement factor I, isoform CRA_b) 29,30 6,87E+07 65,06 No No No 
P18669 Phosphoglycerate mutase 1 (EC 3.1.3.13) (EC 5.4.2.11) (EC 5.4.2.4) (BPG-
dependent PGAM 1) (Phosphoglycerate mutase isozyme B) (PGAM-B) 
39,68 6,86E+07 28,804 No No No 
A0A075B6J7 Protein IGLV3-21 (Fragment) 38,66 6,69E+07 12,446 No No No 
Q9UHI8 A disintegrin and metalloproteinase with thrombospondin motifs 1 
(ADAM-TS 1) (ADAM-TS1) (ADAMTS-1) (EC 3.4.24.-) (METH-1) 
48,36 6,60E+07 105,358 No No No 
P01615 Ig kappa chain V-II region FR 12,91 6,60E+07 12,66 No No No 
P01593 Ig kappa chain V-I region AG 12,51 6,58E+07 11,992 No No No 
P06311 Ig kappa chain V-III region IARC/BL41 8,37 6,57E+07 14,07 No No No 
P01604 Ig kappa chain V-I region Kue 7,03 6,57E+07 12,127 No No No 
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Q9UNN8 Endothelial protein C receptor (Activated protein C receptor) (APC 
receptor) (Endothelial cell protein C receptor) (CD antigen CD201) 
15,35 6,52E+07 26,671 No No No 
P06733 Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (C-myc 
promoter-binding protein) (Enolase 1) (MBP-1) (MPB-1) (Non-neural 
enolase) (NNE) (Phosphopyruvate hydratase) (Plasminogen-binding 
protein) 
44,43 6,43E+07 47,169 No No No 
P06727 Apolipoprotein A-IV (Apo-AIV) (ApoA-IV) (Apolipoprotein A4) 68,87 6,33E+07 45,399 No No No 
D6REQ6 Ribonuclease T2 (Ribonuclease T2, isoform CRA_c) 14,87 6,31E+07 25,309 No No No 
P05164 Myeloperoxidase (MPO) (EC 1.11.2.2) [Cleaved into: Myeloperoxidase; 89 
kDa myeloperoxidase; 84 kDa myeloperoxidase; Myeloperoxidase light 
chain; Myeloperoxidase heavy chain] 
24,71 6,20E+07 83,869 Yes No No 
F8WE65 Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) 12,36 6,20E+07 13,022 Yes No No 
Q9UBN7 Histone deacetylase 6 (HD6) (EC 3.5.1.98) 6,77 6,19E+07 131,419 No No No 
P01622 Ig kappa chain V-III region Ti 20,14 6,08E+07 11,788 No No No 
P40926 Malate dehydrogenase, mitochondrial (EC 1.1.1.37) 32,89 6,02E+07 35,503 No No No 
P63267 Actin, gamma-enteric smooth muscle (Alpha-actin-3) (Gamma-2-actin) 
(Smooth muscle gamma-actin) 
8,38 6,01E+07 41,877 No No No 
A0A0C4DH24 Protein IGKV6-21 (Fragment) 7,56 6,00E+07 12,43 No No No 
P01708 Ig lambda chain V-II region BUR 12,18 5,96E+07 11,506 No No No 
Q15113 Procollagen C-endopeptidase enhancer 1 (Procollagen COOH-terminal 
proteinase enhancer 1) (PCPE-1) (Procollagen C-proteinase enhancer 1) 
(Type 1 procollagen C-proteinase enhancer protein) (Type I procollagen 
COOH-terminal proteinase enhancer) 
105,29 5,93E+07 47,972 No No No 
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P04406 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) 
(Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-) 
59,74 5,89E+07 36,053 Yes Yes No 
A0A0G2JL54 Complement C4-B 16,05 5,86E+07 187,716 No No No 
P35606 Coatomer subunit beta' (Beta'-coat protein) (Beta'-COP) (p102) 40,39 5,69E+07 102,487 No No No 
P07858 Cathepsin B (EC 3.4.22.1) (APP secretase) (APPS) (Cathepsin B1) [Cleaved 
into: Cathepsin B light chain; Cathepsin B heavy chain] 
34,32 5,66E+07 37,822 No No No 
P14550 Alcohol dehydrogenase [NADP(+)] (EC 1.1.1.2) (Aldehyde reductase) 
(Aldo-keto reductase family 1 member A1) 
49,07 5,51E+07 36,573 No No No 
P10643 Complement component C7 29,36 5,26E+07 93,518 No No No 
P08294 Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1) 27,74 5,18E+07 25,851 No No No 
P78417 Glutathione S-transferase omega-1 (GSTO-1) (EC 2.5.1.18) (Glutathione S-
transferase omega 1-1) (GSTO 1-1) (Glutathione-dependent 
dehydroascorbate reductase) (EC 1.8.5.1) (Monomethylarsonic acid 
reductase) (MMA(V) reductase) (EC 1.20.4.2) (S-(Phenacyl)glutathione 
reductase) (SPG-R) 
24,44 5,12E+07 27,566 No No No 
F8WDW9 Endothelial cell-selective adhesion molecule 27,21 5,11E+07 26,701 No No No 
F8VV32 Lysozyme C 22,57 5,11E+07 11,488 Yes No No 
A0A0B4J1Y8 Protein IGLV9-49 22,19 5,08E+07 13,024 No No No 
A0A087X0M8 Neural cell adhesion molecule L1-like protein 62,79 5,06E+07 130,795 No No No 
G3V357 Ribonuclease pancreatic 24,21 4,84E+07 13,05 No No No 
A0A075B6I2 Protein IGLV6-57 77,88 4,79E+07 15,95 No No No 
O95865 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 (DDAH-2) 
(Dimethylarginine dimethylaminohydrolase 2) (EC 3.5.3.18) (DDAHII) 
(Dimethylargininase-2) (Protein G6a) (S-phase protein) 
29,32 4,78E+07 29,644 No No No 
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P30048 Thioredoxin-dependent peroxide reductase, mitochondrial (EC 1.11.1.15) 
(Antioxidant protein 1) (AOP-1) (HBC189) (Peroxiredoxin III) (Prx-III) 
(Peroxiredoxin-3) (Protein MER5 homolog) 
22,21 4,65E+07 27,693 No No No 
P09467 Fructose-1,6-bisphosphatase 1 (FBPase 1) (EC 3.1.3.11) (D-fructose-1,6-
bisphosphate 1-phosphohydrolase 1) (Liver FBPase) 
36,50 4,62E+07 36,842 No No No 
P04206 Ig kappa chain V-III region GOL (Rheumatoid factor) 17,74 4,60E+07 11,83 No No No 
P06870 Kallikrein-1 (EC 3.4.21.35) (Kidney/pancreas/salivary gland kallikrein) 
(Tissue kallikrein) 
16,57 4,57E+07 28,89 No No No 
O00187 Mannan-binding lectin serine protease 2 (EC 3.4.21.104) (MBL-associated 
serine protease 2) (Mannose-binding protein-associated serine protease 
2) (MASP-2) [Cleaved into: Mannan-binding lectin serine protease 2 A 
chain; Mannan-binding lectin serine protease 2 B chain] 
23,03 4,53E+07 75,702 No No No 
P48595 Serpin B10 (Bomapin) (Peptidase inhibitor 10) (PI-10) 35,66 4,52E+07 45,403 No No No 
P11021 78 kDa glucose-regulated protein (GRP-78) (Endoplasmic reticulum 
lumenal Ca(2+)-binding protein grp78) (Heat shock 70 kDa protein 5) 
(Immunoglobulin heavy chain-binding protein) (BiP) 
40,89 4,51E+07 72,333 No No No 
P01596 Ig kappa chain V-I region CAR 7,35 4,48E+07 11,704 No No No 
A0A087WVW2 Ig gamma-3 chain C region 17,80 4,46E+07 57,156 No No No 
P01701 Ig lambda chain V-I region NEW 12,82 4,46E+07 11,453 No No No 
A0A075B7D4 Protein IGKV1OR2-108 (Fragment) 6,52 4,45E+07 12,535 No No No 
Q9H6B4 CXADR-like membrane protein (Adipocyte adhesion molecule) 
(Coxsackie- and adenovirus receptor-like membrane protein) (CAR-like 
membrane protein) 
22,52 4,45E+07 41,281 No No No 
A0A0B4J1V0 Protein IGHV3-15 (Fragment) 24,26 4,44E+07 12,926 No No No 
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P30740 Leukocyte elastase inhibitor (LEI) (Monocyte/neutrophil elastase 
inhibitor) (EI) (M/NEI) (Peptidase inhibitor 2) (PI-2) (Serpin B1) 
26,31 4,33E+07 42,742 No No No 
X6R868 Carboxylic ester hydrolase (EC 3.1.1.-) 36,02 4,21E+07 79,667 No No No 
K7EJB9 Calreticulin (Fragment) 26,97 4,19E+07 28,432 No No No 
P08246 Neutrophil elastase (EC 3.4.21.37) (Bone marrow serine protease) 
(Elastase-2) (Human leukocyte elastase) (HLE) (Medullasin) (PMN 
elastase) 
18,97 4,06E+07 28,518 Yes No No 
P07686 Beta-hexosaminidase subunit beta (EC 3.2.1.52) (Beta-N-
acetylhexosaminidase subunit beta) (Hexosaminidase subunit B) (Cervical 
cancer proto-oncogene 7 protein) (HCC-7) (N-acetyl-beta-
glucosaminidase subunit beta) [Cleaved into: Beta-hexosaminidase 
subunit beta chain B; Beta-hexosaminidase subunit beta chain A] 
46,80 4,03E+07 63,111 No No No 
P31431 Syndecan-4 (SYND4) (Amphiglycan) (Ryudocan core protein) 38,71 4,01E+07 21,642 No No No 
B4DQI4 Alpha/beta hydrolase domain-containing protein 14B (cDNA FLJ52723, 
highly similar to Abhydrolase domain-containing protein 14B) 
26,25 4,01E+07 19,756 No No No 
B1AH49 Sulfurtransferase 47,10 3,99E+07 24,982 No No No 
P35030 Trypsin-3 (EC 3.4.21.4) (Brain trypsinogen) (Mesotrypsinogen) (Serine 
protease 3) (Serine protease 4) (Trypsin III) (Trypsin IV) 
13,93 3,96E+07 32,529 No No No 
Q9H3G5 Probable serine carboxypeptidase CPVL (EC 3.4.16.-) (Carboxypeptidase, 
vitellogenic-like) (Vitellogenic carboxypeptidase-like protein) (VCP-like 
protein) (hVLP) 
25,89 3,85E+07 54,164 No No No 
A0A0J9YXX1 Uncharacterized protein (Fragment) -2,00 3,85E+07 12,773 No No No 
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Q9Y4E8 Ubiquitin carboxyl-terminal hydrolase 15 (EC 3.4.19.12) 
(Deubiquitinating enzyme 15) (Ubiquitin thioesterase 15) (Ubiquitin-
specific-processing protease 15) (Unph-2) (Unph4) 
33,04 3,82E+07 112,419 No No No 
O00462 Beta-mannosidase (EC 3.2.1.25) (Lysosomal beta A mannosidase) 
(Mannanase) (Mannase) 
54,21 3,81E+07 100,895 No No No 
O14498 Immunoglobulin superfamily containing leucine-rich repeat protein 26,42 3,78E+07 45,997 No No No 
B0YJC4 Vimentin (Vimentin variant 3) 39,43 3,70E+07 49,653 No No No 
Q92692 Nectin-2 (Herpes virus entry mediator B) (Herpesvirus entry mediator B) 
(HveB) (Poliovirus receptor-related protein 2) (CD antigen CD112) 
31,44 3,69E+07 57,742 No No No 
P02649 Apolipoprotein E (Apo-E) 51,55 3,65E+07 36,154 No No No 
P06889 Ig lambda chain V-IV region MOL 7,97 3,60E+07 11,272 No No No 
P01778 Ig heavy chain V-III region ZAP 31,60 3,57E+07 12,582 No No No 
P01763 Ig heavy chain V-III region WEA -2,00 3,57E+07 12,256 No No No 
Q01459 Di-N-acetylchitobiase (EC 3.2.1.-) 13,02 3,50E+07 43,76 Yes No No 
Q12860 Contactin-1 (Glycoprotein gp135) (Neural cell surface protein F3) 35,05 3,49E+07 113,32 No No No 
Q14019 Coactosin-like protein 28,18 3,43E+07 15,945 No No No 
A0A075B708 Protein TRAJ61 (Fragment) 6,89 3,42E+07 2,35 No No No 
P04066 Tissue alpha-L-fucosidase (EC 3.2.1.51) (Alpha-L-fucosidase I) (Alpha-L-
fucoside fucohydrolase 1) (Alpha-L-fucosidase 1) 
26,57 3,42E+07 53,689 No No No 
Q06323 Proteasome activator complex subunit 1 (11S regulator complex subunit 
alpha) (REG-alpha) (Activator of multicatalytic protease subunit 1) 
(Interferon gamma up-regulated I-5111 protein) (IGUP I-5111) 
(Proteasome activator 28 subunit alpha) (PA28a) (PA28alpha) 
33,06 3,38E+07 28,723 No No No 
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P22792 Carboxypeptidase N subunit 2 (Carboxypeptidase N 83 kDa chain) 
(Carboxypeptidase N large subunit) (Carboxypeptidase N polypeptide 2) 
(Carboxypeptidase N regulatory subunit) 
26,01 3,37E+07 60,557 No No No 
P12110 Collagen alpha-2(VI) chain 20,66 3,34E+07 108,579 No No No 
P00918 Carbonic anhydrase 2 (EC 4.2.1.1) (Carbonate dehydratase II) (Carbonic 
anhydrase C) (CAC) (Carbonic anhydrase II) (CA-II) 
32,42 3,30E+07 29,246 No No No 
H0Y5H9 Serpin B4 (Fragment) 18,15 3,29E+07 42,499 No No No 
A0A075B6K1 Protein IGLV2-14 (Fragment) 30,00 3,23E+07 12,597 No No No 
E5RFN6 ATP-binding cassette sub-family A member 10 7,59 3,22E+07 150,865 No No No 
P16152 Carbonyl reductase [NADPH] 1 (EC 1.1.1.184) (15-hydroxyprostaglandin 
dehydrogenase [NADP(+)]) (EC 1.1.1.197) (NADPH-dependent carbonyl 
reductase 1) (Prostaglandin 9-ketoreductase) (Prostaglandin-E(2) 9-
reductase) (EC 1.1.1.189) (Short chain dehydrogenase/reductase family 
21C member 1) 
35,32 3,20E+07 30,375 No No No 
A0A0A0MS12 Protein IGHV4-34 (Fragment) 6,67 3,17E+07 13,815 No No No 
C9JEE0 Immunoglobulin lambda-like polypeptide 1 (Fragment) 11,87 3,17E+07 19,227 No No No 
Q9UHL4 Dipeptidyl peptidase 2 (EC 3.4.14.2) (Dipeptidyl aminopeptidase II) 
(Dipeptidyl peptidase 7) (Dipeptidyl peptidase II) (DPP II) (Quiescent cell 
proline dipeptidase) 
45,88 3,15E+07 54,341 No No No 
P08603 Complement factor H (H factor 1) 40,93 3,14E+07 139,096 No No No 
P00558 Phosphoglycerate kinase 1 (EC 2.7.2.3) (Cell migration-inducing gene 10 
protein) (Primer recognition protein 2) (PRP 2) 
24,96 3,11E+07 44,615 No No No 
E7EMM4 Acid ceramidase 17,35 3,07E+07 41,796 No No No 
Q96RW7 Hemicentin-1 (Fibulin-6) (FIBL-6) 14,96 3,03E+07 613,39 No No No 
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P13796 Plastin-2 (L-plastin) (LC64P) (Lymphocyte cytosolic protein 1) (LCP-1) 42,53 3,02E+07 70,288 No No No 
C9JGG1 Paired immunoglobulin-like type 2 receptor alpha (Fragment) 49,54 2,95E+07 18,888 No No No 
Q86VQ0 Lebercilin (Leber congenital amaurosis 5 protein) 10,67 2,93E+07 80,554 No No No 
Q13421 Mesothelin (CAK1 antigen) (Pre-pro-megakaryocyte-potentiating factor) 
[Cleaved into: Megakaryocyte-potentiating factor (MPF); Mesothelin, 
cleaved form] 
28,91 2,93E+07 68,986 No No No 
A0A0B4J1U1 Protein IGLV1-44 (Fragment) 12,23 2,87E+07 12,299 No No No 
P11279 Lysosome-associated membrane glycoprotein 1 (LAMP-1) (Lysosome-
associated membrane protein 1) (CD107 antigen-like family member A) 
(CD antigen CD107a) 
19,20 2,86E+07 44,882 No No No 
P01616 Ig kappa chain V-II region MIL 11,14 2,82E+07 12,057 No No No 
P27105 Erythrocyte band 7 integral membrane protein (Protein 7.2b) (Stomatin) 36,89 2,81E+07 31,731 No No No 
P39060 Collagen alpha-1(XVIII) chain [Cleaved into: Endostatin] 34,24 2,77E+07 178,188 No No No 
E7EQ29 Beta-galactosidase 23,88 2,77E+07 60,483 No No No 
A0A087WTK0 Receptor-type tyrosine-protein phosphatase eta 41,34 2,76E+07 146,073 No No No 
P01780 Ig heavy chain V-III region JON 10,40 2,71E+07 12,564 No No No 
Q5JP53 Tubulin beta chain 18,06 2,67E+07 47,767 Yes Yes No 
J3QRN2 Beta-2-glycoprotein 1 (Fragment) 12,94 2,62E+07 19,907 No No No 
A0A0A0MSI0 Peroxiredoxin-1 (Fragment) 13,43 2,61E+07 18,976 No No No 
Q86UY0 TXNDC5 protein 25,71 2,60E+07 40,369 No No No 
P04080 Cystatin-B (CPI-B) (Liver thiol proteinase inhibitor) (Stefin-B) 18,77 2,60E+07 11,14 No No No 
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Q9BTY2 Plasma alpha-L-fucosidase (EC 3.2.1.51) (Alpha-L-fucoside fucohydrolase 
2) (Alpha-L-fucosidase 2) 
16,89 2,56E+07 54,067 No No No 
P01775 Ig heavy chain V-III region LAY 24,94 2,55E+07 12,858 No No No 
A0A087WT99 Ester hydrolase C11orf54 19,35 2,50E+07 28,683 No No No 
F6TLX2 Glyoxalase domain-containing protein 4 23,04 2,42E+07 54,72 No No No 
Q8WUM0 Nuclear pore complex protein Nup133 (133 kDa nucleoporin) 
(Nucleoporin Nup133) 
6,38 2,40E+07 128,979 No No No 
G5E968 Chromogranin A (Parathyroid secretory protein 1), isoform CRA_b 
(Chromogranin-A) 
23,98 2,39E+07 34,269 No No No 
P07237 Protein disulfide-isomerase (PDI) (EC 5.3.4.1) (Cellular thyroid hormone-
binding protein) (Prolyl 4-hydroxylase subunit beta) (p55) 
28,28 2,33E+07 57,116 No No No 
A0A075B6K4 HCG2043238 (Protein IGLV3-10) (Fragment) 13,18 2,33E+07 12,629 No No No 
P16188 HLA class I histocompatibility antigen, A-30 alpha chain (MHC class I 
antigen A*30) 
29,64 2,29E+07 40,905 No No No 
A0A0A0MS14 Protein IGHV1-45 (Fragment) 6,77 2,27E+07 13,508 No No No 
A0A0J9YVT0 Protein IGHV3-33 (Fragment) 8,55 2,26E+07 12,989 No No No 
V9GYE7 Complement factor H-related protein 2 23,04 2,23E+07 28,912 No No No 
A0A087WUS4 Aminopeptidase B (Fragment) 6,52 2,18E+07 16,322 No No No 
S4R3C6 Transforming growth factor-beta-induced protein ig-h3 (Fragment) 12,27 2,18E+07 23,497 No No No 
P43251 Biotinidase (Biotinase) (EC 3.5.1.12) 14,67 2,16E+07 61,133 No No No 
A0A0C4DFZ2 Arylsulfatase A 13,23 2,10E+07 53,806 No No No 
O95861 3'(2'),5'-bisphosphate nucleotidase 1 (EC 3.1.3.7) (Bisphosphate 3'-
nucleotidase 1) (PAP-inositol 1,4-phosphatase) (PIP) 
19,83 2,10E+07 33,392 No No No 
J3QLM0 T-cell antigen CD7 14,59 2,07E+07 23,041 No No No 
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P01601 Ig kappa chain V-ID region 16 (Ig kappa chain V-I region HK101) 
(Fragment) 
36,48 2,06E+07 12,73 No No No 
P08238 Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) 
(HSP84) 
23,46 2,04E+07 83,264 No No No 
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (EC 5.3.3.-) 21,83 2,04E+07 35,816 No No No 
A0A075B6S4 Protein IGKV1D-17 (Fragment) 7,41 2,03E+07 12,835 No No No 
J3QSE5 Phosphatidylcholine-sterol acyltransferase (Fragment) 49,25 2,00E+07 29,387 No No No 
C9JC71 Low affinity immunoglobulin gamma Fc region receptor III-A (Fragment) 6,90 1,98E+07 11,823 No No No 
A0A0B4J227 Neuroblastoma breakpoint family member 6 (Fragment) 6,36 1,94E+07 64,812 No No No 
O00391 Sulfhydryl oxidase 1 (hQSOX) (EC 1.8.3.2) (Quiescin Q6) 39,57 1,93E+07 82,578 No No No 
Q08830 Fibrinogen-like protein 1 (HP-041) (Hepassocin) (Hepatocyte-derived 
fibrinogen-related protein 1) (HFREP-1) (Liver fibrinogen-related protein 
1) (LFIRE-1) 
18,64 1,87E+07 36,379 No No No 
A0A0A0MTR1 Cadherin-13 30,13 1,85E+07 76,969 No No No 
F2Z393 Transaldolase (EC 2.2.1.2) 18,92 1,85E+07 35,329 No No No 
Q15485 Ficolin-2 (37 kDa elastin-binding protein) (Collagen/fibrinogen domain-
containing protein 2) (EBP-37) (Ficolin-B) (Ficolin-beta) (Hucolin) (L-
ficolin) (Serum lectin p35) 
15,29 1,85E+07 34,001 No No No 
P01764 Ig heavy chain V-III region 23 (Ig heavy chain V-III region VH26) 
(Immunoglobulin heavy variable 3-23) 
18,80 1,84E+07 12,582 No No No 
P01605 Ig kappa chain V-I region Lay 8,80 1,83E+07 11,834 No No No 
Q9HAT2 Sialate O-acetylesterase (EC 3.1.1.53) (H-Lse) (Sialic acid-specific 9-O-
acetylesterase) 
7,67 1,81E+07 58,315 No No No 
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Q9BXP8 Pappalysin-2 (EC 3.4.24.-) (Pregnancy-associated plasma protein A2) 
(PAPP-A2) (Pregnancy-associated plasma protein E1) (PAPP-E) 
9,53 1,80E+07 198,539 No No No 
P07711 Cathepsin L1 (EC 3.4.22.15) (Cathepsin L) (Major excreted protein) (MEP) 
[Cleaved into: Cathepsin L1 heavy chain; Cathepsin L1 light chain] 
17,90 1,78E+07 37,564 No No No 
P20142 Gastricsin (EC 3.4.23.3) (Pepsinogen C) 27,88 1,78E+07 42,426 No No No 
A6NI73 Leukocyte immunoglobulin-like receptor subfamily A member 5 (CD85 
antigen-like family member F) (Immunoglobulin-like transcript 11) (ILT-
11) (Leukocyte immunoglobulin-like receptor 9) (LIR-9) (CD antigen 
CD85f) 
24,07 1,73E+07 32,755 No No No 
P21695 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (GPD-C) 
(GPDH-C) (EC 1.1.1.8) 
20,46 1,71E+07 37,568 No No No 
A0A0G2JQJ0 Protein IGKV1D-8 (Fragment) 12,58 1,70E+07 12,962 No No No 
A0M8Q6 Ig lambda-7 chain C region 8,50 1,68E+07 11,303 No No No 
P30039 Phenazine biosynthesis-like domain-containing protein (EC 5.1.-.-) 
(MAWD-binding protein) (MAWDBP) (Unknown protein 32 from 2D-page 
of liver tissue) 
42,96 1,67E+07 31,785 No No No 
Q8WZ75 Roundabout homolog 4 (Magic roundabout) 11,28 1,65E+07 107,457 No No No 
P46926 Glucosamine-6-phosphate isomerase 1 (EC 3.5.99.6) (Glucosamine-6-
phosphate deaminase 1) (GNPDA 1) (GlcN6P deaminase 1) (Oscillin) 
18,00 1,65E+07 32,669 No No No 
P61981 14-3-3 protein gamma (Protein kinase C inhibitor protein 1) (KCIP-1) 
[Cleaved into: 14-3-3 protein gamma, N-terminally processed] 
78,94 1,63E+07 28,303 No No No 
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Q6UX06 Olfactomedin-4 (OLM4) (Antiapoptotic protein GW112) (G-CSF-
stimulated clone 1 protein) (hGC-1) (hOLfD) 
33,50 1,61E+07 57,28 No No No 
Q9Y279 V-set and immunoglobulin domain-containing protein 4 (Protein Z39Ig) 6,47 1,61E+07 43,987 No No No 
F8WC59 Aminoacylase-1 18,12 1,60E+07 22,709 No No No 
H3BMU8 Group XV phospholipase A2 (Fragment) 14,52 1,59E+07 33,878 No No No 
Q9H257 Caspase recruitment domain-containing protein 9 (hCARD9) 7,55 1,58E+07 62,241 No No No 
B1AKQ8 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 
(Fragment) 
90,26 1,57E+07 12,285 No No No 
P17050 Alpha-N-acetylgalactosaminidase (EC 3.2.1.49) (Alpha-galactosidase B) 15,17 1,49E+07 46,565 No No No 
P01603 Ig kappa chain V-I region Ka 13,31 1,48E+07 11,9 No No No 
P01719 Ig lambda chain V-V region DEL 29,27 1,46E+07 11,343 No No No 
A0A0C4DGY8 Enolase-phosphatase E1 15,73 1,45E+07 16,533 No No No 
Q7Z7M0 Multiple epidermal growth factor-like domains protein 8 (Multiple EGF-
like domains protein 8) (Epidermal growth factor-like protein 4) (EGF-like 
protein 4) 
13,58 1,42E+07 303,1 No No No 
P17174 Aspartate aminotransferase, cytoplasmic (cAspAT) (EC 2.6.1.1) (EC 
2.6.1.3) (Cysteine aminotransferase, cytoplasmic) (Cysteine transaminase, 
cytoplasmic) (cCAT) (Glutamate oxaloacetate transaminase 1) 
(Transaminase A) 
21,80 1,41E+07 46,248 No No No 
P31946 14-3-3 protein beta/alpha (Protein 1054) (Protein kinase C inhibitor 
protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein beta/alpha, N-terminally 
processed] 
19,75 1,41E+07 28,082 No No No 
A0A0B4J1U9 Protein IGHV3-11 (Fragment) 10,14 1,40E+07 12,909 No No No 
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A0A087WXL1 Folate receptor gamma 20,10 1,31E+07 27,885 No No No 
E9PKP4 Macrophage colony-stimulating factor 1 (Fragment) 12,10 1,27E+07 13,253 No No No 
A0A087WWP7 Receptor-type tyrosine-protein phosphatase gamma 19,01 1,26E+07 151,539 No No No 
P01624 Ig kappa chain V-III region POM 9,95 1,24E+07 11,922 No No No 
A0A087WWY0 Apolipoprotein(a) 32,93 1,24E+07 62,554 No No No 
E5RHP7 Carbonic anhydrase 1 (Fragment) 7,88 1,23E+07 27,754 No No No 
P15814 Immunoglobulin lambda-like polypeptide 1 (CD179 antigen-like family 
member B) (Ig lambda-5) (Immunoglobulin omega polypeptide) 
(Immunoglobulin-related protein 14.1) (CD antigen CD179b) 
6,82 1,23E+07 22,963 No No No 
P01609 Ig kappa chain V-I region Scw 16,28 1,23E+07 11,764 No No No 
H0YMZ1 Proteasome subunit alpha type (EC 3.4.25.1) (Fragment) 12,99 1,22E+07 24,583 No No No 
Q9BS40 Latexin (Endogenous carboxypeptidase inhibitor) (ECI) (Protein MUM) 
(Tissue carboxypeptidase inhibitor) (TCI) 
13,12 1,21E+07 25,75 No No No 
P20160 Azurocidin (Cationic antimicrobial protein CAP37) (Heparin-binding 
protein) (HBP) (hHBP) 
17,50 1,19E+07 26,886 No No No 
A0A075B6K3 Protein IGLV2-11 (Fragment) -2,00 1,19E+07 12,644 No No No 
Q96KP4 Cytosolic non-specific dipeptidase (EC 3.4.13.18) (CNDP dipeptidase 2) 
(Glutamate carboxypeptidase-like protein 1) (Peptidase A) 
18,52 1,16E+07 52,878 No No No 
E9PSE5 Palmitoyl-protein thioesterase 1 8,04 1,16E+07 10,016 No No No 
Q9BRF8 Serine/threonine-protein phosphatase CPPED1 (EC 3.1.3.16) 
(Calcineurin-like phosphoesterase domain-containing protein 1) 
(Complete S-transactivated protein 1) 
13,90 1,16E+07 35,548 No No No 
D6RAR4 Hepatocyte growth factor activator 18,83 1,14E+07 71,483 No No No 
F5GWF3 Complement C1r subcomponent-like protein 14,02 1,14E+07 33,679 No No No 
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X6R5C5 Carboxypeptidase (EC 3.4.16.-) 15,35 1,11E+07 54,256 No No No 
O00299 Chloride intracellular channel protein 1 (Chloride channel ABP) (Nuclear 
chloride ion channel 27) (NCC27) (Regulatory nuclear chloride ion 
channel protein) (hRNCC) 
12,90 1,10E+07 26,923 No No No 
H3BPE1 Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 6,51 1,09E+07 856,879 No No No 
P32004 Neural cell adhesion molecule L1 (N-CAM-L1) (NCAM-L1) (CD antigen 
CD171) 
25,57 1,09E+07 140,003 No No No 
O15144 Actin-related protein 2/3 complex subunit 2 (Arp2/3 complex 34 kDa 
subunit) (p34-ARC) 
14,73 1,08E+07 34,333 No No No 
A0A087WX97 Bcl-2-like protein 13 6,94 1,07E+07 54,389 No No No 
A0A087X1Z3 Proteasome activator complex subunit 2 27,41 1,06E+07 29,127 No No No 
A0A0A0MRJ7 Coagulation factor V 6,46 1,06E+07 252,236 No No No 
A0A075B6Q5 Protein IGHV3-64 (Fragment) 11,57 1,03E+07 12,891 No No No 
P11597 Cholesteryl ester transfer protein (Lipid transfer protein I) 16,84 1,02E+07 54,756 No No No 
Q08ET2 Sialic acid-binding Ig-like lectin 14 (Siglec-14) 12,40 1,01E+07 43,97 No No No 
P17900 Ganglioside GM2 activator (Cerebroside sulfate activator protein) (GM2-
AP) (Sphingolipid activator protein 3) (SAP-3) [Cleaved into: Ganglioside 
GM2 activator isoform short] 
17,34 9,94E+06 20,838 No No No 
R4GNC0 N-acylethanolamine-hydrolyzing acid amidase (Fragment) 13,53 9,90E+06 24,836 No No No 
A0A087X0P6 Protein IGKV2D-29 9,11 9,88E+06 11,192 No No No 
A6NIW5 Peroxiredoxin 2, isoform CRA_a (Peroxiredoxin-2) 12,36 9,87E+06 15,138 No No No 
Q14112 Nidogen-2 (NID-2) (Osteonidogen) 12,46 9,81E+06 151,254 No No No 
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P01031 Complement C5 (C3 and PZP-like alpha-2-macroglobulin domain-
containing protein 4) [Cleaved into: Complement C5 beta chain; 
Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' 
chain] 
12,32 9,71E+06 188,305 No No No 
P22492 Histone H1t (Testicular H1 histone) 6,32 9,36E+06 22,019 No No No 
Q9NUM4 Transmembrane protein 106B 11,79 9,25E+06 31,127 No No No 
O95154 Aflatoxin B1 aldehyde reductase member 3 (EC 1.-.-.-) (AFB1 aldehyde 
reductase 2) (AFB1-AR 2) 
7,23 9,22E+06 37,206 No No No 
P54802 Alpha-N-acetylglucosaminidase (EC 3.2.1.50) (N-acetyl-alpha-
glucosaminidase) (NAG) [Cleaved into: Alpha-N-acetylglucosaminidase 82 
kDa form; Alpha-N-acetylglucosaminidase 77 kDa form] 
17,63 9,14E+06 82,266 No No No 
H0Y5U1 Agrin (Fragment) 12,02 9,09E+06 28,773 No No No 
Q5H9B4 Metalloproteinase inhibitor 1 (Fragment) 6,53 9,05E+06 10,707 No No No 
P02675 Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta 
chain] 
17,94 9,02E+06 55,928 No No No 
P07360 Complement component C8 gamma chain 13,41 9,00E+06 22,277 No No No 
A0A0C4DGX4 Cullin-1 -2,00 8,94E+06 87,388 No No No 
P23142 Fibulin-1 (FIBL-1) 11,01 8,86E+06 77,214 No No No 
J3KSN0 Secreted and transmembrane protein 1 (Fragment) 7,65 8,71E+06 15,958 No No No 
A0A0G2JNK4 Ig gamma-1 chain C region 8,49 8,65E+06 50,916 No No No 
F6X2W2 Neuronal growth regulator 1 12,23 8,59E+06 32,85 No No No 
E9PKE3 Heat shock cognate 71 kDa protein 23,10 8,37E+06 68,806 No No No 
A0A087X2E2 Carcinoembryonic antigen-related cell adhesion molecule 8 6,88 8,22E+06 37,528 No No No 
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E9PIF4 Sialidase-1 16,76 8,14E+06 29 No No No 
Q14126 Desmoglein-2 (Cadherin family member 5) (HDGC) 9,76 8,10E+06 122,294 No No No 
P17066 Heat shock 70 kDa protein 6 (Heat shock 70 kDa protein B') 23,52 8,06E+06 71,028 No No No 
P17931 Galectin-3 (Gal-3) (35 kDa lectin) (Carbohydrate-binding protein 35) (CBP 
35) (Galactose-specific lectin 3) (Galactoside-binding protein) (GALBP) 
(IgE-binding protein) (L-31) (Laminin-binding protein) (Lectin L-29) 
(Mac-2 antigen) 
10,57 7,91E+06 26,152 No No No 
P13727 Bone marrow proteoglycan (BMPG) (Proteoglycan 2) [Cleaved into: 
Eosinophil granule major basic protein (EMBP) (MBP) (Pregnancy-
associated major basic protein)] 
7,19 7,81E+06 25,206 No No No 
A0A0G2JQF3 Mucin-20 (Fragment) 9,04 7,80E+06 13,357 No No No 
H3BNH4 Protein ADGRG1 (Fragment) 10,91 7,80E+06 22,299 No No No 
P51688 N-sulphoglucosamine sulphohydrolase (EC 3.10.1.1) (Sulfoglucosamine 
sulfamidase) (Sulphamidase) 
11,85 7,69E+06 56,695 No No No 
A0A087WY82 Junctional adhesion molecule A 7,31 7,61E+06 30,197 No No No 
H3BS70 Enoyl-CoA delta isomerase 1, mitochondrial (Fragment) 12,10 7,41E+06 24,705 No No No 
D6RA82 Annexin 12,07 7,39E+06 32,119 No No No 
P08311 Cathepsin G (CG) (EC 3.4.21.20) 17,15 7,39E+06 28,837 No No No 
A0A0A0MR14 Osteoclast-associated immunoglobulin-like receptor 12,14 7,36E+06 27,603 No No No 
A0A0B4J1R6 Transketolase 6,51 7,18E+06 49,91 No No No 
Q9HB40 Retinoid-inducible serine carboxypeptidase (EC 3.4.16.-) (Serine 
carboxypeptidase 1) 
12,36 7,16E+06 50,831 No No No 
Q93088 Betaine--homocysteine S-methyltransferase 1 (EC 2.1.1.5) 13,31 6,97E+06 44,998 No No No 
A0A075B7D0 Protein IGHV1OR15-1 (Uncharacterized protein) (Fragment) 6,96 6,84E+06 13,012 No No No 
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Q8NBJ4 Golgi membrane protein 1 (Golgi membrane protein GP73) (Golgi 
phosphoprotein 2) 
14,17 6,80E+06 45,333 No No No 
Q03591 Complement factor H-related protein 1 (FHR-1) (H factor-like protein 1) 
(H-factor-like 1) (H36) 
12,06 6,79E+06 37,651 No No No 
E5RJD2 2,4-dienoyl-CoA reductase, mitochondrial (Fragment) 8,67 6,72E+06 15,898 No No No 
Q10567 AP-1 complex subunit beta-1 (Adaptor protein complex AP-1 subunit 
beta-1) (Adaptor-related protein complex 1 subunit beta-1) (Beta-1-
adaptin) (Beta-adaptin 1) (Clathrin assembly protein complex 1 beta large 
chain) (Golgi adaptor HA1/AP1 adaptin beta subunit) 
11,11 6,50E+06 104,637 No No No 
A0A0J9YX35 Uncharacterized protein (Fragment) -2,00 6,39E+06 12,823 No No No 
O00592 Podocalyxin (GCTM-2 antigen) (Gp200) (Podocalyxin-like protein 1) (PC) 
(PCLP-1) 
11,68 6,34E+06 58,635 No No No 
O43490 Prominin-1 (Antigen AC133) (Prominin-like protein 1) (CD antigen 
CD133) 
17,54 6,33E+06 97,202 No No No 
Q8NHP8 Putative phospholipase B-like 2 (EC 3.1.1.-) (76 kDa protein) (p76) 
(LAMA-like protein 2) (Lamina ancestor homolog 2) (Phospholipase B 
domain-containing protein 2) [Cleaved into: Putative phospholipase B-like 
2 32 kDa form; Putative phospholipase B-like 2 45 kDa form] 
11,83 6,32E+06 65,472 No No No 
A0A0A0MSN4 Angiotensin-converting enzyme 6,54 6,27E+06 142,42 No No No 
Q9HD89 Resistin (Adipose tissue-specific secretory factor) (ADSF) (C/EBP-epsilon-
regulated myeloid-specific secreted cysteine-rich protein) (Cysteine-rich 
secreted protein A12-alpha-like 2) (Cysteine-rich secreted protein FIZZ3) 
7,19 6,21E+06 11,419 No No No 
P18510 Interleukin-1 receptor antagonist protein (IL-1RN) (IL-1ra) (IRAP) (ICIL-
1RA) (IL1 inhibitor) (Anakinra) 
6,59 6,13E+06 20,055 No No No 
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D6RAX3 Protocadherin-1 10,76 6,06E+06 41,443 No No No 
Q9NZH0 G-protein coupled receptor family C group 5 member B (A-69G12.1) 
(Retinoic acid-induced gene 2 protein) (RAIG-2) 
19,86 5,86E+06 44,795 No No No 
I3NI28 Chymotrypsin-like protease CTRL-1 (Fragment) 12,34 5,86E+06 20,086 No No No 
Q29940 HLA class I histocompatibility antigen, B-59 alpha chain (MHC class I 
antigen B*59) 
10,31 5,69E+06 40,584 No No No 
Q9Y646 Carboxypeptidase Q (EC 3.4.17.-) (Lysosomal dipeptidase) (Plasma 
glutamate carboxypeptidase) 
11,65 5,67E+06 51,888 No No No 
Q5TFQ8 Signal-regulatory protein beta-1 isoform 3 (SIRP-beta-1 isoform 3) 11,68 5,58E+06 43,359 No No No 
P49257 Protein ERGIC-53 (ER-Golgi intermediate compartment 53 kDa protein) 
(Gp58) (Intracellular mannose-specific lectin MR60) (Lectin mannose-
binding 1) 
9,02 5,48E+06 57,549 No No No 
Q9Y2S2 Lambda-crystallin homolog (EC 1.1.1.45) (L-gulonate 3-dehydrogenase) 
(Gul3DH) 
17,15 5,41E+06 35,419 No No No 
H0YLJ2 Solute carrier family 12 member 1 (Fragment) 11,31 5,32E+06 70,369 No No No 
A0A087X243 Glutathione S-transferase P (Fragment) 6,34 5,30E+06 7,449 No No No 
Q9NQR4 Omega-amidase NIT2 (EC 3.5.1.3) (Nitrilase homolog 2) 12,34 5,18E+06 30,608 No No No 
C9JA05 Immunoglobulin J chain (Fragment) 7,52 5,17E+06 8,168 No No No 
P05451 Lithostathine-1-alpha (Islet cells regeneration factor) (ICRF) (Islet of 
Langerhans regenerating protein) (REG) (Pancreatic stone protein) (PSP) 
(Pancreatic thread protein) (PTP) (Regenerating islet-derived protein 1-
alpha) (REG-1-alpha) (Regenerating protein I alpha) 
11,80 5,09E+06 18,731 No No No 
P25788 Proteasome subunit alpha type-3 (EC 3.4.25.1) (Macropain subunit C8) 
(Multicatalytic endopeptidase complex subunit C8) (Proteasome 
component C8) 
14,15 5,08E+06 28,433 No No No 
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P12955 Xaa-Pro dipeptidase (X-Pro dipeptidase) (EC 3.4.13.9) (Imidodipeptidase) 
(Peptidase D) (Proline dipeptidase) (Prolidase) 
6,72 5,05E+06 54,548 No No No 
Q96L35 EPH receptor B4, isoform CRA_b (Ephrin type-B receptor 4) (Receptor 
protein tyrosine kinase variant EphB4v1) 
7,09 4,97E+06 102,558 No No No 
A0A024R644 Ceroid-lipofuscinosis neuronal protein 5 (Ceroid-lipofuscinosis, neuronal 
5, isoform CRA_a) 
6,39 4,84E+06 46,339 No No No 
Q496F6 CMRF35-like molecule 2 (CLM-2) (CD300 antigen-like family member E) 
(CMRF35-A5) (Immune receptor expressed on myeloid cells 2) (IREM-2) 
(Polymeric immunoglobulin receptor 2) (PIgR-2) (PIgR2) (Poly-Ig 
receptor 2) (CD antigen CD300e) 
6,64 4,82E+06 22,918 No No No 
Q9H6X2 Anthrax toxin receptor 1 (Tumor endothelial marker 8) 12,70 4,79E+06 62,789 No No No 
D6REY1 Chitotriosidase-1 11,35 4,79E+06 40,239 No No No 
J3KS60 Rho GDP-dissociation inhibitor 1 7,51 4,69E+06 9,944 No No No 
A0A0B4J1V6 Protein IGHV3-73 (Fragment) 7,06 4,53E+06 12,858 No No No 
B1AHL2 Fibulin-1 9,39 4,47E+06 78,329 No No No 
I3L297 Adapter molecule crk 7,30 4,41E+06 25,504 No No No 
A0A087WWY3 Filamin-A 10,91 4,32E+06 245,851 No No No 
O75636 Ficolin-3 (Collagen/fibrinogen domain-containing lectin 3 p35) 
(Collagen/fibrinogen domain-containing protein 3) (Hakata antigen) 
10,90 4,31E+06 32,903 No No No 
F5GWG3 Retinoic acid-induced protein 3 (Fragment) 6,76 4,28E+06 30,618 No No No 
P15086 Carboxypeptidase B (EC 3.4.17.2) (Pancreas-specific protein) (PASP) 12,48 4,05E+06 47,368 No No No 
M0QYG8 Glia maturation factor gamma 11,53 4,04E+06 10,99 No No No 
Q5T0R7 Adenylyl cyclase-associated protein (Fragment) 6,59 3,64E+06 19,202 No No No 
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D6RGG3 Collagen alpha-1(XII) chain 12,03 3,58E+06 333,202 No No No 
Q8IY13 FBLN7 protein (Fibulin-7) (Fragment) 10,65 3,57E+06 28,038 No No No 
A0A087WVQ9 Elongation factor 1-alpha 1 11,21 3,57E+06 47,883 No No No 
Q9H8L6 Multimerin-2 (EMILIN-3) (Elastin microfibril interface located protein 3) 
(Elastin microfibril interfacer 3) (EndoGlyx-1 p125/p140 subunit) 
6,31 3,48E+06 104,409 No No No 
E9PJ29 Out at first protein homolog 6,67 3,43E+06 18,092 No No No 
A0A075B6J1 Protein IGLV5-37 (Fragment) 7,77 3,41E+06 13,277 No No No 
Q96NY8 Nectin-4 (Ig superfamily receptor LNIR) (Poliovirus receptor-related 
protein 4) [Cleaved into: Processed poliovirus receptor-related protein 4] 
11,60 3,41E+06 55,454 No No No 
P06681 Complement C2 (EC 3.4.21.43) (C3/C5 convertase) [Cleaved into: 
Complement C2b fragment; Complement C2a fragment] 
6,38 3,37E+06 83,268 No No No 
P00505 Aspartate aminotransferase, mitochondrial (mAspAT) (EC 2.6.1.1) (EC 
2.6.1.7) (Fatty acid-binding protein) (FABP-1) (Glutamate oxaloacetate 
transaminase 2) (Kynurenine aminotransferase 4) (Kynurenine 
aminotransferase IV) (Kynurenine--oxoglutarate transaminase 4) 
(Kynurenine--oxoglutarate transaminase IV) (Plasma membrane-
associated fatty acid-binding protein) (FABPpm) (Transaminase A) 
12,82 3,27E+06 47,518 No No No 
P29622 Kallistatin (Kallikrein inhibitor) (Peptidase inhibitor 4) (PI-4) (Serpin A4) 10,81 3,25E+06 48,542 No No No 
F8W0P7 ATP synthase subunit beta, mitochondrial (Fragment) 7,21 3,09E+06 28,393 No No No 
Q99574 Neuroserpin (Peptidase inhibitor 12) (PI-12) (Serpin I1) 6,60 3,04E+06 46,427 No No No 
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Q9H3H3 UPF0696 protein C11orf68 (Basophilic leukemia-expressed protein 
Bles03) (Protein p5326) 
6,60 3,03E+06 27,355 No No No 
Q15181 Inorganic pyrophosphatase (EC 3.6.1.1) (Pyrophosphate phospho-
hydrolase) (PPase) 
6,99 2,98E+06 32,66 No No No 
Q9UGN4 CMRF35-like molecule 8 (CLM-8) (CD300 antigen-like family member A) 
(CMRF-35-H9) (CMRF35-H9) (CMRF35-H) (IRC1/IRC2) (Immunoglobulin 
superfamily member 12) (IgSF12) (Inhibitory receptor protein 60) 
(IRp60) (NK inhibitory receptor) (CD antigen CD300a) 
7,09 2,89E+06 33,201 No No No 
A0A096LPE1 Vinculin 6,76 2,68E+06 6,087 No No No 
A0A0B4J1R4 4-hydroxyphenylpyruvate dioxygenase 6,39 2,39E+06 44,964 No No No 
E9PHY0 Lysosomal acid phosphatase 10,63 2,09E+06 40,99 No No No 
P08572 Collagen alpha-2(IV) chain [Cleaved into: Canstatin] 17,78 1,91E+06 167,553 No No No 
C9JPK6 HMG box-containing protein 1 (Fragment) -2,00 9,25E+05 3,219 No No No 









PRM Patient Information 
Table A 8 Patient information for urine samples for PRM experiments 
Sample number Protein conc (µg/µl) TB status HIV status 
17 0.41 Positive Negative 
27 1.31 Positive Negative 
30 0.45 Positive Negative 
32 6.11 Positive Negative 
36 1.00 Positive Negative 
37 0.75 Positive Negative 
39 0.99 Positive Negative 
55 7.89 Positive Negative 
64 3.24 Positive Negative 
105 0.82 Positive Negative 
1204 7.94 Positive Positive 
1244 8.40 Positive Positive 
1245 1.24 Positive Positive 
1250 7.86 Positive Positive 
1259 13.42 Positive Positive 
1275 1.78 Positive Positive 
1291 3.19 Positive Positive 
1350 10.82 Positive Positive 
1397 9.71 Positive Positive 
1475 10.70 Positive Positive 
1100 11.36 Negative Positive 
1102 1.53 Negative Positive 
1103 0.56 Negative Positive 
1104 6.05 Negative Positive 
1107 1.77 Negative Positive 
1113 1.52 Negative Positive 
1123 0.58 Negative Positive 
1136 0.74 Negative Positive 
1180 28.62 Negative Positive 
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Sample number Protein conc (µg/µl) TB status HIV status 
1070 0.68 Negative Negative 
1073 1.02 Negative Negative 
1075 0.60 Negative Negative 
1083 1.17 Negative Negative 
1091 0.98 Negative Negative 
1119 0.56 Negative Negative 
2031 0.60 Negative Negative 
2064 0.25 Negative Negative 
2102* 1.10 Negative Negative 
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Isolation List for Targeted Proteomics 
Table A 9 Isolation list for targeted proteomics (ESAT-6 and CFP-10) 
Mass [m/z] CS [z] Polarity NCE Comment 
1002.492692 2 Positive 27 TQIDQVESTAGSLQGQWR (light) 
668.66422 3 Positive 27 TQIDQVESTAGSLQGQWR (light) 
501.749984 4 Positive 27 TQIDQVESTAGSLQGQWR (light) 
571.817461 2 Positive 27 GAAGTAAQAAVVR (light) 
381.547399 3 Positive 27 GAAGTAAQAAVVR (light) 
286.412368 4 Positive 27 GAAGTAAQAAVVR (light) 
659.335881 2 Positive 27 QELDEISTNIR (light) 
439.893012 3 Positive 27 QELDEISTNIR (light) 
330.171578 4 Positive 27 QELDEISTNIR (light) 
454.732866 2 Positive 27 QAGVQYSR (light) 
303.491002 3 Positive 27 QAGVQYSR (light) 
227.870071 4 Positive 27 QAGVQYSR (light) 
834.862134 2 Positive 27 ADEEQQQALSSQMGF (light) 
556.910514 3 Positive 27 ADEEQQQALSSQMGF (light) 
417.934705 4 Positive 27 ADEEQQQALSSQMGF (light) 
954.465946 2 Positive 27 LAAAWGGSGSEAYQGVQQK (light) 
636.646389 3 Positive 27 LAAAWGGSGSEAYQGVQQK (light) 
477.736611 4 Positive 27 LAAAWGGSGSEAYQGVQQK (light) 
950.979221 2 Positive 27 WDATATELNNALQNLAR (light) 
634.321906 3 Positive 27 WDATATELNNALQNLAR (light) 
475.993248 4 Positive 27 WDATATELNNALQNLAR (light) 
1036.966804 2 Positive 27 TISEAGQAMASTEGNVTGMFA (light) 
691.646961 3 Positive 27 TISEAGQAMASTEGNVTGMFA (light) 
518.98704 4 Positive 27 TISEAGQAMASTEGNVTGMFA (light) 
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Figure A 3 Total Ion Chromatogram (TIC) for MS1 and MS2 spectra for rESAT-6 and 
rCFP-10 spiked into a healthy volunteer urine sample. 
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Targeted Proteomics Results 
 
Figure A 4  Comparison of peak areas for transition peaks of WDATATELNNALQNLAR between 
the spectral library,  the rESAT-6 control spike and patient samples. 
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Figure A 5 Comparison of peak areas for transition peaks of peptide LAAAWGGSGSEAYQGVQQK 
between the spectral library,  the rESAT-6 control spike and patient samples. 
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Figure A 6 Comparison of peak areas for transition peaks of peptide 
LAAAWGGSGSEAYQGVQQKWDATATELNNALQNLAR between the spectral library,  the rESAT-
6 control spike and patient samples. 
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Figure A 7 Comparison of peak areas for transition peaks of  peptide TQIDQVESTAGSLQGQWR 
between the spectral library,  the rCFP-10 control spike and patient samples. 
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Figure A 8 Comparison of peak areas for transition peaks of  peptide GAAGTAAQAAVVR 
between the spectral library,  the rCFP-10 control spike and patient samples. 
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Figure A 9 Comparison of peak areas for transition peaks of  peptide TDAATLAQEAGNFER 
between the spectral library,  the rCFP-10 control spike and patient samples. 
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Figure A 10 Transition chromatogram of the rESAT-6 control spike for peptide 
LAAAWGGSGSEAYQGVQQK and four representative patient chromatograms from each patient 
group at the same retention time. 
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Figure A 11 Transition chromatogram of the rESAT-6 control spike for peptide 
LAAAWGGSGSEAYQGVQQKWDATATELNNALQNLAR and four representative patient 
chromatograms from each patient group at the same retention time. 
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Figure A 12 Transition chromatogram of the rCFP-10 control spike for peptide 
TQIDQVESTAGSLQGQWR and four representative patient chromatograms from each patient 
group at the same retention time. 
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Figure A 13 Transition chromatogram of the rCFP-10 control spike for peptide 
GAAGTAAQAAVVR and four representative patient chromatograms from each patient group at 
the same retention time. 
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CFP-10 from M. tuberculosis (H37Rv) 
UniProt: P0A566 
Mass (Da): 10,794 
HIS tagged recombinant protein: MW: 10,794 + ~1 kDa (6x HIS tag) = 11.8 kDa 
>sp|P9WNK5|ESXB_MYCTU ESAT-6-like protein EsxB OS=Mycobacterium 
tuberculosis (strain ATCC 25618 / H37Rv) GN=esxB PE=1 SV=1 
MAEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVVRFQEAANKQK
QELDEISTNIRQAGVQYSRADEEQQQALSSQMGF 
ESAT-6 from M. tuberculosis (H37Rv) 
UniProt: P9WNK7 
Mass (Da): 9,904 
HIS tagged recombinant protein: MW: 9,904+ ~1 kDa (6x HIS tag) = 10.9 kDa 
>sp|P9WNK7|ESXA_MYCTU 6 kDa early secretory antigenic target 
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KatG from M. tuberculosis (H37Rv) 
UniProt: P9WIE5 
Mass (Da): 80,605 
HIS tagged recombinant protein: MW: 80,605 + ~1 kDa (6x HIS tag) = 81.6 kDa 
>sp|P9WIE5|KATG_MYCTU Catalase-peroxidase OS=Mycobacterium 
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Target concentrations 




mg/ml µl µg µM 
Aliquot 1 0.063 0.048 165 7.88 0.60 
Aliquot 2 0.209 0.238 20 4.75 2.99 
Combined (Final) * 0.068 185 12.63 0.85 
 




mg/ml µl µg µM 
Aliquot 1 0.244 0.169 50 8.43 14.28 
Aliquot 2 0.202 0.227 185 42.08 19.27 
Combined (Final) * 0.215 235 50.51 18.21 
 




Table A 13 Amounts of targets loaded onto the PAGE gel 
Target  (µg) 
Biotinylated KatG 0.24 
Biotinylated CFP-10 0.34 
Biotinylated LAM ~2 
LAM-biotin mg/ml µl µg µM 
Final 0.1 900 90 5,88 
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Table A 14 Concentrations of targets incubated with magnetic beads.  







Table A 15 PCR Optimisation Summary  
 Primer (µM) Template (µl) Cycle number 
PCR_1.1 0.4 10 4-20 
PCR_1.2 0.2 20 16 
PCR_1.3 0.01 20 16 & 20 
PCR_1.4 0.1 20 16 & 20 
PCR_1.5 0.1 20 25 & 30 
PCR_1.6  0.1 1 (1ng/µl) 15 
PCR_2.1 0.1 20 16, 20 & 24 
PCR_2.2 0.1 40 20 & 24 
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Table A 16 Final nanodrop readings of pooled putative aptamers and amounts aliquoted for 
sequencing 










#1 Positive Control 19.9 5.03 * * 
#2 KatG 31.8 3.14 * * 
#3 CFP-10 12.3 * * 24.4 
# 4 LAM 17.3 5.78 * * 
#5 Negative Control 23.5 4.26 * * 
#1b Positive Control 68.3 * 2.93 * 
#3b CFP-10· ESAT-6 54.2 1.85 * 5.54 
#5b Negative Control 22.9 * 8.73 * 
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Putative X-Aptamer Sequences 
Table A 17 Putative X-Aptamer Sequences 
W=INDOLE; X=HYDROXYMETHYL; Y=PHENOL; Z=BORON 
KatG (corresponding to enrichment in fraction 2) 
KATG.2.1 TTTTT AC ACGA GYXCCTAACAGTCTAAACTXGCCTGTYTTG TCGT TTTTT 
KATG.2.2 TTTTT AC TCGT GYXCCTGAATGTGCCGCTGCCTAACCTG TCGT TTTTT 
KATG.2.3 TTTTT CA ACGA CGTTCZGGTTATCCGTWACZGAAAGAACAT TCGT TTTTT 
KATG.2.4 TTTTT CA ACGA CGGATAGGTTATCTCZATCZGATTCTACAT TCGT TTTTT 
KATG.2.5 TTTTT CA TCGT AGCCAWTGCTATCTAAATCGTATCGACAGZ TCGT TTTTT 
KATG.2.6 TTTTT CA ACGA CGCCCTACATATACTCCTCGGZ TCGT TTTTT 
KATG.2.7 TTTTT CA TCGT CGGACZGGCCAGCCAAWAAAACTTCTCACA TCGT TTTTT 
KATG.2.8 TTTTT CA ACGA AGGGCZGGGTATCCACATCGACTA ACGA TTTTT 
KATG.2.9 TTTTT CA TCGT AGGGTAGGCCCACCCZATATGATCAZACTA TCGT TTTTT 
CFP-10·ESAT-6 + CFP-10 only (corresponding to enrichment in fraction 3) 
CE.3.1 TTTTT CA TCGT CGGGCAGGCCCATCAATCCZAGTCCTCGTA TCGT TTTTT 
CE.3.5 TTTTT CA ACGA GWGGTAGCTTAGTAACTCATTATCGAACCA ACGA TTTTT 
CE.3.6 TTTTT CA ACGA AGGGCAACCCCATACZWACZAGAAWGCATA TCGT TTTTT 
CE.3.7 TTTTT CA ACGA CGTTCAGGCTAGCTGTTCATAGTCAZACTA TCGT TTTTT 
CE.3.8 TTTTT CA TCGT AGCCTAGCCTGWCCCZWAATACTTAZCGGZ TCGT TTTTT 
CE.3.9 TTTTT CA TCGT CGGATAACCCAGCCCZWACZTATCGAACTA TCGT TTTTT 
LAM (corresponding to enrichment in fraction 4) 
LAM.4.1 TTTTT CA ACGA AGCCCAGGTTATTCACWACZAGAAWGCAAT TCGT TTTTT 
LAM.4.2 TTTTT CA TCGT CGCCTAGGTTAGCTACWAATTATTGAACTA TCGT TTTTT 
LAM.4.3 TTTTT CA ACGA ZGGACZGCCTATTCGTATCZTATCGAACTA TCGT TTTTT 
LAM.4.4 TTTTT AC ACGA GYGCAGGATGGTTCCCYAAAGCAGGTGT TCGT TTTTT 
LAM.4.5 TTTTT CA TCGT GWCCCZGGTTATCCACTCCZACTCAZCATA TCGT TTTTT 
LAM.4.6  TTTTT CA TCGT AGGATAGGTTAGCTACTTCZACTTWGCGAT TCGT TTTTT 
LAM.4.7  TTTTT CA ACGA AGTTCATGCTCACCACATCZACCGCTCATA TCGT TTTTT 
LAM.4.8  TTTTT CA ACGA AGGGCZTGCTATTCACATAAAGTCGACATA TCGT TTTTT 
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APPENDIX C 
X-Aptamer binding curves: CFP-10 
 
 
Figure A 14 Binding Curves with rCFP-10 (1 nM) and two-fold serial dilutions of 
X-Aptamers (0.004-0.5 µM). A) CE 3.1 B) CE 3.6. All wells were performed in duplicate.  
ELONA: Streptavidin BSAX-AptamerrCFP-10-HISAnti-HIS-HRP 
Control 1: StreptavidinBSA X-Aptamer PBS Anti-HIS-HRP (Ctrl 1: X-Apt Only) 
Control 2: StreptavidinBSA PBS PBS Anti-HIS-HRP (Ctrl 2: No X-Apt; No CFP-10) 
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Figure A 15 Binding Curves with rCFP-10 (1 nM) and two-fold serial dilutions of 
X-Aptamers (0.5-0.004 µM). A) CE 3.8 B) CE 3.9. All wells were performed in 
duplicate.  
ELONA: Streptavidin BSAX-AptamerrCFP-10-HISAnti-HIS-HRP 
Control 1: StreptavidinBSA X-Aptamer PBS Anti-HIS-HRP (Ctrl 1: X-Apt Only) 
Control 2: StreptavidinBSA PBS PBS Anti-HIS-HRP (Ctrl 3: No X-Apt; No ESAT-6) 
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Figure A 16 Binding Curves with HIS tagged rESAT-6 (1 nM) and two-fold serial 
dilutions of X-Aptamers (0.5-0.004 µM). All wells were performed in duplicate. 
A) CE 3.6 B) CE 3.9. Points indicate the mean reading of duplicate or triplicate 
wells.  Error bars indicate the minimum and maximum readings taken.  
ELONA/ELISA: Streptavidin BSAX-AptamerrESAT-6-HISAnti-HIS-HRP 
Control 1: StreptavidinBSA X-Aptamer (CE 3.9) PBS Anti-HIS-HRP (Ctrl 1: X-Apt Only) 
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Biolayer Interferometry  
OCTET Red 
 





Bianca Amos-Brown- October 2018     287 
 
 
Figure A 18 LAM in PBS 
LAM at 500nM or 0nM in different buffers. 
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Figure A 19 Optimising Loading time 
 
